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Abstract 
The components of the extracellular matrix (ECM) are produced in situ by cells and 
are either completely secreted from the cell into the ECM or remain associated with 
the cell membrane. Amongst them are polysaccharides of the glycosaminoglycans 
(GAG) family, which are either free or covalently bound to proteins to make 
proteoglycans (PGs). These form a highly-hydrated compartment in which the 
proteins are embedded. At the molecular level, all ECM components are structured 
to execute their function and have been implicated in regulating intercellular 
communication. The sulfated GAGs interact with a wide range of proteins and their 
structure and tissue localisation is related to their function. Thus, certain GAGs may 
be particularly enriched in specific tissues, e.g., dermatan sulfate in skin, but they are 
found in all tissues; and heparan sulfate (HS) has the widest range of interacting 
protein partners. These partners include both the permanent ECM residents and the 
transients, such as the fibroblast growth factors (FGFs), which transmit signals from 
one cell to another in paracrine signalling involved in tissue development, 
differentiation and homeostasis. The aims of this thesis are (1) to use a simple 
biomimetic model of ECM in the form of a GAG brush to determine if FGF binding 
leads to different supramolecular structures. (2) To determine if these 
supramolecular arrangements allow FGF mobility as observed in vivo. The model GAG 
brush was assembled layer by layer by one-end grafting of biotinylated GAGs on a 
streptavidin monolayer, itself attached to a supported lipid bilayer. The structure of 
these brushes was probed using different recombinant human FGFs (FGF1, 
HaloFGF1, FGF2, HaloFGF2, FGF4, HaloFGF6, FGF9, FGF10, HaloFGF10, FGF17, FGF18 
and HaloFGF20) with well characterised HS binding sites (HBSs) and where “Halo” 
refers to an N-terminal Halotag fused to the FGF for fluorescence labelling. 
Rigidification of soft and highly hydrated films was assessed by quartz crystal 
microbalance with dissipation monitoring (QCM-D), spectroscopic ellipsometry (SE) 
was used to quantify the biomolecules at the surface, and fluorescence recovery 
after photobleaching (FRAP) was employed to assess the lateral diffusion of the GAGs 
and the (Halo)FGFs. FGFs showed a preference in binding stoichiometry for specific 
disaccharide structures, and the ensuing interactions led to different supramolecular 
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organisations of the brush/FGF films. Upon binding to the brushes, FGFs possessing 
multiple HBSs (‘multivalent’ FGFs) with acidic borders delimiting their HBSs were able 
to immobilise the GAG chains; some of these FGFs, e.g. HaloFGF1, remained mobile, 
whereas others were trapped in the film, e.g. HaloFGF2. Monovalent FGFs, and 
multivalent FGFs with no acidic borders around their HBSs, were found to not cross-
link the brushes and remained mobile.  
To test the idea that acidic borders on the protein surface play an important role in 
determining the ability of an FGF to cross-link HS chains and thus regulate mobility 
of the FGF in the matrix, the behaviour of fluorescently labelled Halo-FGFs were 
measured in the native pericellular matrix of fixed human keratinocytes. HaloFGF2 
was immobile in HS brushes and in the pericellular matrix of HaCaT cells. This 
indicates that although the other components of the pericellular matrix may also play 
roles in determining the diffusion dynamics of FGF2, HS would be the main director 
of it. 
Interactions between growth factors such as FGFs with components of the ECM are 
specific to their molecular features and can be precisely monitored in biomimetic 
models. These interactions trigger supramolecular structures that can be 
characterised by their stiffness. It is also possible to assess the mobility of these 
growth factors using a fluorescent label. Interestingly, the mobility of at least 
HaloFGF1, HaloFGF2 and HaloFGF10 in HS brushes was reproduced in pericellular 
matrix of HaCaT cells. A key difference is that the local supramolecular arrangement 
of the pericellular matrix components will be heavily influenced by the interactions 
of the HS chains with endogenous HS binding proteins. This will form a network of 
binding sites for FGFs, which at least in the case of HaloFGF2, did not prevent the 
immobilisation of the growth factor. However, in the case of other FGFs, e.g. 
HaloFGF6 and HaloFGF20 we detected reduced mobility. Thus, bridging the gap 
between the analyses on the HS brush model and on pericellular matrix may require 
the elaboration of a more complex in vitro model, incorporating other molecules into 
the HS brush, such as collagens and fibronectin, which have multiple HBSs and would 
be expected to present to the FGF already cross-linked HS chains and a reduced 
number of available binding sites.  
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1 Introduction  
1.1 Cell communication in multicellular organisms. 
In multicellular organisms, intercellular communication processes are the foundation 
of their growth and expansion, development, function, integrity and regeneration. 
Intercellular communication happens via various modes, the cell can target itself, a 
process that is call “autocrine” signalling or a neighbouring cell by direct molecular 
contacts (juxtacrine signalling) or cytoplasm contacts through gap junctions (1). 
Paracrine signalling is the local communication between cells without a direct 
molecular physical contact. Chemokines, cytokines, growth factors and many 
morphogens are paracrine signalling agents. They are secreted into the pericellular 
matrix of the source cell, and travel throughout the interstitial matrix towards the 
target cells. On the target cell, the paracrine effector binds to a receptor that triggers 
downstream signalling within the cell (2). This is the case of fibroblast growth factors 
(FGFs) signalling via tyrosine kinase receptors (3) and transforming growth factors 
family members such as the bone morphogenetic proteins that bind to the bone 
morphogenetic protein receptor type II in development processes (4). Intercellular 
communication can happen over longer distances, in which case the secreted 
effector travels through the endothelial barrier and is transported in the vascular 
blood flow throughout the body, but only acts on cells expressing the cognate 
receptor. This is the endocrine system and concerns hormones (Figure 1.1). The 
extracellular matrix (ECM) is the extracellular environment in contact with the cell; it 
is implicated in controlling cell fate decisions. During development, morphogen 
gradients are shaped by ECM components, whereas in homeostasis the ECM takes 
part in tissue regeneration and immunity by controlling the activity and transport of 
proteins regulating cell growth, migration and differentiation. Besides the 
components, the physical characteristics of the ECM are also relevant. It was shown 
that the elasticity of the ECM controls the differentiation of stem cells (5) and the 
polarisation of fibroblasts has been related to the stiffness of ECM (6). Stiffness and 
elasticity are both determined by the supramolecular structure of ECM, which in turn 
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depends on its molecular composition and the interactions of the component 
molecules. 
 
Figure 1.1: Forms of signalling in cellular communication.  
Endocrine signalling corresponds to the intercellular communication that occurs via 
transport of the effector by the blood stream. Juxtacrine communication involves contact 
between the signalling and the targeted cell as described in the figure. Autocrine signalling 
depicts the signalling of a cell on itself and the paracrine signalling the one to a neighbouring 
cell. In paracrine and autocrine signalling, the effector molecule is transported in the 
immediate microenvironment of the cells that is the extracellular matrix. 
 
1.2 Extracellular matrix  
 
The ECM has distinct domains, the pericellular matrix is immediately adjacent to the 
cell surface, extending 1-5 µm in some tissues (7). Further away in mesenchymal 
tissues is the interstitial matrix. In epithelial tissues and the vasculature, a specialised 
ECM is found beyond the pericellular matrix, the basement membrane, so called due 
to its molecular density causing it to be heavily stained in a number of classic 
histological preparations. Basement membrane separates these compartments from 
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the underlying mesenchyme (8) (Figure 1.2). At the molecular level, all ECM have 
reasonably well-studied components and these are mainly fibrous proteins such as 
collagens, and the polysaccharides of the glycosaminoglycan (GAGs) family.  
 
 
Figure 1.2: Schematic representation of the extracellular matrix proteoglycan organisation. 
 Here schematized are the ECM with collagen fibrils and GAGs. HSPGs core proteins (blue) 
carrying HS chains (black) are sitting in the ECM or anchored in the cell membrane, with 
bound growth factor (green).  
 
Collagens are the scaffold of extracellular matrices. They are tissue specific, 
organised in fibrils and provide resistance to shear and pressure (9). Type I and type 
III collagens sit in the interstitial matrices of soft tissues, e.g., the dermis (10). In 
bones, collagen I fibrils can represent up to 90% of matrix protein components (11). 
Collagen type IV is the fibrous components of the basement membranes and is 
connected to the interstitial matrix via collagen VI, thus the fibrous scaffolds of 
basement membrane and the interstitial matrix form interconnected networks (12). 
Along with collagen type IV, fibronectins, laminins, nidogen and perlecan are the 
main constituents of the basement membrane. Laminins are connected to collagen 
IV and perlecans by nidogens (13). The ECM is a complex network where the main 
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components, HSPGs, collagens, polysaccharides and proteins are diverse and 
interconnected. However it is not a static environment but rather dynamic, 
constantly remodelled by matrix metalloproteases (MMPs) endoglycosidases such as 
heparanases, sulfatases and sialyltransferases (14). The first human MMPs were 
discovered as having a collagenolytic activity (15, 16), though this large family of 
proteases is now recognised to have many distinct substrates. Their activity is 
required in development (17), cell differentiation (18) and migration (19), 
homeostasis (20) and wound healing (21, 22). HS chains of perlecan in ECM of in vitro 
cultured endothelial cells (23) were shown to be storing FGF2 (24) and releasing it by 
the activity of MMPs such as collagenase and the endoglycosidase heparanase (25). 
Selective proteolysis of the ECM by these enzymes thus allows the release and 
activity of effectors that are stored by virtue of their binding to HS. This is one means 
of generating a gradient of the effector (26). Simple reversible binding of effectors to 
HS in the matrix will also result in a gradient, determined by the binding kinetics and 
the density of binding sites (27). 
1.3 The glycosaminoglycans of the ECM 
Of particular interest for this thesis are GAGs. GAGs in ECM are synthesized in the 
Golgi as post-translational modifications of core proteins, except for HA, which is 
synthesized in the cell membrane by hyaluronan synthases (28). GAGs are elongated 
as disaccharide repeats thus they are classified by those disaccharide repeats.  
1.3.1 Heparan sulfate and heparin 
Heparan sulfate (HS) and heparin are polysaccharides made of a modified repetitive 
disaccharide (50 to 100 repeats). Their biosynthesis is initiated on the serine of a SER-
GLY sequence of the core protein in the Golgi (29). The initiating sequence of sugars 
for heparin and HS (and also for chondroitin sulfate (CS), see below) is a linker of 4 
saccharides added to the serine residue, covalently built up by glycosyltransferases: 
[-4) GlcA β (1-3) Gal β (1-3) Gal β (1-4) Xyl β (1-OSER] (GlcA: glucuronic acid; Gal: 
galactose; Xyl: xylose) (30). The exotosin-like (EXTL) enzymes have a αGlcNAc 
transferase activity and they proceed as a cascade in which EXTL2 catalyses the first 
reaction, the transfer of αGlcNAc (31) to the non-reducing end of the linker. This 
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directs the subsequent synthesis of a HS/heparin chain. The polysaccharide is 
elongated by the alternative transfer of GlcA and GlcNAc, thus [-4) GlcA β (1-4) 
GlcNAc β (1-] n is added to the first GlcNAc (32, 33). The elongation is catalysed by an 
enzymatic complex of exotosin (EXT), EXT1 and EXT2, possessing GlcA and GlcNAc 
transferase activities, respectively (34). The polysaccharide is then modified by N-
deacetylation/N-sulfation on some GlcNAc, which become GlcNS (N-sulfated 
glucosamine) by one of four N-deacetylase/N-sulfotransferase (NDST) enzymes (35-
37). However, the first sulfation may only occur 8-10 saccharide units after the linker. 
Then, the D-glucuronyl C5-epimerase (38) modifies some GlcA-GlcNS to IdoA-GlcNS 
(iduronic acid), thus the HS backbone varies in GlcA-GlcNAc, GlcA-GlcNS and IdoA-
GlcNS (Figure 1.3). Finally, the saccharide units may be successively O-sulfated in 
positions C2 of GlcA and IdoA (the latter is far more common), C6 and/or C3 of GlcNAc 
or GlcNS by O-sulfotransferases (OST): 2OST, 6OST and 3OST and in this strict order 
of action (Figure 1.3). This is the most commonly depicted pathway for HS/heparin 
biosynthesis and leads to the production of the most commonly observed 
disaccharide units: GlcA-GlcNAc, GlcA-GlcNS, IdoA-GlcNS, IdoA,2S-GlcNS, IdoA-
GlcNS,6S and IdoA,2S-GlcNS,6S (39).  
There is also a minor pathway in which the epimerase reaction happens at an earlier 
stage of the biosynthesis, it converts GlcA-GlcNAc to IdoA-GlcNAc. This minor 
pathway leads to less represented sulfation patterns such as IdoA,2S-GlcNAc and 
IdoA-GlcNAc,6S (40). These modifications and their hierarchical dependence result in 
an organised structure of the polymer: it is an alternative succession of N-acetylated 
(NA), N-acetylated/N-sulfated (NA/NS) domains, and sulfated domains (S). NA 
domains are a sequence of [-4) D-GlcA α (1-4) D-GlcNAc β (1-] residues, so unmodified 
polymer, delimited by a GlcNS residue. The limiting GlcNS residue is usually part of a 
NA/NS domain, where GlcNS and GlcA alternate. The definition of these is resistance 
to scission by K5 lyase, which requires four successive GlcNAc residues (41). Thus, 
NA/NS can contain up to three successive GlcNAc disaccharides. S domains contain 
contiguous GlcNS disaccharides, which are respectively [-4) D-GlcNS β (1-4) D-GlcA β 
(1-, -4) D-GlcNS α (1-4) L-IdoA α (1-] and [-4) D-GlcNS (+/- 6S) α (1-4) L-IdoA (2S) α (1-
] (Figure 1.4) (41). Sulfation on the 3-O position of the GlcNAc or GlcNS residue may 
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occur in NA/NS and NS domains, but is relatively rare, compared to the other 
sulfations. A single chain of HS may contain varying numbers of these domains of 
different lengths. Heparin (Hep) follows the same synthesis pathway as HS, but is 
excised from the parent HS chains by the action of heparanase, an endo beta D-
glucuronidase. Hep is of the order of 15 to 20 disaccharides in length, has longer 
tracts of GlcNS and so a higher proportion of IdoA (42) and sulfate groups, averaging 
2.5 sulfate groups per disaccharides, whereas HS has less than 2 (43). Thus, HS and 
hep share a common disaccharide backbone (Figure 1.3), but differ in the level of 
sulfation (44). 
 
 
Figure 1.3: Heparan sulfate disaccharide repeat unit. 
A: product of the initial polymerisation, [-4) D-GlcA β (1-4) D-GlcNAc β (1-]. B: possible final 
disaccharide with the C5 GlcA’s epimer, L-IdoA. R is a possible sulfation position. C: The 
modifications of a disaccharide are hierarchical and ordered. Molecular structures drawn in 
ChemBioDraw. 
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Figure 1.4: Model of alternating sulfation domains in HS proteoglycans.  
Adapted from Murphy et al., 2004 (41).Proteins bind to sulfated motifs in S and NA/NS 
domains and many different patterns of sulfation are possible. Thus, HS/hep clearly has a 
large number of different potential binding sites for different protein partners including 
fibroblast growth factors (FGFs) (45).  
1.3.2 Chondroitin sulfate and dermatan sulfate 
Chondroitin sulfate (CS) chains are also elongated from core proteins and follow the 
same pathway as HS and Hep until the elongation step when the first GalNAc is added 
to the GlcA by GalNAc transferase I instead of a GlcNAc in the elongation of 
HS/heparin. The disaccharide repeat is then a [-4) GlcA β (1-3) GalNAc β (1-]n (see 
Figure 1.5), a repeat of glucuronic acid “β 1-3” linked to a galactosamine, respectively 
elongated by GlcA transferase II and GalNAc transferase II. The GlcA residues can be 
epimerised to IdoA to produce dermatan sulfate (DS, also called CS-B); with a single 
disaccharide repeat of IdoA and GalNAc: [-4) IdoA β (1-3) GalNAc β (1-] n in the chain 
sufficient for it to be called dermatan sulfate, though in general there are far more 
(46). O-sulfations occur on R positions of the GalNAc unit and of the GlcA/IdoA unit 
leading to different CS types: chondroitin-4-sulfate (CS-A), chondroitin-6-sulfate (CS-
C), chondroitin-2,6-sulfate (CS-D) and chondroitin-4,6-sulfate (CS-E). In DS, the first 
sulfation occurs in position 4 of the GalNAc unit, it can also be further sulfated in 
position 6 of the GalNAc or position 2 of the IdoA.  
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Figure 1.5: Chondroitin sulfate disaccharide repeat unit. 
[-4) D-GlcA β (1-3) D-GalNAc β (1-]. R is a possible sulfation position. Molecular structures 
drawn in ChemBioDraw. 
 
1.3.3 Molecular features, conformation and protein binding. 
GAGs are linear elongated chains and offer a large range of structures for protein 
binding. Cataloguing the binding partners of hep and HS has identified, at least 480 
proteins (47, 48), including the FGFs. The elucidation of the conformational structure 
of HS/hep oligosaccharides, which was done by NMR and computational calculations, 
showed that it involves multiple parameters. Intra- and inter-saccharide unit 
hydrogen bonds confer rigidity to the saccharide backbone. Sulfate groups in GlcNS 
units engage in hydrogen bounds with nearby C3 hydroxyl groups in IdoA2S and thus 
can maintain the conformation in one state. It also showed that inter- and intra-
residue hydrogen bonds compete with each other, suggesting a locally dynamic 
structure rather than a fixed conformation (49-51). Weaker interactions, ionic 
interactions and dipole-dipole interactions between the residues and the solvent also 
play a role in the stabilisation of the GAG 3D structure (51). NMR studies have shown 
the in solution changes in conformational arrangements due to the hanging sulfate 
groups (52). The presence of cations in the vicinity of the chains modifies the 
conformation of the polysaccharide chain (53). The pyranose residues in the HS/hep 
and DS chains can adopt several conformations: boat or chair named after the shape 
formed by the sugar ring if the glycosidic bonds are in the same or opposite direction 
respectively. HS/hep and DS chains contain GlcA/IdoA residues that confer them 
higher flexibility because of its ability to adopt various stable ring conformations (54). 
In the 1C4 and 2S0 conformations, the C-2 and C-3 are in diaxial and diequatorial 
positions generating torsions/directional changes in the chain (Figure 1.6). The 
computational study suggested that in IdoA2S this equilibrium is displaced towards 
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the 2S0 conformation by a ratio of 15:85 (1C4: 2S0) and that it changes upon protein 
binding (51). (49-53, 55) 
GAG chains were shown to stabilise FGFs in thermostability assays (56, 57) and for 
FGF1, but not FGF2 this was related to its ability to signal on cells (58). The molecular 
features required for a GAG chain to stabilise an FGF and the structural determinant 
that make an FGF sensitive to it are unknown.  
The versatility of GAG chain with their multiple sulfation pattern combination 
possibilities and 3D conformational changes offers a variety of binding and thus 
stabilisation possibilities for proteins, including cytokines such as FGFs. Those lead to 
different requirements for FGF signalling even for FGFs from the same subfamily such 
as FGF1 and FGF2 (59).  
 
Figure 1.6: Conformational changes in saccharide rings.    
Different conformation structure of L-IdoA2S and D-GlcA in GAG chains. The 1C4 (A) 
conformation of L-IdoA2S presents the C-2 and C-3 diaxially oriented whereas the 4C1 (B) in 
GlcA and 2S0 (C) in IdoA present them diequatorially oriented and generate torsions in the 
chain. Adapted from Casu et al, 2010 (60).  
 
1.4 Fibroblast growth factors: structures, functions and interactions 
with the ECM. 
HSPGs have been shown to be involved in embryonic development in Drosophila. 
Mutants of genes encoding enzymes essential for HS biosynthesis (NDST and uracil-
diphosphate-glucose, UDP-glucose dehydrogenase) have presented the same 
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characteristics as fibroblast growth factor receptor (fgfr) knock-out mutants (61). The 
UDP-glucose dehydrogenase mutation in mammals (mouse) prevented the complete 
mesodermal and endodermal migration during gastrulation, which stopped 
embryogenesis. Although the production of FGF was not altered, the transduction of 
its signal was not observed. Such experiments have contributed to the evidence that 
HS is indispensable for much of FGF signalling during embryogenesis (62). Further 
studies have suggested that HS is responsible for the formation of morphogen 
gradients, the movement of morphogens and, therefore, their activity (63). The 
mechanism under which HS operates to influence gradients, and to allow the 
transport of morphogens in the ECM is still debated. Free diffusion of morphogens in 
the extracellular matrix is limited by their interaction with their cognate receptor and 
extracellular matrix components (GAGs and fibrous proteins). Receptors have been 
found to control the formation of morphogen gradients by retaining them on the cell 
surface (64) and at times trigger their endocytosis for degradation (65). In Drosophila, 
HSPGs too have been shown to retain morphogens, thus enabling the formation of a 
reservoir of gradient formation (66). Although the role of HSPGs in the formation of 
gradients is relatively well documented in some vertebrates (67), there is a lack of 
information about the mechanisms under which they operate. In 2012, Duchesne et 
al. tracked the movements of FGF2 in the ECM of fibroblasts using gold nanoparticles 
(68). The study suggests that the diffusive movement of FGF2 in fibroblast pericellular 
matrix depends on the long-range order of FGF2 binding sites in the HS. The observed 
heterogeneous spatial organisation of these HS binding sites determined whether 
the motion of FGF2 was locally confined or was diffusive (in some instances clearly 
directional) over long distances, corresponding to the length of many extended HS 
chains (69).  
1.4.1 Historical discovery  
The members of the FGF family have a wide range of expression and localisation in 
the organism, from the pre-implantation embryo to adult tissues and they have very 
diverse activities in development, homeostasis and disease (70).  
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The first fibroblast growth factor (FGF) was discovered in 1973 as a pituitary and brain 
agent enhancing fibroblast proliferation (5, 6, 71). This was subsequently termed 
basic FGF (bFGF), as in 1975, Gospodarowicz et al. discovered the acidic FGF (aFGF), 
which also showed a cell proliferation enhancing activity in myoblasts (72). aFGF and 
bFGF were so called because of their isoelectric points, which are, respectively, acidic 
and basic. Today 22 genes encoding FGFs have been identified in humans named 
from fgf1 (aFGF), fgf2 (bFGF) to fgf23, but fgf15 is “missing” since it has not been 
identified in the human genome, but is present in mice. However, human fgf19, 
which is not found in mice, has been suggested to be a homologous form of the 
murine fgf15 (73, 74).  
The FGF family comprises cell signalling molecules implicated in diverse cellular 
processes such as cell differentiation in embryonic development. They can induce 
cell proliferation, but also delay cell differentiation as observed by Gospodarowicz et 
al. in 1975. The discovery of other FGF subfamily members is summarised below.  
➢ FGF3 was discovered as the proto-oncogene int-2 and then related to the FGF 
family because of its sequence homology to FGF1 and FGF2 (75) and to FGF4, 
FGF5 and FGF6 (45).  
➢ FGF4 was first studied as an oncogene, but the analysis of its gene and protein 
coding sequence showed that it was closely related to FGFs 1 to 6; therefore 
it was included in the FGF family (76). 
➢ FGF5 and FGF6 were discovered as oncogenes as well. FGF5 was found to be 
involved in embryogenesis (77, 78). FGF6 was identified as the product of the 
hst-2 gene and related to the FGF family for its similarities with hst-1 gene, 
FGF4 (69, 79). 
➢ FGF7 was initially called keratinocyte growth factor (KGF), as a consequence 
of its apparent specificity for keratinocytes (80, 81).  
➢ FGF8 was isolated as an FGF-like and androgen-induced growth factor in 
mouse. It was shown that it is actually a distinct FGF protein, now called FGF8 
(82). 
➢ FGF9 was identified as a glia activating factor (83). 
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➢ The cDNA of FGF10 was isolated from rat embryos and identified by homology 
as a new FGF protein, initially called KGF2, as it is most closely related to FGF7 
(KGF) (84). 
➢ Four proteins, homologous to FGFs and referred to as FGF homologous factors 
(FHF), are mainly expressed in nervous systems and have been named FGF11 
to FGF14 (85). They are intracellular and do not bind FGF receptors or HS. 
➢ FGF16 to FGF21 (except FGF19) have all been identified by using homology 
based polymerase chain reaction cloning strategies (86-90).  
➢ FGF19 was identified as a homologue of mouse FGF15 (91). 
➢ FGF22 was isolated from human placenta and identified as an FGF family 
member mainly expressed in hair follicles (92). 
➢ FGF23 was first identified in 2000 (93), and further characterised as a hormone 
which regulates the metabolism of phosphate and vitamin D (94).  
There are many similarities in amino acid sequence, protein structure and gene 
organisation between the FGFs. Indeed, these have served as a basis for the 
identification of many members of the FGF family. Figure 1.7 shows a phylogenetic 
tree of the mammalian FGF family and its subfamilies based on the alignment of their 
protein sequences. Some invertebrate FGFs are related to the vertebrate ones, but 
there are also other FGFs in invertebrates, which have been apparently lost in the 
vertebrate lineage in the course of evolution (74).  
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Figure 1.7: Radial phylogram of the FGF family. 
Phylogenic tree based on protein sequence alignment extracted from Laestander and 
Engstorm (95). 
 
1.4.2 Structure-function relationship in FGFs and consequences for HS 
binding. 
 In vertebrates, FGF proteins are between 17 and 34 kDa in size and share a 
conserved sequence containing 28 identical amino acids and 6 conserved residues 
(77). Crystallisation of FGF2 has shown that the protein folds in a succession of four 
stranded antiparallel β sheets to form a “β-trefoil” (Figure 1.8) (78, 96, 97). This core 
structure is present in all the other FGF proteins, with variations occurring in the 
length of loops and the N- and C-termini (Figure 1.8). Hep binding sites (HBS) are 
present on the surface of FGFs with growth factor/morphogen activity and they 
contain arginine and lysine residues. There is a canonical HBS required for receptor 
signalling, HBS1 (55, 98), and several secondary HBSs may also be present. This core 
structure may also contain the FGF receptor binding site as identified in FGF4 (99). 
The secondary HBSs in FGF1 and FGF2 were suggested in early studies (100-102) and 
recently confirmed in FGF2 by specific identification using selective labelling and 
mass spectrometry (103). The locations of HBS1, HBS2 and HBS3 on the surface of 
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FGF2 are shown in Figure 1.9 along with identified binding lysines. Lysines residues 
in FGFs that are engaged in binding with HS have been catalogued and characterised 
using the protect/label technique (56, 103, 104).  
FGFs have preferences for sulfation patterns, and thus potentially specific 
localisations of the HS chains in tissues; the sulfation patterns and so the ‘decision’ 
as to whether a cell’s HS can bind a particular FGF are made in the Golgi during HS 
biosynthesis (105). Thus 2-O and 6-O sulfation are the most common in NS domains 
(106) and it was shown that FGF2, but not FGF1 and FGF4 presented an increased 
affinity for an HS with low 6-O sulfation but high 2-O sulfation compared to standard 
HS(59). It suggested that the binding of FGF to hep showed that FGF1, FGF2 and FGF4 
had different and specific requirements to enable their function (59). The presence 
of N- and 2-O sulfation was enough for FGF1 to bind HS and enable signalling (59), 
however the 6-O sulfation was shown to consequently increase the affinity of FGF1 
for HS/hep(107) and thus its function. However, FGF4 responded to the sole 
presence of the 2-O or 6-O sulfation in heparin, both separately could bind FGF4 and 
enable signalling in cells. It is therefore suggested that the biological function of each 
FGF may reside in its ability to bind and be stabilised by well-defined structures in 
heparin/HS and that the discrimination is driven by the HBSs on the FGFs which also 
present variabilities. FGFs bind a range of different sulfation patterns in HS/hep but 
do present preferences of which some have been catalogued and reported (56).  
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Figure 1.8: β-trefoil structure of FGFs. 
The X-ray structure of FGF2 (P09038) amino acids 1-155. “β-trefoil” structure drawn in 
PyMol®: in red and the N-terminal in grey. PDB accession number: 1BLA. 
 
 
Figure 1.9: Surface electrostatic potential mapping and position of heparin binding lysines in 
FGF2. 
Identified hep binding lysines in HBS1, HBS2 and HBS3 in FGF2 (1BLA) are labelled in green 
(103). The electrostatic mapping of partial charges [-1.8 (red), 0 (white) and +1.8 (blue)] was 
generated using the Poisson-Boltzmann algorithm in Swiss PDB viewer (SPDBV). The N-
terminal residue is labelled in black. 
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However additional specificity is suggested at the level of the formation of a signalling 
complex of FGF with HS and FGF receptors (FGFRs). The organisation of the ternary 
complex by which the function of FGFs are transduced is still debated. Whilst multiple 
studies support a symmetric model of interaction between two HS chains, two FGFs 
and two FGFRs (98, 108), others have depicted the possible establishment of an 
asymmetric complex of a single HS chain engaging with 2 FGFs and two FGFRs (100). 
Deciphering the molecular features involved in the interactions of these three may 
bring an understanding of the actual structure of the complex. Evidence shows that 
additionally to the N- and 2-O sulfation necessary for FGF2 binding (109), 6-O 
sulfation was required for the signal transduction of FGF2, which is due to this sulfate 
engaging the FGFR in the ternary signalling complex (107, 110, 111). More recently, 
the presence of an NS domain at the reducing end of the HS chains, or within the HS 
chains, has been suggested to be preferred for FGF2 signalling via the FGF receptor 
(FGFR) 1c over other sulfation patterns (112, 113). This suggests that the binding 
preferences of FGFs for HS might also take in account their interaction with FGFRs in 
the ternary complex. Known and identified HBSs in FGFs were previously reported 
along with their binding preference for HS sulfation patterns and oligosaccharide 
sizes (Figure 1.10) (56, 103, 104). Together they suggest that there is a gap in our 
understanding of the relationship between the molecular details and the biological 
function of FGFs. One reason for this gap is that in vivo FGFs bind HS chains which 
may engage multiple HBS on a FGF and multiple partners in the ECM. In contrast, 
molecular studies use small and well-defined fragments of GAGs, and thus neglect 
the complexity of the multi-partner presentation in the ECM. 
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Figure 1.10: HBSs, sulfation pattern and oligosaccharide size preferences in FGF.  
Asterisks represent data from (103, 104, 114), dp is “degree of polymerisation”. The FGF 
evolutionary tree is annotated with their sulfation pattern, oligosaccharide length and GAG 
preferences along with identified HBSs in the literature. NS: N-sulfated. 2S: 2-O sulfated. 6S: 
6-O sulfated. HS: heparan sulfate. DS: dermatan sulfate. CS: chondroitin sulfate. Data 
summarized from (56, 103, 114, 115). 
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1.5 FGF and polysaccharide interactions. 
FGFs are globular proteins, and engage with the solvent through weak atomic bonds 
in the same way as the polysaccharide chains. The weak interactions identified as 
contributors to FGF interaction with HS/hep have been mapped for FGF1 by 
computation (116). Hydrogen bonds occur when a hydrogen covalently bound to an 
electronegative element (C, N, O, F) is located in the vicinity of another 
electronegative element. (117) The two polar groups are electrostatically attracted 
to one another creating bonds. In polysaccharides, this can involve any hydroxyl and 
sulfated group. In proteins, it involves the polar aminoacid residues at the protein 
surface: asparagine, cysteine, glutamine, histidine, serine, threonine, tryptophan and 
tyrosine. (117, 118) Ionic interactions also play their part in FGF-GAG binding, and 
this feature is used in our methods (see Chapter 4.1) to purify FGFs by hep affinity. 
The ionic interactions are stronger than hydrogen bonds and involve charged 
aminoacids: arginine, lysine, aspartate, and glutamate. The strength of a hydrogen 
bond ranges between 0.2 to 7.4 kcal.mol-1 for polar groups available in proteins (102, 
117, 118), for reference that is 10 to 100 fold weaker than a covalent bond (119). 
FGFs and GAGs have relatively well defined and characterised molecular features, 
and as described here, their interactions are subject to multiple factors including 
internal dynamic structural organisations: secondary and ternary structure of 
globular proteins and intra-residue/chain interactions in GAGs. They are also 
influenced by their interaction with solvated components such as ions and 
environmental conditions. Heparin and FGF co-crystals have been studied to 
elucidate which sub-molecular features were involved in the interactions. Using FGF2 
and heparin tetra- and hexasaccharides, the study showed the presence of both ionic 
and hydrogen bonds between sulfate and hydroxyl groups in the heparin 
oligosaccharides and the lysines, arginines, asparagine and glutamine residues in the 
protein (55).  
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1.6 Other methods for studying FGF and GAG interactions.  
1.6.1 Quartz crystal microbalance with dissipation monitoring (QCM-D). 
Quartz crystal microbalance with dissipation monitoring (QCM-D) allows real-time 
measurement of the changes in resonance frequency and dissipation of a quartz 
crystal sensor upon adsorption of material on the surface. This acoustic technique 
provides information on binding kinetics and rigidity of the adsorbed films. 
Viscoelastic modelling of the extracted data can give quantitative information on the 
thickness and viscoelastic properties of the adsorbed materials.  
QCM-D originated from a method that first described the use of an ultrasonic wave 
to evaluate the viscoelastic properties of liquids. Mason used an oscillating 
piezoelectric crystal to apply a rapid shear motion to liquid and measured its 
response. The liquid presented a viscous effect, change in resonant frequency and a 
shear elastic effect as an increased resistance at resonance (126). The method was 
further explored and applied to polymer solutions (127) and developed to allow the 
simultaneous monitoring of the dissipation factor and the resonance frequency of 
the crystal : the “ring-down” method (128). Amongst others, Rodahl et al. 
successfully applied this method to adsorbed proteins, lipid, and cells (129). 
Theoretical principle 
QCM-D uses a piezoelectric quartz crystal placed between two gold electrodes (Error! 
Reference source not found.). When an alternating current is applied to the crystal, 
it oscillates (Error! Reference source not found.) and generates a standing shear 
wave at a frequency, fi (Error! Reference source not found.) close to the resonance 
frequency, f1 (4.95 MHz for AT-cut quartz crystals from Biolin Scientific) or its odd 
overtones (i = 3, 5, 7, 9, 11, 13, corresponding to resonance frequencies of fi ≈ 15, 25, 
35 … 65 MHz). When the alternating external current is turned off, the oscillation 
decays exponentially. From the decay curve, the resonance frequency (f) and the 
energy dissipation (D) can be extracted.  
20 
 
The resonance frequency, fi is related to the mass at the surface and the frequency 
change upon mass adsorption can be directly related to the absorbed areal mass 
density for rigid films, as the Sauerbrey equation states:  
∆𝒎 = –  𝑪 ∗  ∆𝒇/𝒊     Equation 1 
 
where the Sauerbrey constant, C, is 18 ng Hz-1 cm-2 for a crystal with a resonance 
frequency f1 of 5 MHz. Rigidity or softness of the film can be measured by the 
dissipation of energy into the film, we are able to measure D:  
𝑫 =  𝑬𝒍𝒐𝒔𝒕 / 𝟐 𝝅 𝑬𝒔𝒕𝒐𝒓𝒆𝒅     Equation 2 
Where Elost is the energy lost (dissipated) during one oscillation cycle and Estored is the 
total energy stored in the oscillator. D is dependent of the ability of the surface to 
store/ dissipate energy and thus varies with the composition of the medium at the 
surface (Figure 1.11Error! Reference source not found.). 
  
Figure 1.11: The working principle of QCM-D.  
(A) Picture of a 4.95 MHz AT-cut quartz crystal sandwiched between 2 gold electrodes from 
Biolin Scientific. (B) Illustration of the opposite movement of the top and bottom parts of the 
crystal upon application of an alternating current. The fundamental frequency (black) and its 
3rd overtone (blue) are represented. (C) Resonances, characterised by their frequency, f and 
their bandwidth, Γ, are observed for a crystal in air (blue) and liquid (red). The dissipation 
factor, D can be extracted from the equation: D= 2 Γ/f. (D) The “ring-down” method allows 
to record the frequency decay curve and extract the resonance frequency, f, and the 
dissipation, D. The blue curve represent the oscillation of the crystal in air and the red curve 
the dissipation of 1.6 * 10-1. Extracted from Reviakine et al., 2011 (130). 
 
Δf, the change in frequency, and ΔD, the change in dissipation, are related to the 
physical properties of the film at the surface (density, mass bound to the surface, 
ridigity). QCM-D measurements were performed with a Q-Sense E4 system (Q-Sense 
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AB, Västra Frölunda, Sweden). Δf and ΔD were measured at 7 overtones. We chose 
to represent Δf as Δfi/i and the ΔD for the third overtone (i = 3). Solutions were 
infused in passivated (see below) chambers using a syringe pump at 20 µL/min or as 
stated otherwise. The temperature was set and controlled at 23°C. 
1.6.2 Spectroscopic ellipsometry. 
Ellipsometry is an optical technique that is used to measure changes at interfaces. It 
can be applied to quantify the refractive index and the thickness of nanofilms made 
of biomolecules, but also the surface density of adsorbed molecules (132). We have 
applied SE to characterise our ECM models and probe the binding propensity of FGFs 
to the GAG brushes. 
SE measures the changes in polarisation of light at a range of wavelengths upon 
reflection on a planar surface. In particular, it measures the changes in Δ and Ψ, 
ellipsometric angles which characterise the polarised light. The presence of films on 
the surface directs the changes in Δ and Ψ. Thus, from the changes in Δ and Ψ, the 
parameters of the film can be extracted: the refractive index and the thickness. By 
fitting the collected data to models, we quantified the areal molar density of 
biomolecules: proteins and GAGs. 
Principle of spectroscopic ellipsometry . 
Spectroscopic ellipsometry (SE) uses polarized light, light as an electromagnetic wave 
is propagated in a 3 dimensional vector field: E, the amplitude of the electric field 
strength, B, the amplitude of the magnetic field and the directional vector of 
propagation, z. According to James Clerk Maxwell, E and B are perpendicular to each 
other and to z. The wave is characterised by its electric field, E which is the 
superposition of two components, Ex and Ey, orthogonal to z as presented in Figure 
1.12. 
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Figure 1.12: Polarization of light as an electromagnetic wave.  
The electric wave E, is decomposed in its two orthogonal components Ex and Ey. The 
superposition of Ex and Ey forms an elliptical pattern in the x-y plan (as illustrated in the 
figure) as the phase shift, δy - δx is π/4. Extracted from (133). 
 
E, the electric field wave is described by an amplitude and frequency by (133):  
𝑬 =  𝑬𝟎 𝒄𝒐𝒔 (𝒒𝒛 –  𝝎 𝒕 +  𝜹    Equation 3 
 
Where E0 is the amplitude of E, q = 2π/λ is the wave number, ω is the angular 
frequency, t is time and δ is the phase constant. The equation 3 can be decomposed 
into two as the superposition of Ex and Ey, as follows (133):  
𝑬𝒙 =  𝑬𝟎𝟏 
𝒄𝒐𝒔 (𝒒𝒛 –  𝝎 𝒕 +  𝜹𝒙)    Equation 4 
𝑬𝒚 =  𝑬𝟎𝟐 𝒄𝒐𝒔 (𝒒𝒛 –  𝝎 𝒕 +  𝜹𝒚)     Equation 5 
Where E01 and E02 are the amplitudes of the components Ex and Ey, and δx and δy 
their phase constants. The phase shift between Ex and Ey determines the type of 
polarization, in linearly polarized light, Ex and Ey are in phase, δx - δy is null. Circularly 
polarized light is characterised by a phase shift equal 90° (133). In elliptically polarized 
light, δx - δy is between 0° and 90° and the vector E describes an ellipse when 
observed along z. 
When linearly polarized light is reflected on a homogenous bulk substrate or biofilm 
as described in Figure 1.13, the reflected light becomes elliptically polarized.  
23 
 
 
Figure 1.13: Reflection of polarized light.  
The reflection of a linearly polarized light on a bare (a) or film-covered (b) surface. (a) When 
the incident beam, Ei (a superposition of its components Eip and Eis, respectively parallel and 
perpendicular to the plane of incidence) reaches the plane of incidence (POI) with an angle 
of incidence 1- θ0, it is partially transmitted and reflected as Er (a superposition of its 
components Erp and Ers). Upon reflection there is a change in phase shift and amplitude of 
the components of the light wave. The changes in polarization of the light are dependent of 
the surface composition and optical properties and can be measured by ellipsometry. (b) The 
effect of a thin film on the reflection of a polarized light beam. Extracted from (133) 
 
The detected change in polarisation is represented by the complex reflectance ratio, 
ρ (104, 133, 134). 
 
𝝆 =  𝐭𝐚𝐧 (𝛙) 𝐞𝐱𝐩 (𝒊𝚫) =  −
𝒓𝒑
𝒓𝒔
⁄     Equation 6 
Where Δ is the phase shift δrp – δrs and ψ the amplitude difference between Erp – Ers. 
The ratio “rp⁄rs” is the ratio of Fresnel amplitudes and is directly related to the angle 
of incidence and the wavelength of the light, the thickness of the biofilm and the 
refractive indexes of the substrate, the solvent and the biofilm (133-135). 
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Therefore, the measured Δ and Ψ are directly related to the refractive index and the 
thickness of the film. In the present study, Δ and Ψ were measured over a range of 
wavelengths from 380 to 1000 nm with an angle of incidence of 70 degrees. In 1978, 
De Freijter et al. (136) described the use of SE to relate the refractive index 
increment, dn/dc with the areal mass density (Γ) of adsorbed BSA and other proteins 
and established the Equation 9, the De Freijter approximation of areal mass. Using 
SE, one can therefore quantify the amount of biomolecules on a given surface area. 
1.6.3 Confocal microscopy 
Confocal microscopy originated as a technique to overcome optical challenges in 
traditional fluorescence microscopy. In fluorescence microscopy, when the sample is 
illuminated, the resulting fluorescence that is detected by the photodetector comes 
from the whole sample, so areas both in and outside the focal plane. In confocal 
microscopy the fluorescence that is detected goes through a pinhole to reduce the 
out-of-focus fluorescence. The diameter of the pinhole can be adjusted to detect the 
fluorescence in an area of interest, though this may alter the amount of out-of-focus 
light that is eliminated (Figure 1.14Error! Reference source not found.). 
Fluorescence occurs when a molecule absorbs a photon and then, following internal 
energy transfers, re-emits a photon at a longer wavelength. Fluorescent tags are 
often used in cell biology to track biomolecules and label cellular components. In this 
study, we used fluorescently labelled SAv as a marker of lateral mobility of GAG 
brushes and tracked halotagged FGFs in models of the ECM and on fixed cells.  
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Figure 1.14: Diagram of the confocal microscopy working principle.  
A simplified diagram of the confocal microscope and its optical components. A laser is 
beamed on a sample and the emitted fluorescence is focused at a pinhole placed before the 
detector (blue lines). Any emitted light that was out of the focal plane (pink lines) is not 
focused and thus will not be included in the images. Extracted from (146). 
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2 Aims and objectives 
The aim of this thesis is to start to develop an understanding of how the structure of 
the ECM may regulate signalling by its transient protein residents that enable 
intercellular communication, such as growth factors, morphogens, cytokines and 
chemokines. This thesis focuses on FGFs, and the study will start by using biomimetic 
models of ECM, and probing these with FGFs. The biomimetic models consist of an 
HS brush formed by one-end anchoring HS chains via a streptavidin (SAv)-biotin bond 
on a lipid bilayer. The effect of FGF binding on the organisation of these ECM and HS 
chains can then be probed quantitatively and we can also observe and evaluate the 
mobility of FGFs in them. In parallel the binding and mobility of FGFs in native fixed 
pericellular matrix of keratinocytes will be measured to provide an insight into 
similarities and differences between the HS brush model and ECM. In this way, an 
understanding will be gained of: 
1. the effect of FGF binding on the supramolecular organisation of 
glycosaminoglycans, 
2. the effect of glycosaminoglycan (model) matrices on FGF retention and 
mobility, and 
3. the comparability of the binding and diffusion of FGFs in ECM models and 
in the native pericellular matrix of keratinocytes 
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3 Experimental strategy 
3.1 A well-defined biomimetic model of the ECM  
The model was first established in previous studies (120) and consists of a soft and 
highly hydrated arrangement of GAG chains specifically anchored on a lipid bilayer 
through a SAv linkage (Figure 3.1). The 2-dimensional mobility of SAv, and thus of the 
GAG brush can be restrained by increasing the SAv coverage. The SAv coverage is 
determined by the percentage of biotinylated lipids in the SUV preparation (see 
Chapter 4.2.2). The model is a simple representation of the ECM that can be built 
layer-by-layer in different experimental setups and, therefore, various 
characterization techniques can be applied that are not accessible for the 
characterization of the ECM on cells. We used spectroscopic ellipsometry to quantify 
the surface density of molecular components, QCM-D to measure viscoelastic 
changes upon protein interaction with the GAG brushes and fluorescence microscopy 
after photobleaching (FRAP) to evaluate the molecular mobility of the SAv, as a proxy 
for the HS chains and of the FGFs. 
 
 
Figure 3.1: HS brush – a well-defined ECM model. 
Experimental model supported by a SiO2 sensor (in QCM-D and SE apparatus) or a glass cover 
slip (in FRAP assays). The supported lipid bilayer is formed by the adsorption and subsequent 
rupture of biotinylated small unilamellar vesicles (SUVs). The 2 dimensionally mobile SAv or 
Sav* (Atto488 labelled Sav) layer is specifically formed on the bilayer and further exposed to 
biotinylated GAGs. FGFS are presented to the model and changes upon binding are 
monitored by QCM-D, SE and FRAP imaging. Legend: purple dots: biotin, red dot: biotin 
binding pocket in Sav. 
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3.2 Production and purification of FGF proteins 
A bank of plasmids containing FGF proteins is available in Liverpool along with protein 
expression Escherichia coli strains. The purification of FGF proteins is based on their 
affinity to heparin, their surface charge, and whether or not they contain a halotag 
or a 6-histidine tag. The purification principles that will be used are hep affinity, ion-
exchange and Immobilized metal ion affinity chromatography (IMAC) on Ni2+. 
Available proteins include FGF1, FGF2, FGF4, FGF6, FGF7, FGF9, FGF10, FGF17, FGF18 
and FGF20, and mutants of FGF2 where the hep binding residues in the secondary 
sites were mutated to alanine. 
3.3 Quartz crystal microbalance with dissipation monitoring and 
spectroscopic ellipsometry monitoring of the establishment of 
ECM models 
The preparation of ECM models will be followed and assessed using the quartz crystal 
microbalance with dissipation monitoring (QCM-D) technology. The system allows 
the monitoring of the deposition of soft films on the sensors. The processed data 
gives information on the areal mass density deposited on the surface (including 
hydrodynamically coupled solvent) and the viscoelastic properties of the film. The 
two are related since the amount of substances on the surface might impact the 
structural organisation of the film, and thus the softness. The ECM models used are 
well-defined (Figure 3.1Error! Reference source not found.) and the QCM-D 
technology allows the assessment of the interactions of FGF proteins with the ECM 
models.  
Spectroscopic ellipsometry (SE) allows the monitoring of the formation of the ECM 
models by measuring the changes in polarisation of light after reflection at a surface. 
The technique enables the quantification of the areal mass density of adsorbed 
material on the surface and, therefore, the determination of the absolute areal mass 
density of GAGs and FGFs. 
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3.4 FRAP assessment of FGF interaction with HS films. 
Fluorescent labelling and imaging of the streptavidin monolayer allows the analysis 
of the lateral diffusion of HS in the brush (Figure 3.1). Cross-linking of HS by the 
binding of multivalent FGF proteins can restrain the mobility of HS, and as a 
consequence, the mobility of streptavidin (SAv). The relative cross-linking of HS 
brushes by FGF proteins can be observed by a decrease in the lateral mobility of the 
SAv monolayer. To do so, a biotinylated lipid bilayer is formed on a glass slide and 
labelled with a fluorescent partial monolayer of SAv. The HS film is formed on the 
SAv monolayer through the biotinylated reducing end of the polysaccharide. The 
formed HS film is then exposed to FGFs, and FRAP enables quantification of changes 
in the physical parameters that characterise the mobility of HS, i.e., the mobile 
fraction(s) and their associated diffusion constants. It will also be possible to evaluate 
the mobility of fluorescently labelled FGFs in the ECM models. For this purpose, HS 
will be grafted on a complete SAv monolayer, in which case SAv forms two-
dimensional crystal on the supported lipid bilayer and therefore is largely immobile, 
and FGF proteins will be produced with an N-terminal Halo tag. The latter will then 
be labelled specifically with a fluorescent dye. The mobility of the complex in the ECM 
model and the pericellular matrix of fixed keratinocytes (HaCaT cells) will be assessed 
by FRAP. 
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4 Methods 
4.1 FGF production, purification and molecular biology 
4.1.1 Media, buffers and plate preparation 
Lysogeny broth (LB) agar plates were prepared by solubilizing 27 g LB agar (Merck, 
Hertfordshire, UK) granules in 1 L of reverse osmosis (RO) water and pipetting 15 mL 
of the autoclaved solution into petri dishes. Antibiotic supplemented LB agar plates 
were prepared by adding the desired amount of antibiotic to the cooled LB agar 
solution before adding it to the petri dishes. LB media solution was prepared by 
solubilizing 20 g LB granules in 800 mL of RO water and autoclaving it. For 1 L of super 
optimal broth (SOB), 20 g of bactotryptone® (SLS, Nottingham, UK), 5 g of yeast 
extract (Merck), 0.5 g of sodium chloride (Sigma-Aldrich, Dorset, UK) were solubilized 
in 990 mL of RO water and autoclaved. The SOB media was completed by adding 10 
mL of magnesium chloride (2 M) after autoclaving. For 500 mL of frozen storage 
buffer (FSB), 5 mL of potassium acetate (1 M, pH 7.5), 4.45 g of manganese (II) 
chloride tetrahydrate, 0.78 g of calcium chloride dihydrate, 3.37 g of KCl, 0.40 g of 
Hexamine cobolt chloride and 50 mL of glycerol (all chemicals were from Sigma-
Aldrich) were solubilised in RO water, sterile filtered and stored at 4°C before usage. 
Phosphate buffer saline (PBS): 137 mM NaCl, 2.7 mM KCl and 10 mM disodium 
phosphate and 1.8 mM potassium phosphate monobasic pH 7.4 was prepared by 
dissolving PBS tablets (Sigma) in the suggested amount of RO water. 
4.1.2 Expansion of competent cells (DH5α and C41 (DE3) pLysS) 
Escherichia coli strains DH5α and C41 were expanded and made competent for 
plasmid intake using the Hanahan method. A 50 µL aliquot of cells from the in-house 
stock was spread on a LB agar plate and incubated overnight at 37°C. One colony was 
picked and inoculated in a round bottomed flask with 100 mL SOB medium. The 
culture was incubated at 37°C while shaking at 240 rpm until OD600 reached 0.5 A.U. 
The cells were cooled on a wet ice bath for 20 min before being harvested by 
centrifugation (10 min, 1100 g at 4°C). The pellets were gently resuspended in 24 mL 
of ice cold FSB and incubated on wet ice for another 20 min. The cells were harvested 
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by centrifugation and gently resuspended in 8 mL of cold FSB. dimethylsulfoxide 
(DMSO) (Sigma-Aldrich) (280 µL) was added to the cells and they were incubated for 
5 min on ice, this step was repeated and the cells were dispensed 100 µL in sterile 
Eppendorf tubes. The aliquots were flash frozen in a dry-ice-ethanol bath before 
being stored at -80°C.  
4.1.3 Plasmid design, transformation and amplification 
The DH5α strain was transformed for plasmid amplification. An aliquot of the frozen 
cells and of plasmid were thawed on ice for 5 min. 1-2 µL (200 ng) of plasmid were 
added to the cell aliquot and the mixture was placed on ice for 40 min. The mixture 
was then heat shocked in a 42°C water for 45 s and chilled on ice for 2 min before 
being plated on a LB agar plate supplemented with the appropriate antibiotic (50 
μg/mL ampicillin or 100 μg/mL kanamycin sulfate) (Sigma-Aldrich); the plate was 
then incubated overnight at 37°. The expression plasmids based on the pET-14-b and 
pETM-11 vectors contain a gene encoding for resistance to ampicillin and kanamycin, 
respectively. Cells transformed with pET-14-b and pETM-11 plasmids were cultured 
in the presence of ampicillin and kanamycin, respectively, as a means of selection. 
On the next day, a single colony was inoculated into 50 mL LB medium supplemented 
with the appropriate antibiotic and incubated overnight (37°C, 250 rpm). The next 
day the bacteria were collected by centrifugation (15 min, 2800 g, 4°C). The 
supernatant was discarded, the plasmid was extracted using the QIAprep Spin 
Miniprep Kit (Qiagen, Manchester, UK) according to the manufacturer’s instructions 
and stored at -20°C. 
A cDNA encoding for a mutant of FGF2 with a silenced hep binding site 3 (160K/A, 
163K/A and 164R/A) (FGF2 HBS3-) (Life Technologies, Paisley, UK) with restriction 
sites for BamHI (New England Biolabs, Ipswich, USA) and NcoI (New England Biolabs) 
was amplified by polymerase chain reaction and inserted in the plasmid vector pET-
M11 using the T4 DNA ligase (New England Biolabs)  
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4.1.4 Protein expression and purification 
One hundred ng pET-14b-FGF2 (Uniprot P09038-2; residues 1-155), pETM-11-FGF9 
(Uniprot P31371; residues 1-208), pET-M11-HBS3, pET-M11-FGF18 (Uniprot O76093; 
residues 1-207), pET-14b-HaloFGF2, pET-14b-HaloFGF6 (Uniprot P10767; residues 
38-208) or pET-14b-HaloFGF20 (Uniprot Q9NP95; residues 1–211) plasmids were 
transformed into CL41 (DE3) cells and plated on lysogeny broth, LB-agar plates 
supplemented with appropriate antibiotic (see 4.1.34.1.3). The plate was incubated 
for 16 h at 37°C. LB supplemented with the appropriated antibiotic (50 mL) was 
inoculated with 1 colony from the plate and incubated for 16 h at 37°C at a shaking 
rate of 240 rpm. Three flasks of 800 mL of LB supplemented with the appropriated 
antibiotic were inoculated with 800 µL of the previous culture and incubated at 37°C 
at a shaking rate of 240 rpm until the OD600 reached 0.4-0.5 AU. The expression of 
protein was then induced by adding isopropyl β-D-1-thiogalactopyranoside (IPTG) to 
1 mM at 16°C and shaking at 180 rpm for 16 h. The cells were collected by 
centrifugation at 11000 g and 4°C for 30 min. The supernatant was discarded and the 
cell pellet resuspended in 60 mL cell lysis buffer P1: 0.6 M NaCl (Sigma-Aldrich), 10 
mM HEPES (Sigma-Aldrich), 1 mM dithiothreitol (DTT, Sigma-Aldrich), pH 7.4. Cell 
breakage was achieved by sonicating (40 % duty cycle) the suspension for 30 s and 
placing it on ice for 1 min. This cycle was repeated 6 times and the suspension was 
centrifuged at 38000 g, 4°C for 30 min to remove cell debris and insoluble protein 
aggregates/inclusion bodies. Recombinant protein was purified from the 
supernatant using procedures previously established in the research group (56, 104, 
121). FGF1, HaloFGF1, FGF4, FGF10, HaloFGF10, FGF17, HaloFGF17 and HaloFGF18 
were previously purified following these procedures by group members: Sun 
Changye, Li Yong, Bui Phuong Thao and Ngamlert Pawin.  
4.1.4.1 FGF2 purification 
A 0.45 µm filter was used to clarify the supernatant containing FGF2 protein, which 
was then applied onto a 1 mL agarose hep (BioRad, Hercules, USA) column at 1 
mL/min. Following a wash with 30 mL of P1, bound protein was eluted with 8 mL of 
(2 M NaCl, 10 mM HEPES, 1mM DTT, pH 7.4). The eluate was then diluted 3-fold with 
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P0 (10 mM HEPES, 1mM DTT, pH 7.4), applied to a 1 mL Hitrap Hep column and eluted 
with a NaCl gradient from 0.9 M NaCl to 1.5 M NaCl in 10 mM HEPES, pH 7.4 using an 
AKTA system. The collected fractions were analysed on a SDS-PAGE gel and the 
fractions containing a protein with a size around 17 kDa (the size of FGF2 is 17.2 kDa) 
were kept for further purification. The fractions containing FGF2 were pooled and 
diluted 10-fold with P0. The sample was applied to a cation-exchange column (1 mL 
CaptoS, GE Healthcare) and eluted with a NaCl gradient between 0.1 M and 2 M NaCl 
in 10 mM HEPES, pH 7.4 using the same AKTA system. The fractions were analysed 
by SDS PAGE and the ones containing a band around 17 kDa were kept for further 
purification. These fractions were pooled and diluted 4-fold with P0. The sample was 
loaded on a 1 mL Hitrap Hep column, washed with P1 (10 mM HEPES, 0.6 M NaCl, pH 
7.4) and eluted with P4 (10 mM HEPES, 2 M NaCl, pH 7.4). The protein concentration 
was measured by reading the absorbance at 280 nm, and the sample stored at -80°C 
in aliquots before usage. 
4.1.4.2 Purification of halotagged FGFs 
The samples containing Halo tagged FGF2 (HaloFGF2) protein were applied onto a 1 
mL agarose hep (Bio-Rad, Hercules, USA) column at 1 mL/min, and then washed with 
30 mL P1. The proteins were then eluted with 8 mL of P4, and the eluate was diluted 
3-fold with P0. The diluted sample was applied onto a 1 mL Hitrap Hep column and 
eluted with a NaCl gradient between 0.9 M and 1.5 M NaCl in 10 mM HEPES, pH 7.4 
using an AKTA system. The collected fractions were analysed on a SDS-PAGE gel and 
the fractions containing a protein with a size around 52 kDa (which corresponds to 
the size of HaloFGF2) were kept for further purification. The fractions were pooled 
and diluted 10-fold with P0. The sample was applied to an anion-exchange column (1 
mL CaptoQ, GE Healthcare) and the halotagged FGF eluted with a 0.2 M NaCl, 10 mM 
HEPES, pH 7.4. The protein concentration was measured by measuring the 
absorbance at 280 nm and stored at -80°C in aliquots. 
4.1.4.3 Purification of his tagged FGFs FGF2 HBS3-, FGF18 and FGF9 
His tagged FGF9 (FGF9) and FGF18 (FGF18) proteins have an N-terminal his6 
sequence. FGF2 HBS3- is an in-house engineered protein where the identified lysines 
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and arginine residues considered to be part of HBS3 (82) were mutated to alanine. 
The DNA was ordered and ligated into pET-M11. Thus the plasmid, pET-M11-HBS3 
was designed to produce an N-terminally his tagged FGF2 with a non-functional 
HBS3. 
For all three proteins, following cell breakage and purification on hep agarose 
(Section 4.1.4.1, the eluate was diluted 3-fold with 10 mM HEPES, 60 mM imidazole, 
1 mM DTT, pH 7.4. The diluted sample was loaded on a 1 mL Histrap nickel (GE 
Healthcare) column and eluted with a competitor gradient between 50 mM and 500 
mM imidazole in 10 mM HEPES, 0.5 M NaCl, pH 7.4 using an AKTA system. In each 
case, the collected fractions were analysed by SDS-PAGE and the fractions containing 
proteins with a size around 26 kDa (for hisFGF9), 18 kDa (for FGF2 HBS3-) and 23 kDa 
(for FGF18) were kept for further purification. The fractions were pooled and loaded 
on a 1 mL Hitrap Hep column, washed with P1) and eluted with P4. The protein 
concentration was measured by reading the absorbance at 280 nm, the sample 
stored at -80°C in aliquots. 
4.1.5 SDS-PAGE electrophoresis 
For SDS-PAGE, samples were mixed with 5× sample buffer: 2% (w/v) bromophenol 
blue (Sigma-Aldrich), 50 % (v/v) glycerol, 10 % (w/v) SDS and 25 % (w/v) 2-
mercaptoethanol (Sigma-Aldrich) in 315 mM Tris (hydroxymethyl) methylamine Cl 
(Tris-Cl, Sigma-Aldrich, pH 6.8) in a ratio of 4:1 (v/v). Five µL of this sample was mixed 
with 45 μL 1× sample buffer. The samples were then heated at 95°C for 10 min and 
centrifuged at 13000 rpm for 10 min to remove any insoluble material. The gels were 
loaded with 10 µL sample per well and electrophoresis was carried out at 200 volt (V) 
and 60 milliampere per gel for 45 min. The gels were either 4-15 % (acrylamide w/v) 
gradient SDS-PAGE gels purchased from Bio-Rad via Teknovas (San Sebastian, Spain) 
or prepared as follows: the gels were prepared in a 0.75 mm thick spacer glass plate 
apparatus, where 3.4 mL of the resolving gel was poured and polymerized in situ, 
covered by a layer of water. After polymerization, the water was discarded and 
replaced by the stacking gel solution. A 10-well forming comb was placed in the 
stacking gel solution and let to mould the well while the gel polymerized. The gels 
35 
 
were then soaked in a Coomasie blue solution, 1% (w/v) Coomasie blue (Sigma-
Aldrich), 1.5% (v/v) glacial acetic acid and 25% (v/v) ethanol in water for 30 min, then 
de-stained in de-staining buffer, 10% (v/v) glacial acetic acid (Sigma-Aldrich) and 30 
% (v/v) ethanol (Sigma-Aldrich) in water, until the background became clear. 
For the preparation of 4 gels with a 15 % (w/v) acrylamide/bis-acrylamide (Sigma-
Aldrich) resolving gel and a 6% (w/v) acrylamide/bis-acrylamide stacking gel, the two 
solutions were prepared as described in Table 1. 
Table 1: SDS PAGE gel preparation recipe 
Components Resolving gel 
(volume) 
Stacking gel (volume) 
Acrylamide/bis-acrylamide 
stock (30%, w/v) 
10 mL 1.4 mL 
Tris-Cl (3 M, pH 8.8) 5.2 mL x 
Tris-Cl (1.25 M, pH 6.8) x 2.5 mL 
Water 4.4 mL 3 mL 
10% (w/v) SDS 200 µL 100 µL 
TEMED 20 µL 10 µL 
Ammonium persulfate (50 g/l) 200 µL 100 µL 
 
4.2 Supported extracellular matrix models. 
The HEPES buffer (HB) was prepared in glass bottles that were cleaned by rinsing with 
acetone, ethanol (2 times) and water (10 times) and subsequent drying. HEPES and 
NaCl were dissolved in ultrapure water at 10 mM and 150 mM, respectively, the pH 
was adjusted to 7.4 with HCl. The solution was filtered through 2 µm pore filters. 
4.2.1 Treatment of substrates for QCM-D, SE and FRAP measurements.  
Silica coated QCM-D sensors (QSX303, Q-sense, Gothenburg, Sweden) were placed 
in 2% (w/v) sodium dodecyl sulfate for 30 min, rinsed with ultrapure water and dried 
under a nitrogen flow. The surfaces were further cleaned by treatment with 
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UV/ozone for 30 min using a Compact UV-Ozone Cleaner Chamber (BioForce 
Nanosciences, Ames, IA, USA). The surfaces were then placed in the QCM-D chamber 
for QCM-D measurements. 
Silicon wafers with a native silicon oxide coating for spectroscopic ellipsometry were 
cleaned with acetone, rinsed with water and dried under nitrogen flow. The surfaces 
were further cleaned by treatment with UV/ozone for 30 min. 
For FRAP, 1.5 mm glass cover slips were cleaned by dipping them in piranha solution, 
a 3:1 mixture of H2SO4 (99% pure, Sigma) and 30% H2O2 for 1 h, rinsed with ultrapure 
water and blow dried with nitrogen. Before use, the cover slips were rinsed with 
absolute ethanol, ultrapure water, blow dried under nitrogen and further cleaned by 
UV/ozone treatment for 30 min. 
4.2.2 Preparation of small unilamellar vesicles (SUV) for supported lipid 
bilayers. 
To form small unilamellar vesicles (SUV), a standardised sonication procedure was 
applied to the lipid components (122). A mixture of 1,2-dioleoyl-sn-glycero-3-
phosphocholine (DOPC; Avanti, Alabaster, USA) and 1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine-cap-biotin (DOPE-CAP-B; Avanti) in chloroform was dried and 
re-solubilised in HB at the desired concentration and ratio. For a 95:5 ratio of DOPC: 
DOPE-CAP-B SUVs: 1.79 mg of DOPC (64.31 µL of the 27.87 g/L stock solution in 
chloroform) and 0.13 mg of DOPE-CAP-B (5.06 µL of the 26.2 g/L stock solution in 
chloroform) were mixed, dried and resuspended in 0.96 mL HB. The final 
concentration of DOPC: DOPE-CAP-B was 2 mg.mL-1. For the preparation of 99.5:0.5 
DOPC:DOPE-CAP-B SUVs, 1.88 mg DOPC and 0.01 mg DOPE-CAP-B were mixed, dried 
and resuspended in 0.95 mL of HB. The solution was frozen in liquid nitrogen and 
thawed repetitively 5 times and then sonicated twice on a wet-ice bath for 15 min 
using a 3 mm microtip sonicator (Branson 450 Cell disruptor, Branson, Connecticut, 
Danbury, USA) in pulse mode at 30 % duty cycle. The solution was centrifuged 10 min 
at 16000 g to remove any titanium particles coming from the tip sonicator. The SUV 
solutions were then stored in aliquots at 4°C under an argon atmosphere. 
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4.2.3 Biotinylated glycosaminoglycans  
Biotinylated HS was kindly provided by Dhruv Thakar (Université Grenoble Alpes, 
France). Briefly, HS from porcine intestinal mucosa (Celsus Laboratories, Cincinnati, 
OH, USA) was conjugated with biotin via a 1 nm long oligoethylene glycol linker. 
Oxime ligation was used to specifically conjugate the HS at the reducing end with a 
hydrazide functionalised biotin (123). The HS was previously characterised as 
polydisperse with an average molecular weight of 12 kDa and a dispersity index, Đ of 
1.59 (124). Biotinylated hep (Hep, 13 kDa), chondroitin sulfate A (CS-A, 30 kDa), 
chondroitin sulfate C (CS-C, 26 kDa), chondroitin sulfate E (CS-E, 26 kDa) and 
dermatan sulfate (DS, 6.5 kDa) were provided by Xu Wang (University of Illinois, 
Arizona). Their disaccharide composition and average molecular weight are 
presented in Table 2. Monodisperse DS (dp18) was purchased from Iduron (Alderley 
Edge, United Kingdom) and is characterised by 88% of IdoA – GalNAc,4S and 7% of 
IdoA,2S – GalNAc,4S (125). DS (dp18) was biotinylated by Pawin Ngamlert (University 
of Liverpool). In all these cases oxime ligation was used.  
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Table 2: Disaccharide repeat of glycosaminoglycans. 
Table adapted from information provided by Xu Wang (University of Illinois, Arizona) 
GAG (average size) Disaccharide unit 
CS-A (30 kDa) 
GlcA-GalNAc-4S 
 
CS-C (26 kDa) 
GlcA-GalNAc-6S 
 
CS-E (chemically sulfated CS-C, 26 kDa) 
GlcA-GalNAc-4,6-diS 
 
DS (6.5 kDa) 
IdoA-GalNAc-4S 
 
 
4.3 Quartz crystal microbalance with dissipation monitoring (QCM-
D). 
4.4 Quartz crystal microbalance with dissipation monitoring (QCM-
D). 
Prior to QCM-D measurement an old sensor was placed in the chamber as a template 
to help passivation of the chamber walls. The chamber was infused with an aqueous 
solution of 10 g/L of BSA then rinsed with water, both steps for 20 min at a 20 µL/min 
flow. The template sensor was then removed from the chamber, and the chamber 
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walls were dried under a flow of nitrogen. During QCM-D measurements, all 
substances were infused through passivated tubings at 20 µL/min or as stated 
otherwise. 
To investigate the softness of the GAG brushes upon interaction with cytokines, -
ΔD/Δf as a function of Δf, with ΔD/Δf being proportional to the elastic compliance (a 
physical measure of softness), and Δf, a measure of areal mass density of the film at 
the surface. Our models (see Chapter 3.1) fall under the condition of being films much 
thinner than the penetration depth of the shear wave in liquid which is 250 nm for 
the fundamental frequency in water (130, 131), and the following equation (130) can 
then be exploited:  
𝜟𝜞𝒊
𝜟𝒇𝒊
=  − 𝒊 𝝎𝑭 𝜼 𝑳 𝑱’ ∗  (𝝆𝑳/𝝆)     Equation 7 
 
Thus, 
𝜟𝑫/𝜟𝒇 =  (𝟒 𝝅 𝒊 𝜼𝑳 𝝆𝑳/𝝆)  ×  𝑱′    Equation 8 
 
Where J’ is the elastic compliance of the film, ηL and ρL are the viscosity and the 
density of the liquid bulk solution, ρ the density of the film and ωF = 2 π f1 is the 
angular fundamental resonance frequency. In our conditions, ηL = 0.89 mPa·s, ρL = 
1.0 g cm−3 and ρ ≈ 1.0 g cm−3.  
 
4.5 Spectroscopic ellipsometry applied to ECM models. 
In-house designed 110 µL chambers for in situ SE measurements (137) were cleaned 
as follows: 2% SDS for 10 min, thoroughly rinsed with ultrapure water, ethanol and 
ultrapure water again. The chamber was dried under nitrogen flow before being 
passivated in 10 mg.mL-1 bovine serum albumin (BSA) for 10 - 20 min. The chamber 
was rinsed with ultrapure wat er and dried under nitrogen flow before usage. 
The data, Δ and Ψ as a function of λ was fitted with a multi-layer model using the 
software CompleteEASE. The model consisted of a planar silicon substrate, followed 
by a thin silicon oxide layer, the biomolecular film and the ambient solvent. The 
optical properties of the silicon substrate are tabulated in the software. The optical 
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properties of the silicon oxide layer, the biomolecular film and the ambient were 
approximated as Cauchy materials. In 1836, Cauchy described, for transparent 
materials, which do not absorbed light in the visible range, the relationship between 
their refractive index and the wavelength they are exposed to, and found the relation 
n (λ) = A + B / λ2 to fit the data well. 
The initial silicon oxide layer was modelled as a transparent Cauchy layer and its 
parameters Ao and Bo determined the refractive index, no (λ) = Ao + (Bo / λ2). The 
parameters Ao and Bo, and the Thickness of the dry and in-solvent silicon oxide layer 
were characterised before each measurement to be used as a reference. To do so, 
the refractive index of the solvent ns was calculated from available tables in the 
literature as ns (λ) = 1.325 + (0.00322 / λ2) (132, 138).  
To calculate the molecular density of adsorbed layers of biomolecules on the silicon 
oxide layer, we treated the biomolecular film as a single transparent and 
homogenous layer. Their parameter Blayer was fixed to 0.00322 (that is, identical to 
the solvent) and Alayer and the thickness, θlayer were used as adjustable fit parameters 
in the model. From the results, the refractive index of the biomolecular film is given 
by nlayer (λ) = Alayer + Blayer / λ2. The molar surface density of biomolecules is then given 
by De Fejter’s equation (139): 
Equation 9:      Γ =  
1
𝑀𝑊
 
θlayer (nlayer−ns)
𝑑𝑛 𝑑𝑐
⁄
 
Here, dn/dc is the refractive index increment of the biomolecule (132), and reflects 
how the refractive index n changes with the concentration c. We used refractive 
index increments, dn/dc, of 0.132 cm3/g for hep(140) (141), 0.180 cm3/g for all 
proteins (142) and 0.169 cm3/g for lipids (143-145). 
4.6 FRAP of extracellular matrix models 
A LSM700 confocal microscope (Zeiss, Jena, Germany) was used to acquire imaging 
data with a 561 nm excitation laser and a 590 nm emission filter for detection. For all 
FRAP measurements, a 63×/1.4 oil DIC oil immersion lens was used and images were 
120 * 120 µm2 (256*256 pixels). The laser intensities were 0.6 % for imaging and 100 
% for bleaching. The pinhole size was 1 airy unit and the intensity resolution 12 bit. 
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4.6.1 FRAP assessment of the lateral mobility of GAG 
To assess the mobility of HS brushes in the absence and presence of FGFs, we used a 
well-defined model of the ECM, as presented in Chapter 3.1. This model was 
established in a previous study (120). The cover slips were glued to a 4-well teflon 
holder using freshly mixed bi-component dental glue (Picodent) (Figure 4.1). After 
the glue had dried, the supported lipid bilayer (SLB) was formed by adding SUVs of 
DOPC: DOPE-CAP-B 99.5:0.5 (mole/mole) on the dry and clean surface to a final 
concentration of 50 µg/mL. The SUVs were incubated for 30 min in the well before 
rinsing. The SLB was labelled with fluorescent SAv by adding atto 565-SAv to a final 
concentration of 20 µg/mL and incubating for 30 min. After rinsing, the biotinylated 
GAGs were added to the wells at a final concentration of 5 µg/mL and incubated for 
30 min. After rinsing, FGF proteins were added at the concentrations indicated in the 
figure legends and FRAP measurements were taken at each step.  
 
 
Figure 4.1: Schematic illustration of the custom-made sample holder for FRAP 
measurements. 
 
FRAP measurement were set as follows: 3 images were taken before bleaching of a 
circular region of interest. The fluorescence recovery due to lateral mobility of lipids 
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was measured by a series of images, every second up to 1 minute, then every 5 
seconds up to 2 minutes and finally every 15 seconds until the end of the experiment. 
The images were treated using a Matlab based program that fits the collected data 
with a lateral diffusion model (83). For each image taken after bleaching, the Time-
resolved Profile Analysis (TPA) algorithm program corrects for the background 
fluorescence and generates an average radial profile (147). The profile is then 
compared to the solution of a diffusion equation. The diffusion model contains one 
mobile fraction and one immobile fraction. The mobile fraction is defined by its 
relative proportion and diffusion constant (147, 148). The fluorescent recovery 
curves were also plotted according to the data treatment process explained in 4.6.4. 
4.6.2 FRAP assessment of growth factor mobility  
To assess the mobility of FGFs in the GAG brushes, HS chains were immobilised via 2-
D SAv crystals. 2-D SAv crystals were previously observed on lipid bilayers using 
atomic force microscopy and occur when a high concentration of SAv is used on a 
SLB with a high proportion of biotinylated lipid (149). Thus, by using these conditions 
the formation of virtually immobile fluorescent SAv crystals was observed (Figure 
4.2). Immobilising the GAGs on the immobile SAv, therefore, allowed the mobility of 
fluorescently labelled Halo tagged FGFs in the brushes to be measured with no 
interference from the intrinsic mobility of the HS brush due to the lateral mobility of 
lipids. 
The immobile GAG brushes were supported on a glass cover slip as described in 4.6. 
The SLB was formed by adding SUVs of DOPC:DOPE-CAP-B 95:5 (mole/mole) on the 
dry and clean surface to a final concentration of 50 µg.mL-1. The SUVs were incubated 
for 30 min in the well before rinsing. The SLB was labelled with fluorescent SAv or 
functionalised with SAv by adding atto-SAv or SAv, respectively to a final 
concentration of 20 µg/mL and incubating for 30 min. After rinsing, the biotinylated 
GAGs were added to the wells at a final concentration of 5 µg/mL and incubated for 
30 min. The 5% (mole/mole) biotinylated lipid fraction allows full coverage of the 
bilayer with atto-SAv. 2-D SAv crystallisation depends on the assay conditions 
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including pH and ionic strength (150), and the incubation buffer (50 mM HEPES, 150 
mM NaCl, pH 7.4) allows the formation of immobile 2-D SAv crystals (Figure 4.2).  
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Figure 4.2: Time resolved formation of streptavidin crystals for GAG immobilisation on a 
supported lipid bilayer. 
The SLB was made from 95:5 DOPC: DOPE-CAP-Biotin SUVs, and incubated with fluorescent 
SAv at a final concentration of 20 µg/mL. Fluorescent images were taken in series 
immediately after the injection of the fluorescent SAv at different times to follow the 
formation of SAv crystals. The expansion of crystals was observed over time. The variable 
intensities between crystallites are likely due to the different orientation of the fluorophores 
in the polarized laser light which affects fluorescence excitation. 
 
After rinsing, halotagged FGF proteins were added at the concentrations indicated in 
the figure legends and FRAP measurements were taken as follows: 3 images were 
taken before bleaching of a circular region of interest. The fluorescence recovery due 
to mobility of halotagged FGFs was measured by a series of images (intervals: every 
second for 1 minute then every 5 seconds for 1 minute and finally every 15 seconds) 
for 300 or 600 seconds. Collection of the average fluorescence in the bleached area 
as a function of time gives information on the potential mobility of FGFs in ECM 
models. The fluorescence recovery curves were plotted according to the data 
treatment process explained in 4.6.4. 
4.6.3 FRAP of labelled FGFs on HaCaT cells 
The mobility of fluorescently labelled FGFs was assessed in the pericellular matrix of 
keratinocytes. To do so, the cells were fixed as described in 4.7 so innate cellular and 
cytoskeletal movement would not contribute to the movement of the labelled FGF. 
Halotagged FGFs were labelled by reacting the halotag with a fluorescent 
chloroalkane ligand, chloroalkane-Tetramethylrhodamine, chloroalkane-TMR 
(Promega, Southampton, UK). Halotagged FGFs were mixed with the chloroalkane 
TMR at a 1:5 molar ratio and incubated at room temperature for 30 minutes before 
usage directly on the fixed cells. The native matrix served as a mean of in situ 
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purification step, it retained the labelled HaloFGF while the free dye was removed by 
rinsing.  
The fixed cells were incubated with 2 nM of TMR-Halo-FGF by adding the labelled 
protein to the dishes and placing them in the incubator for 30 min. Before the FRAP 
measurement, the cells were rinsed three times with PBS. A LSM780 confocal 
microscope (Zeiss, Jena, Germany) was used to acquire cell imaging data with a 561 
nm excitation laser and a 590 to 765 nm emission filter for detection. For all FRAP 
measurements, a 63X/1.4 oil DIC oil immersion lens was used and images were 22.49 
*22.49 µm2 (256*256 pixels) in size. The laser intensities were 0.6% for imaging and 
100% for bleaching. The pinhole size was 1 airy unit (0.47 µm) and the intensity 
resolution 8 bit. The fluorescence was recorded in three regions of interest (ROI) of 
2.5 µm (radius), a reference, a background and a bleached area. Six images were 
taken before bleaching, images were taken every second for 300 seconds after 
bleaching. The bleaching step consisted in radiating the ROI. 
4.6.4 Fluorescence recovery curves 
For all measurements the absolute fluorescence intensities of each region was 
extracted using the ZEN 2012 software (Zeiss). The intensities in the different ROIs 
are defined as: Ir in the reference area, Ib in the background and I in the bleached 
area at each time point. The photobleaching was corrected by the intensities in the 
reference area and normalised by the intensities before bleaching. The mean of the 
three or six (X= 3 or 6) values of the reference, Ir [1-X], was used to normalise the 
data. For the FRAP measurements on GAG brushes, the fluorescence recovery was 
monitored in the reference and the bleached areas only. However, an average 
background measurement was taken prior to the FRAP measurement (Figure 4.3).  
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Figure 4.3: Lateral mobility of an HS brush.  
An HS brush was established as described in 4.6.1 and the fluorescence in the Ib and the Ir 
was recorded. In this experiment, the HS brush recovered 100% of its fluorescence in the ROI 
within 100 seconds.  
 
The background and bleach corrected recovery level, Icn at a given time point was 
calculated as follows: 
Icn = Ic/Ic [1-X]     Equation 10 
 
Where Ic [1-X] is the average intensity in the X prebleach images and Ic is the corrected 
intensity as follow: 
 
Ic = (I – Ib) * (Ir [1-X] - Ib)/ (Ir – Ib)  Equation 11 
 
Where Ib is the intensity in the background area recorded prior to or concomitantly to the 
FRAP measurement. 
 
A graph of recovery level (Icn) = f(time) starting after bleaching was presented as 
means of at least 3 experiments as shown for bare HS brushes in Figure 4.4. 
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Figure 4.4: Fluorescence recovery curve of HS brushes.  
Illustrative curve of the lateral mobility of a bare HS brush as followed by FRAP. The mean 
recovery level of 8 measurements (including the figure 18), highlighted in black, is a plotted 
as a function of time. The grey area around the curve represents the standard deviation.  
 
4.7 Preparation of native extracellular matrix from eukaryotic cells. 
4.7.1 Cell culture routine 
The spontaneously immortalised human keratinocyte cell line (HaCaT) (151) was 
used. The HaCaT cells were grown in Dulbecco’s modified Eagle’s medium (DMEM, 
Life Technologies, Paisley, UK) supplemented with 10% (v/v) fetal calf serum (FCS, 
Labtech International Ltd, East Sussex, UK), 1% (v/v) antibiotics (10,000 μg/mL 
streptomycin and 10,000 units/mL penicillin) and 4 mM L-glutamine (Life 
Technologies) at 37°C with 10% (v/v) CO2 in a 10 cm round culture dishes (Corning, 
Nottingham, UK). Cells were subcultured when they reached 90% confluence by two 
washes with 10 mL sterile PBS and then incubated with 3 mL versene (Life 
technologies) for 5 min at 37°C, 10% (v/v) CO2. The versene was discarded and 
replaced by 1 mL versene/trypsine (versene containing 2.5% (v/v) of trypsin, Life 
technologies) and incubated for 5 more min at 37°C, 10% (v/v) CO2 to detach the 
cells. The action of the versene/trypsine was stopped by resuspending the cells in 9 
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mL of culture medium and2 mL of the resuspended cells was added to a new dish 
along with 8 mL of culture medium. 
4.7.2  Fixation of HaCaT cells 
From imaging purposes, HaCaT cells were cultured on glass-bottomed imaging dishes 
(CELLview™ culture dish: 35mm non-treated glass bottom, Greiner Bio-one, 
Stonehouse, UK). To do so, 0.5 mL of resuspended cells (see Section 4.7.1) were 
added to the dishes and supplemented with 1.5 mL of culture media, the dishes were 
then placed in the incubator for 24-48 h until they reached 90% confluence. The 
medium was then removed and the cells were washed three times with 2 mL sterile 
PBS and then fixed by adding 2 mL 4% (w/v) paraformaldehyde (PFA) in PBS for 15 
min at room temperature. The fixed cells were washed with PBS three times and 
incubated with 2 mL 10 mg/mL BSA in PBS for 15 min to block any remaining activity 
of the PFA. The BSA was discarded and the cells were incubated with the fluorescent 
probes or stored in 0.02% (v/v) sodium azide in PBS at 4°C before use. 
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5 Surface charges and heparin binding site distribution 
regulate dynamics of fibroblast growth factors in 
extracellular matrix models. 
5.1 Introduction 
In this chapter, the interaction of FGFs with HS brushes (section 5.2) and the 
subsequent supramolecular changes in the brush are measured.  The amino acid 
sequence of the FGFs provides a clear phylogenetic relationship of this family of 
proteins (Figure. 5.1). This reflects also their functions, so that FGFs in the same 
subfamily (so most closely related and on the same branch) possess more conserved 
structure-function relationships (section 1.4).  
 
 
Figure 5.1: Phylogenetic tree of FGFs.  
A phylogenetic tree of similarities was generated based on sequence multiple alignment with 
Clustal Omega online tool. The identified and reported HBSs are annotated (56, 104). The 
amino acid sequences of FGF 1 (P05230-1, residues 1-155), FGF2 (P09038-2, residues 1-155), 
FGF2 HBS3- (27 K/A, 30 K/A P09038-2, residues 1-155), FGF4 (P08620-1, residues 1-200), 
FGF6 (P10767-1, residues 1-208), FGF9 (P31371-1, residues 1- 208), FGF10 (O15520-1, 
residues 1-208), FGF17 (O60258-1, residues 1-216), FGF18 (O76093-1, residues 1-207), 
FGF20 (Q9NP95-1, residues 1-211) were submitted for similarity analysis on the Clustal 
Omega platform and a phylogenetic tree was generated from the results. Other FGFs used 
in this study were also included in the sequence alignment and are shown faded in grey. 
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HS brushes as a model of the ECM was used to quantify the binding of FGFs and 
assess the changes in mechanical properties of the brush when bound by different 
FGFs. FGFs of different subfamilies presenting a variety of HBSs combination were 
presented to the HS brush. Our study suggests that the presence of multiple HBSs 
and acidic borders isolating them regulates the cross-linking and the possible 
immobilization of HS chains in the brush. Here we suggest a hypothetical dichotomy 
based on surfaces charges to predict the entrapment of FGFs in HS brushes and their 
mobility. 
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Abstract 
Some fibroblasts growth factors (FGFs) have multiple heparin binding sites (HBS): a canonical (HBS1) 
and lower affinity secondary sites e.g. FGF2 and some are monovalent e.g. FGF9. The interaction of 
their HBS with heparan sulfate (HS) controls their interaction with FGF receptors (FGFRs) and their 
transport in the extracellular matrix (ECM). The native ECM is a complex compartment that contains 
many proteins and glycosaminoglycans that are interacting with each other in the manner of a bloc 
copolymer. To study its interactions with chemokines, we designed simple biomimetic models of the 
pericellular matrix heparan sulfate (HS). The models have been assembled layer by layer by graphting 
biotinylated HS oligosaccharides on a supported lipid bilayer via a streptavidin layer. These have been 
challenged with various FGFs and the interactions were followed by quartz crystal microbalance with 
dissipation (QCM-D), spectroscopic ellipsometry (SE) and fluorescence recovery after dissipation 
(FRAP). FGF2 has been shown to cross link HS chains, it is not known if this is a general property of 
FGFs with multiple HBS. If it is, then this raises some interesting possibilities, for example (i) FGFs may 
change the organization of extracellular matrix by cross linking HS chains; (ii) cross linking HS chains 
may result in FGFs becoming immobile, thus confined in the ECM. The data shows that FGF2 and 
mutants of its third heparin biding sites (HBS3): FGF2 HBS3-, FGF9 and FGF18 bind effectively heparan 
sulfate (HS) brushes in our systems. Real-time monitoring by QCM-D of the HS film interaction with 
FGFs allowed us to appreciate the binding of the FGFs by looking at the changes in frequency shift. 
The analysis of the dissipation data upon binding of FGFs gave clues about the rigidification of the HS 
film thus the potential crosslinking of the brushes. FRAP imaging of the streptavidin layer confirmed 
he crosslinking of HS brushes for FGF2, FGF2 HBS3- and FGF18 when FGF9 was found to not crosslink 
the brushes. Data from spectroscopic ellipsometry allowed us to quantify number of FGFs per HS. It 
revealed that FGF2 and FGF2 HBS3- equally bind HS brushes; this suggests that the functionality of 
some HBS is not necessary to the binding and confinement of FGF2 in HS brushes. Understanding the 
relative implication of the HBS in the function of the FGFs may give an understanding of their 
conservation/deletion throughout the FGF subfamilies. Acido-basic mapping of residues at the 
surfaces of FGFs allowed us to understanding that the presence and repartition of acidic borders 
around the HBSs is implicated in the HS crosslinking properties of FGFs. 
Introduction 
Many effectors, including morphogens, growth factors, cytokines and chemokines, 
such as fibroblast growth factors (FGFs) exert a local, paracrine activity to regulate 
cell communication in development and homeostasis (152-154). An important 
property in this respect is their interactions with glycosaminoglycans (GAGs) of the 
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extracellular matrix (ECM), particularly the sulfated GAGs, heparan sulfate (HS) and 
chondroitin sulfate (CS) (155), which regulate their transport between cells and 
often, their subsequent interactions with cognate signalling receptors on target cell 
surfaces (156-158). In the organism, the variability of structure and type of sulfated 
GAG depends on the tissue (159-161), which provide scope for tissue-specific 
regulation (162) of the activity of these paracrine effectors (163-165) and of tissue 
regeneration (166). These protein-polysaccharide interactions are modulated by the 
type, size and sulfation patterns of the GAG (55, 56, 167-171), and in the protein by 
its heparin binding sites (HBS), so called because heparin is often used as an 
experimental proxy for cell HS. The variability and diversity of HBSs lead to selective 
interaction with HS (103, 104, 172).  
So far, 435 extracellular heparin binding proteins have been reported (47), and the 
identification of their HBS demonstrates them to consist of a surface cluster of basic 
amino acids arginine, lysine (165, 173, 174). Amongst the heparin binding proteins, 
the 15 paracrine fibroblast growth factors (FGFs) have a well conserved structure and 
possess a canonical HBS (HBS1) (55) and in many instances secondary HBS(s) of lower 
affinity (102, 175). The amino acids engaging in the interaction of FGFs with 
heparin/HS were initially identified using synthetic peptide (101) recently the lysines 
involved in binding were identified using the “protect and label” method (56, 104). 
The number and type of secondary HBSs has been found to follow the phylogeny of 
the FGF. That is, FGFs from the same subfamily have a more similar pattern of 
secondary HBSs than those from different subfamilies. This relationship holds for 
preference for binding particular sulfated structures in GAGs, FGF receptor binding 
and function (56, 104, 175, 176). Consequently, it would appear that the secondary 
HBSs have been subjected to the same natural selection pressures that drove the 
diversification of FGFs and they are likely to be of functional importance. However, 
the role secondary HBSs in FGF function remains enigmatic. A previous study 
demonstrated that the presence of secondary HBSs in FGF2 correlated with the cross-
linking of HS chains, because cross-linking was not observed with FGF9, which 
possesses just an HBS1 and no secondary HBSs (148). Here, “cross-linking” of brushes 
is defined by the ability of a protein to stably restrain the mobility of the GAG chains. 
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However, this study is limited by the fact that only two FGFs from different 
subfamilies were examined. It is not a general phenomenon. 
To address this question, we probed the dynamics of interaction of seven FGFs with 
a HS brush model of the ECM: biotinylated HS oligosaccharides grafted on a 
supported lipid bilayer via a streptavidin linker. These FGFs would encompass 
members of the same subfamily (FGF1, FGF2, and FGF17, FGF18), so two pairs of 
FGFs with very similar secondary HBSs and cover a total of five subfamilies, with 
characterised and distinct patterns of secondary HBSs. Three complementary 
techniques were used. Quartz crystal microbalance with dissipation (QCM-D) 
evaluated the changes in viscoelastic properties of the HS brush upon binding of the 
FGFs; spectroscopic ellipsometry (SE) determined the stoichiometry of binding and 
fluorescence recovery after photobleaching (FRAP) measured the changes in 
movement of the HS chains and of the FGF protein. The results demonstrate that 
some FGFs with multiple HBSs do not cross-link HS chains. Thus, the property of 
cross-linking HS chains is not dependent solely on the number of HBSs. Analysis of 
the surface electrostatic potential of the FGFs suggests that the presence of acidic 
borders around HBSs is also required for the FGF to cross-link HS chains. The 
importance of such cross-linking is that it may contribute to determine the mobility 
of FGFs in the ECM and may also change the supramolecular structure of ECM, which 
would in turn have pleiotropic effects. 
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Methods 
Buffer, heparan sulfate and proteins  
The working buffer used for all experiments and for protein dilution was made of 150 
mM NaCl (Sigma Aldrich, Madrid, Spain), 10 mM HEPES (Sigma Aldrich), pH 7.4 in 
ultrapure water. Bovine serum albumin (BSA, 66 kDa), streptavidin (SAv, 60 kDa) and 
streptavidin labelled with the atto 565 fluorophore (SAv-atto, 61 kDa) were 
purchased from Sigma Aldrich. Biotinylated heparan sulfate (HS) was prepared as 
described previously (123). Briefly, HS from porcine intestinal mucosa (Celsus 
Laboratories, Cincinnati, OH, USA) with an average molecular weight of 12 kDa was 
biotinylated at the reducing end by oxime ligation via an oligoethylene glycol linker. 
Plasmid sequences encoding for FGF1, HaloFGF1, FGF2, FGF2 HBS3- (FGF2 160K/A, 
163K/A and 164R/A), HaloFGF2, FGF4, HaloFGF6, FGF9, FGF10, HaloFGF10, FGF17, 
FGF18 and HaloFGF20, methods for their transformation in expressing cells, 
expression and purification protocol were described in previous studies (56, 57, 104, 
121, 177). Briefly, plasmids encoding FGF2 (18 kDa), FGF2 HBS3- (18 kDa), FGFs with 
an N-terminal hexahistidine tag, [FGF1 (18 kDa), FGF4 (23 kDa), FGF9 (24 kDa), FGF10 
(24 kDa), FGF17 (25 kDa) and FGF18 (25 kDa)], and FGFs with an N-terminal halo tag: 
HaloFGF1 (52 kDa), HaloFGF2 (52 kDa), HaloFGF6 (57 kDa), HaloFGF10 (57 kDa) and 
HaloFGF20 (57 kDa) were transformed in C41 (DE3) cells and cultured at 37 °C for 3 
h until OD600 reached 0.5. The proteins were expressed by induction of the lac operon 
with 1 mM isopropyl-1-thio-β-d-galactopyranoside (IPTG, Sigma Aldrich) at 16 °C for 
16 h.  
Preparation of small unilamellar vesicles (SUVs) for suppo rted lipid bilayers. 
SUVs were prepared as described previously (39). Briefly, mixtures of 
dioleoylphosphatidylcholine (DOPC) and dioleoylphospatidylethanolamine-CAP-
Biotin (DOPE-CAP-B) (both Avanti Polar Lipids, Alabaster, AL, USA) in chloroform were 
dried and re-suspended in working buffer at a concentration of 2 mg.mL-1. The 
suspensions were homogenized by five cycles of freezing in liquid nitrogen and 
thawing. SUVs were produced by sonication, for twice 15 min using a 3 mm microtip 
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sonicator (Branson 450 Cell disruptor, Branson, Connecticut, Danbury, USA) in pulse 
mode at 30% duty cycle on an iced water bath. The SUV solution was centrifuged for 
10 min at 14000 g to remove titanium particles coming from the sonicator tip, and 
then stored at 4°C under argon atmosphere and used within a year. 
Treatment of substrates.  
Surfaces treatment have been described in detail in a previous study (120). Silica-
coated sensors for QCM-D measurements (QSX303; Biolin Scientific, Västra Frölunda, 
Sweden) were cleaned in 2% (w/v) sodium dodecyl sulfate (Sigma Aldrich) in 
ultrapure water (30 min), rinsed with ultrapure water and blow-dried with nitrogen 
gas. Silicon wafers with a native SiO2 coating (University Wafers, South Boston, MA, 
USA) for spectroscopic ellipsometry (SE) measurements were first rinsed with 
acetone and blow-dried with nitrogen gas, and then rinsed with water and blow-
dried with nitrogen gas. Glass cover slips (0.15 mm thick, 24 × 24 mm2; Menzel Gläser, 
Braunschweig, Germany) for fluorescence recovery after photobleaching (FRAP) 
measurements were cleaned by immersion in piranha solution (3:1 (v/v) mixture of 
concentrated H2SO4 and H2O2; both Sigma Aldrich) for 1 h, rinsed with ultrapure 
water and blow-dried with nitrogen gas. Before use, the cover slips were rinsed with 
ethanol (HPLC gradient grade, ≥99.8% pure; Sigma Aldrich), ultrapure water, and 
blow-dried with nitrogen gas. Before use, all substrates were further conditioned by 
UV/ozone (BioForce Nanosciences, Ames, IA, USA) treatment for 30 min. 
Quartz crystal microbalance with dissipation monitoring (QCM -D). 
QCM-D follows the evolution of the resonance frequency and the dissipation of 
quartz crystal sensors upon adsorption of material on their surface. The change in 
frequency, Δf, and the change in dissipation, ΔD, are related to the physical 
properties of the film at the surface such as the areal mass density (including 
hydrodynamically coupled solvent) and mechanical properties. QCM-D 
measurements were performed with a Q-Sense E4 system equipped with Flow 
Modules (Biolin Scientific). Δf and ΔD were measured at 6 overtones (i = 3, 5, 7, 9, 11, 
13, corresponding to resonance frequencies of fi ≈ 15, 25, 35 … 65 MHz). We chose 
to represent Δf = Δfi/i and ΔD = ΔDi for the third overtone (i = 3). All other overtones 
57 
 
provided equivalent data. Prior to each measurement, the walls of tubing and flow 
modules were passivated against non-specific binding of biomolecules. To this end, 
a sacrificial sensor was placed in the flow module, and the fluidic system was infused 
first with an aqueous solution of 10 mg/mL of bovine serum albumin (BSA; 10 min) 
and then ultrapure water (10 min). The sacrificial sensor was then removed and the 
fluidic system blow-dried with nitrogen gas. Solutions were infused in passivated 
modules using a syringe pump (KD Scientific Legato Syringe, Holliston, MA, U.S.A) at 
20 µL/min or as stated otherwise. The working temperature was set and controlled 
at 23°C. For sufficiently rigid films, the analysis of QCM-D data allows to estimate the 
thickness (d) of the film using Sauerbrey’s equation: d = - C Δf / ρ, where C = 18.0 
ng.Hz-1.cm-2 is the mass sensitivity constant for the sensors with a fundamental 
resonance frequency of 4.95 MHz. For the film density, we used ρ = 1 g.cm-3, which 
is a reasonable approximation for strongly hydrated biomolecular films (130). 
Quantification of biomolecular surface densities by spectroscopic 
ellipsometry (SE). 
SE measures the changes in polarisation of light upon reflection on the sample 
surface. Specifically, these changes are characterized by the ellipsometric angles Δ 
and Ψ which are measured for wavelengths ranging from λ = 380 nm to 1000 nm. 
The presence of biomolecular films on the surface directs the changes in Δ and Ψ and 
is caused by the change in refractive index upon film formation. SE was used to 
quantify the surface density of adsorbed biomolecules. 
A M2000V spectroscopic ellipsometer (J. A. Woollam, Lincoln, NE, USA) was used to 
acquire changes in Δ and Ψ every 5 seconds at room temperature. In-house designed 
110 µL open chambers for in situ SE measurements (137) were cleaned by immersion 
in 2% (w/v) SDS for 10 min, thoroughly rinsed with ultrapure water, ethanol and 
ultrapure water, and blow-dried with nitrogen gas. The chambers were passivated 
with 10 mg/mL BSA (10 min), rinsed with ultrapure water and blow-dried with 
nitrogen gas before use. Biomolecules were directly injected into the chamber 
containing buffer and kept homogenised by continuous agitation with a magnetic 
stirrer located at the bottom of the cuvette. Rinsing steps were operated by applying 
an upward buffer flow of 50 µl/min through tubing connected at the bottom (inlet) 
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and at the top (outlet) of the cuvette until apparent stabilisation of the SE signals. 
The HS brushes were formed by sequentially incubating 99.5:0.5 or 95:5 DOPC: 
DOPE-CAP-B SUV at 50 µg.mL-1, SAv at 20 µg.mL-1 and HS at 5 µg.mL-1 and each step 
was followed by a rinsing step with the incubation buffer. The solutions were infused 
for a minimum of 15 minutes and apparent stabilisation of the SE signals.  
The time-resolved ellipsometric data, Δ and Ψ as a function of λ, were fitted with a 
multi-layer model consisting of the opaque silicon substrate, a silicon oxide layer, a 
biomolecular layer and the ambient using the software CompleteEASE (Woollam), as 
previously described (178). The two discrete layers and the ambient were modelled 
as transparent Cauchy media with the dispersion of the refractive index n being 
described by the Cauchy parameters A and B such that n(λ) = A + B / (λ/μm)2. 
Tabulated values were used for the silicon substrate. The Cauchy parameters of the 
silicon oxide layer were determined prior to the formation of biomolecular films by 
simultaneous fitting of data sets from two measurements on the clean wafer surface, 
one in ambient air (for which A = 1 and B = 0) and the other in working buffer (for 
which Abuffer = 1.325 and Bbuffer = 0.00322, calculated from available tables in the 
literature (132, 138)). The thickness of the silicon oxide layer was then determined 
from the measurement on the clean wafer surface in working buffer. For the 
biomolecular layer, the thickness dbml and the Cauchy parameter Abml are the sole 
fitting parameters. Bbml = Bbuffer =0.00322 was fixed. 
To calculate molar surface densities, we used De Fejter’s equation and the (average) 
molecular weight of the biomolecules (139): 
 
Γ =  
1
𝑀W
 
𝑑bml (𝑛bml − 𝑛buffer)
d𝑛 d𝑐⁄
 
where dn/dc is the refractive index increment (132). We used dn/dc = 0.132 cm3/g 
for HS (140), 0.180 cm3/g for all proteins (142) and 0.169 cm3/g for lipids (143-145). 
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FRAP assessment of FGF interaction with HS films.  
FRAP measures the recovery by lateral mobility of fluorescently labelled 
biomolecules following photobleaching of a defined region of interest (ROI). To this 
end, fluorescently labelled SAv (SAv-atto) or HaloFGF were used, together with a 
LSM700 confocal microscope (Zeiss, Oberkochen, Germany). The lateral mobility of 
the components was followed by recording the fluorescence intensity as a function 
of time. 
For FRAP measurements, a clean and dry glass cover slip was glued to a custom-made 
4-well Teflon holder using freshly mixed bi-component dental glue (Picodent; 
Wipperfürth, Germany). All surface functionalization steps were performed in still 
solution. After the glue had dried, each well was filled with 50 µL of SUVs made of 
DOPC:DOPE-CAP-B 99.5:0.5 or 95:5 (mol/mol) to a final concentration of 50 µg/mL in 
working buffer. The SUVs were incubated for 30 min to form supported lipid bilayers 
(SLBs). Subsequent rinsing was achieved by diluting the well content with a two-fold 
excess volume of incubation buffer, mixing by repetitive liquid suction and dispensing 
with a pipette (avoiding bubbles and leaving the glass cover slip wet), and removal of 
the excess buffer; this process was repeated 10 times. The SLB was functionalized 
with SAv (non-labelled or fluorescent, as desired) to a final concentration of 20 µg/mL 
for 30 min. After rinsing, the SAv monolayer was functionalized with HS (5 µg/mL, 30 
min). After rinsing, FGF (non-labelled or halotagged, as desired) was added at 
concentrations indicated in the figure legends. Halotagged FGF were labelled by 
reacting the halotag with a fluorescent chloroalkane ligand, chloroalkane-
Tetramethylrhodamine (TMR) (Promega, Southampton, UK). Halotagged FGFs were 
mixed with the chloroalkane TMR at a 1:5 molar ratio and incubated at room 
temperature for 30 minutes before usage directly on the brushes. FRAP 
measurements were taken at the steps of interest. 
FRAP measurements were performed on a square area (120 × 120 µm2, 256 × 256 
pixels) using a 63× oil immersion objective (63× 1.4 oil DIC) and a fully opened pinhole 
(1 mm diameter). Three images were taken before a circular ROI with a 20 µm 
diameter was bleached, and fluorescence recovery was subsequently monitored. The 
bleaching was effectuated with lasers at maximal intensity at 488, 565 and 633 nm 
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wavelengths for approximately 10 s. The fluorescence recovery was monitored by a 
series of images at intervals of 1 s and/or 5 s. 
FRAP image series were analysed with a time-resolved profile analysis (TPA) routine 
implemented in Matlab, as described in detail elsewhere (148, 179). The routine 
corrects for background fluorescence, bleaching and heterogeneous illumination, 
and generates a radially averaged intensity profile from each image. The profiles are 
then fitted with predictions of diffusion equations using the first post-bleach image 
to define the boundary conditions. The diffusion model used here assumes two 
fractions of fluorescent species, one immobile and the other mobile with a given 
diffusion constant. The only adjustable fit parameters are the size and the diffusion 
constant of the mobile fraction, and both are reported here. 
The mean intensity of the bleached ROI was also extracted for every time point to 
plot recovery curves illustrating the mobility of the HS brushes (i.e. attached to SAv-
atto) or the labelled FGFs. In this case, the background fluorescence measured in the 
glass slide was measured before each measurement and it was used along with the 
fluorescence of a reference ROI to correct for bleaching during imaging. 
To assess the lateral mobility of HS, an incomplete and mobile monolayer of SAv-atto 
(to which the HS was anchored) was used as a reporter. To this end, the 0.5% 
biotinylated SLB was employed. To evaluate the mobility of FGFs, HaloFGFs were 
used as fluorescent probes in HS brushes grafted to dense SAv monolayers on 5% 
biotinylated SLB. The dense SAv monolayers (but not the incomplete monolayers) 
were found to form two-dimensional crystals (150), and in our experimental 
conditions, we observed at least 90% of the surface to be covered by these crystals. 
Results 
Assembly of HS brushes on QCM-D sensor surfaces 
HS brushes are molecular films of HS polymers grafted via their reducing end to a 
planar support. With their distinct molecular orientation and tuneable grafting 
density, they represent a well-defined model of HS-rich ECM that enables 
quantitative analysis (Figure 5.2). The QCM-D allows the monitoring of the formation 
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of the HS brush on a silicon oxide coated sensor (Figure 5.3). Small unilamellar 
vesicles (SUVs) containing 0.5 or 5 mole-% biotinylated lipids spontaneously adsorb 
on the surface of the sensor and rupture to form a supported lipid bilayer (SLB). The 
frequency shift (f) is a measure of wet (with trapped solvent) mass present at the 
surface of the sensor, and decreases upon binding of biomolecules. The dissipation 
(ΔD) is a measure of the stiffness of the film. The resulting shifts in frequency, Δf = -
24  1 Hz, and dissipation, ΔD ≤ 0.4 x 10-6, are similar to those measured previously 
(120) and demonstrate the formation of an SLB of good quality. Subsequent binding 
of SAv to a level commensurate with a mid-dense brush leads to a further decrease 
in Δf (-21  1 Hz) and a small increase in ΔD (0.80 x 10-6). For the dense brushes (5 
mole-% biotinylated SUVs) the SAv monolayer leads to decrease in Δf (-27 ± 1 Hz) and 
a transient small increase in ΔD that returns to the level of a rigid layer (≤ 0.4 x 10-6). 
When HS binds to SAv the decrease in frequency (Δf = 12  1 Hz) is accompanied by 
a large increase in dissipation (𝛥𝐷 = 4.0  0.5 × 10-6). For dense brushes (5 mole-% of 
biotinylated lipids in the SUV), the HS anchorage leads to a higher decrease in Δf (-17 
± 1 Hz) and increase in dissipation (𝛥𝐷 = 5.0  0.5 × 10-6). This is indicative of a soft 
HS brush being formed, that is, HS chains bind selectively through the biotin tag at 
the reducing end, leaving the relatively flexible polysaccharide chains free (39). 
The frequency change reports on the HS brush (HS chains and interacting solvent), 
therefore, to provide quantitative data on bound molecules only, spectroscopic 
ellipsometry (SE) was used to characterise each biomolecular layer with its areal mass 
density (Γ). The SLB possessed an areal mass density of 345 ± 12 ng.cm-2. The surface 
densities of the SAv and HS layers were 1.7 ± 0. 1 pmol.cm-2 and 1.1 ± 0.3 pmol.cm-2, 
respectively. The average distances between SAv molecules and between HS chains 
were extracted and theses values were not significantly different: 12 ± 3 and 12 ±4 
nm respectively, showing the specificity of the SAv-HS anchorage (Supplementary 
figure 5.1). The average molecular weight the HS used in this study is 12 kDa, and 
with the average disaccharide molecular weight being 0.5 kDa and its length 1 nm, 
the average contour length is estimated at 24 nm (180). However, the actual 
molecular weight and contour length at the surface may well be smaller. Indeed the 
smallest HS chains would anchor preferably than the longer ones (120). This well-
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defined HS brush was used in our study as a simple representation of one element of 
extracellular matrix, HS, to determine the molecular features underpinning the 
specific interaction and dynamics of FGFs with HS.  
 
 
Figure 5.2: Representative sketch of HS brushes as a well-defined ECM model.  
A biotinylated lipid bilayer is formed on a planar silica or glass substrate, and the HS chains 
are specifically anchored to it via a streptavidin. Here a mid-dense brush is represented as 
the streptavidin monolayer is partial. This allows the streptavidin, and the attached HS 
chains, to diffuse laterally on the fluid supported lipid bilayer. 
 
 
Figure 5.3: QCM-D monitoring of the formation of a mid-dense (A) and a dense (B) HS brush. 
The changes in Δf represent the evolution of mass adsorption at the surface of the sensor; 
ΔD provides information about the mechanical properties of the film with an increase being 
associated with a softer film. The black arrows represent the infusion step of the particular 
biomolecules, here at 20 µl.min-1. A supported lipid bilayer (SLB) was formed by infusing a 
50 µg.mL-1 SUV solution (containing 99.5:0.5 (A) or 95:5 (B) (mol:mol) DOPC:DOPE-CAP-B) 
on a silica coated QCM-D sensor. The biphasic response upon SUV incubation is characteristic 
for the initial binding of SUVs and their subsequent rupture (green arrow) and formation of 
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a SLB. Δf = -24  1 Hz and ΔD ≤ 0.4 × 10-6 indicate the formation of an SLB of good quality 
(120). The infusion of 1 µg.mL-1 SAv at 6 µl.min-1 (A) prior to infusing at 20 µg.mL-1 (44 min) 
generates as a slow decrease in Δf and increase ΔD, this feature illustrates the ability of QCM-
D apparatus to detect small changes and highlights of the successful passivation of the tubing 
with BSA. The two SAv infusions were carried out for 5 minutes and the final relative Δf and 
ΔD were (A) -22 ± 1 Hz and 0.5 ± 0.2 × 10-6, respectively and (B) -27 ± 1 Hz and 0.2 ± 0.1 × 
10-6. The infusion of HS at 5 µg.mL-1 triggered a further decrease in Δf (-12 ± 1 Hz) and a 
large increase in ΔD (4.0 ± 0.5 × 10-6), values characteristic of a mid-dense brush and -17 ± 1 
Hz (Δf) and 4.0 ± 0.5 × 10-6 (ΔD) for the dense brush. 
 
Viscoelastic changes in HS brushes following binding of FGF1 and FGF2.  
The binding of FGF1 and FGF2 to HS brushes was followed by QCM-D. The specificity 
of FGF binding to the HS brushes was verified by infusing the FGFs in the same 
conditions on the SAv coated SLB. Upon infusion of FGF2 at 0.28 µM (Figure 5.4A), 
we observed a rapid drop in f that stabilised at -28 Hz. This event illustrates the 
binding of FGF2 to the HS brush until it reached a maximum. Rinsing the surface 
caused desorption of some of the bound FGF2 from the HS brush, as f increased to 
-17 Hz. These results are consistent with those published previously with FGF2 
binding to HS brushes (148). The changes in softness of the film upon binding of FGF2 
can be analysed by the parametric plot of D/-f vs. -f. D/-f is a measure for the 
elastic compliance (i.e., softness) of the HS brush, and -f is a measure for the surface 
coverage (130). The parametric plot thus shows the trend of HS brush rigidification 
as protein binds and is particularly useful for comparing the interactions of different 
proteins (130). The parametric plot for FGF2 (Figure 5.4A) shows that the bare HS 
brush has a softness corresponding to 0.20 × 10-6 Hz-1, and that the softness 
decreases by roughly 3-fold (to 0.06 × 10-6 Hz-1) upon FGF2 binding at 0.28 µM. The 
rigidified protein-loaded HS brush retains its rigidity even after rinsing and partial 
release of FGF2, as it did not recover its softness (Figure 5.4A). The specificity of FGF 
binding to the HS brushes and the inertness of the SAv layer to the FGFs was verified 
by infusing the FGFs in the same conditions on the SAv coated SLB (Supplementary 
figure 5.9). 
The closely related FGF1, which is in the same FGF subfamily, has the same pattern 
of HBSs as FGF2 and similar, but not identical binding selectivity for structures in the 
polysaccharide (56, 104, 114). Upon infusion of FGF1 at 0.28 µM, we observed a 
64 
 
decrease in Δf (Figure 5.4Figure 5.4) to a maximum of Δf of -30 Hz, similar to that 
observed for FGF2. However, compared to FGF2, upon rising more FGF1 desorbed, 
as a final Δf of -10 Hz was reached. Moreover, in contrast to FGF2, the dissipation 
response of FGF1 binding to HS (Figure 5.4Figure 5.4) was a rapid increase in ΔD that 
stabilised at 1.0 x 10-6. Upon rinsing the ΔD was largely restored stabilised at 0.6 x 10-
6. Nonetheless, the parametric plot shows a gradual rigidification of the HS brush 
upon binding of FGF1 (Figure 5.4).Figure 5.4). The level of ΔD/-Δf = 0.07 × 10-6 Hz-1 at 
maximal coverage is comparable to FGF2 and FGF2 HBS3-, and a superposition of the 
parametric plots (Figure 5.4Figure 5.4) shows that the rigidification trends upon 
binding are the same for the two FGFs. However, the initial differences in dissipation 
changes discovered on FGF2 and FGF1 and the recovery of the HS-FGF1 film’s 
softness upon rinsing and partial protein release, indicates that these films are not 
identical. Thus, FGF1-loaded HS brushes are softer than HS brushes loaded with FGF2 
after the rinsing step. 
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Figure 5.4: QCM-D monitoring of FGFs from the FGF1 subfamily binding to a mid-dense HS 
brush. 
The frequency (panels A and C) and dissipation (panels B and D) were offset after the 
formation of the HS brush (cf. Figure 5.3). FGF1 (panels A and B) and FGF2 (panels C and D) 
were infused at 0.28 µM until equilibrium (blue arrows indicate the infusion time) before 
rinsing with working buffer.  
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Figure 5.5: FGFs from the FGF1 subfamily bind and rigidify HS brushes. 
Parametric plots of ΔD/-Δf (a measure of softness) vs. -Δf (a measure of surface coverage) 
for the HS film, first without (until -Δf ≈ 12 Hz, process of HS film formation indicated with 
black arrow) and then with FGFs bound (data extracted from Figure 5.4). HS brushes rigidify 
progressively upon FGF1 (A) and FGF2 (B) binding. Upon rinsing (the start of rinsing is 
indicated with a blue arrow head), the FGFs desorbed following protein specific trends (blue 
arrows). In A, we showed the binding (red) and unbinding (black) of FGF1 in different colours 
for clarity purposes. C. Overlay of the three plots shown in A and B. All binding curves fall on 
top of each other, indicating that the three proteins have very similar coverage-dependent 
effects on HS film morphology. Unbinding curves are distinct, however, with FGF1 but not 
FGF2 softening upon protein release. 
Quantification of bound HS, FGF1 and FGF2.  
QCM-D frequency changes provide a first estimate of protein binding, but they are 
also affected by solvent trapping, and by the viscoelastic properties of the GAG-
protein film. To measure the amount of molecules actually bound SE was used, it 
measures the absolute molecular density of each layer of the film. First we 
characterised the HS brush, which has a density of 1.7 ± 0.1 pmol.cm-2 (Figure 5.6). 
At maximum binding, the amounts of FGF1 and FGF2 bound to HS were equivalent 
with no significant difference. Assuming a molecular weight of 12 kDa for the HS 
chains (181), this yielded an average stoichiometry of 6  3 FGF1 and 6 ± 1 FGF2 per 
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HS chain at maximal loading, hence 1 FGF every 4 disaccharides (Figure 5.6). 
However, after rinsing with the working buffer, FGF1 dissociated from the brush and 
stabilised to 2 ± 1 FGF1 per chain or 1 FGF1 every 12 disaccharide, whereas FGF2 
stabilised at 4 ± 1 per HS or 1 FGF2 every 6 disaccharide (Figure 5.6). 
 
Figure 5.6: Stoichiometry of FGF binding to HS, for proteins of the FGF1 subfamily 
Molar FGF surface densities were determined by SE at equilibrium after incubation at 0.28 
µM (left), and after rinsing with working buffer for at least 60 minutes (right), and compared 
to molar HS surface densities obtained in the same measurements. The means comparison 
test was carried out with a Fisher test at a level of significance of 5 %. The data presented is 
the range for a minimum of 2 independent measurements. 
 
Cross-linking of HS brushes by FGF2 and FGF1 
Cross-linking of HS chains by the bound protein can account for the observed 
rigidification of HS brushes, but other processes, such as collapse of individual HS 
chains around the protein may also cause this effect. FRAP of fluorescently labelled 
SAv provides the means to determine whether cross-linking is occurring (148), since 
this will reduce the lateral diffusion of the fluorescent SAv proxy. FRAP on bare 
biotinylated HS brushes confirmed that the lateral mobility of the HS brushes is fast 
and allows full recovery of the fluorescence in the bleached area within 300 seconds 
(Figure 5.7A). The quantitative analysis of the FRAP data characterised an HS brush 
as 97 ± 1% mobile with a diffusion constant of 1.7 ± 0.5 µm2.s-1 (Supplementary figure 
5.2).  
Figure 5.7 shows how the mean intensity of the bleached spot recovers over time for 
a film of bare HS (Figure 5.7A) and for HS films that were incubated with FGFs at 0.28 
µM for 30 min and then rinsed with incubation buffer (Figure 5.7B-C). These plots 
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provide a simple visual comparison of the recovery of fluorescence, and the mobility 
of the fluorescent SAv with bound HS chains. In addition, Supplementary Fig. 2 
provides a quantitative analysis of the size and diffusion constant of the mobile 
fraction. 
 
 
Figure 5.7: FGF2 reduces HS mobility but FGF1 does not. 
FRAP curve of atto488-SAv supporting HS (A) HS-FGF1 (B) and HS-FGF2 (C) films. The black 
curve and the grey region around it are the mean and standard deviation, respectively, of 4 
measurements obtained after rinsing with the working buffer. 
 
FGF2 essentially immobilised the HS chains over 600 s (Figure 5.7), the corrected 
recovery level after bleaching was of 52 ± 1 % was constant during the time of the 
experiment. In contrast, HS brushes with bound FGF1 recovered up to 100% 
fluorescence after bleaching and the mobile fraction of the bHS-FGF1 brush 
remained constant. Comparisons of the mobile fraction and the diffusion constant 
with the Fisher test between HS and HS-FGF1 indicate that FGF1 does not 
significantly affect the mobility of HS brushes (Figure 5.7). Thus, the rigidification of 
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the HS brushes caused by FGF2 is representative of a supramolecular arrangement 
that restrains the mobility of the HS chains, whereas in the case of FGF1 the rigid 
state of the film allows the HS brush to be carried around by the lateral diffusion of 
the lipid. Therefore, these data surprisingly show that although FGF1 and FGF2, 
which are in the same FGF subfamily, possess a high level of amino acid sequence 
conservation and the same configuration of secondary HBSs, they differ markedly in 
their ability to immobilise HS chains. An important conclusion is that the presence 
of secondary HBSs cannot be the sole predictor of whether an FGF immobilise HS 
chains. To identify what other property of FGFs may contribute to determining 
whether the binding of HS chains would lead to cross-linking/immobilisation, 
measurements were undertaken on FGF4, FGF9, FGF10, FGF17 and FGF18, which 
are in other FGF subfamilies. 
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Interactions of FGF4, FGF9, FGF10, FGF17 and FGF18 with midense HS brushes 
As observed previously (148), the binding of FGF9 bound to HS brushes increased 
continuously over 60 min, which was associated with an increasing ΔD (Figure 5.8). 
All other FGFs bound to equilibrium within 60 min. In contrast, the binding of FGF2, 
FGF10, FGF17 and FGF18, like that of FGF1 and FGF2 reached a maximum. The 
binding of FGF4 was rapid, whereas FGF10, FGF17 and FGF18 (Figure 5.8) bound 
more slowly. At equilibrium, the Δf values ranged from -13 Hz for FGF17 to -18 Hz for 
FGF10 and -21 Hz for FGF4 and FGF18. Upon rinsing, FGF4, FGF9 and FGF17 showed 
only small increases in frequency, indicating a low level of protein release, whereas 
FGF10 and FGF18 were not released, since there was no change in frequency at this 
point. The corresponding dissipation shifts were negative, and ranged between -0.5 
and -2.0 × 10-6, providing a first indication for relatively strong stiffening of the HS 
film s. In the case of FGF4 and FGF18, after rinsing the dissipation increased towards 
its starting level. In contrast, the dissipation for FGF10 and FGF17 remained 
unchanged after rinsing.  
The analysis of the parametric plots (Figure 5.9) provided more information on the 
morphologies of the FGF bound HS brushes. All these FGFs induced a rigidification of 
the HS brushes, as evident from the decreasing D/-f upon protein binding. FGF9 
was not desorbed from the brush upon rinsing, and thus the D/-f remained stable 
at a value of 0.08 × 10-6.Hz-1. FGF4 bound the HS brush until D/-f = 0.05 × 10-6.Hz-
1. Upon rinsing, a small fraction of the FGF4 desorbed and there was a degree of 
softness recovery (Figure 5.9B, blue arrow) with the film stabilising at 0.08 × 10-6.Hz-
1. In the case of FGF10, D/-f = 0.03 × 10-6.Hz-1 at maximal binding and immediately 
after rinsing, though the film then became more rigid. FGF17 showed a more potent 
rigidifying effect on the HS brushes that increased considerably after rinsing and the 
release of some FGF17 from the brush, with a final D/-f = 0.01 × 10-6.Hz-1. The 
same trend was observed for FGF18, but less pronounced, with a final D/-f = 0.04 
× 10-6.Hz-1. The rigidification of HS brushes depends on the FGF type. The parametric 
plots of FGF17 and FGF18, which belong to the FGF8 subfamily (Figure 1) are the most 
similar, whereas the parametric plots for the other FGFs, each of which represents a 
different subfamily differ more substantially. 
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Figure 5.8: QCM-D monitoring of FGF binding to HS brushes. 
The frequency (panels A, C, E, G and I) and dissipation (panels B, D, F, H and J) shifts presented 
are data acquired for the 3rd overtone and offset after the formation of the HS brush. FGF9 
(panels A and B), FGF4 (panels C and D), FGF10 (panels E and F), FGF17 (panels G and H) and 
FGF18 (panels I and J) were infused at 0.28 µM until equilibrium or a maximum of 60 minutes 
(blue arrow) before rinsing with the working buffer. The rinsing step was carried out until the 
system reached another equilibrium or for 30 minutes. 
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Figure 5.9: HS film rigidification by FGFs from subfamilies other than FGF1 
Parametric plots of ΔD/-Δf (a measure of softness) vs. -Δf (a measure of surface coverage) 
for the HS film, first without (until -Δf ≈ 12 Hz, process of HS film formation indicated with 
black arrow) and then upon FGF9 (A), FGF4 (B), FGF10 (C), FGF17 (D) and FGF18 (E) binding. 
HS brushes rigidify progressively upon FGF binding for all FGFs. Upon rinsing (the start of 
rinsing is indicated with a blue arrow head), the HS films released FGFs and recovered some 
softness (FGF4 and FGF10) or became more rigid (FGF17 and FGF18). The blue arrows 
represent the trends upon rinsing. The overlap of the parametric plots (F) shows that each 
FGF follows its own rigidification trend unlike previously observed amongst proteins of the 
FGF1 sub-family (Figure 5.5).   
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SE was then used to quantify the amount of HS, and of FGF bound, to assess the 
binding stoichiometry (Figure 5.10). At maximal binding, the stoichiometries were in 
the range of 2 to 6 FGF molecules per HS chain. Specifically, there were 4 ± 1 FGF4, 2 
± 1 FGF9, 5 ± 1 FGF10, 6 ± 1 FGF17 and 2 ± 1 FGF18 per HS chain. After rinsing and 
stabilisation, the stoichiometries were 2 ± 1 FGF4, 1 ± 1 FGF9, 4 ± 1 FGF10, 5 ± 1 
FGF17 and 2 ± 1 FGF18 per HS chain. The HS used in this study is polydisperse, and 
has an average molecular weight of 12 kDa, and so an average of 22 dissacharide 
units (assuming a disaccharide is 0.50-0.55 kDa (180) carrying 1.4 sulfate groups per 
disaccharide (124). Thus this translates to a number a dissacharide available for the 
FGFs to bind: 1 FGF4 every 5, 1 FGF9 every 10, 1 FGF10 every 4, 1 FGF17 every 3 and 
1 FGF18 every10 disaccharides. The differences observed in maximum of binding and 
in final binding after rising will reflect the selectivity of the different FGFs for specific 
sulfated structures in the HS chains (56, 182-184). While the results demonstrate that 
the proteins bound and rigidified the HS brushes, they do not identify the cause of 
this rigidification.  
 
 
Figure 5.10: Stoichiometry of FGF binding to HS, for all tested FGFs.The molar FGF surface 
densities were determined by SE at equilibrium after incubation at 0.28 µM, and after rinsing 
with working buffer for a minimum of 60 minutes, and compared to molar HS surface 
densities obtained in the same measurements. The data presented is for two independent 
measurements, and the mean values and standard deviations are indicated. 
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Two possible mechanisms for rigidification are the collapse of HS chains around a 
protein or to the protein causing the cross-linking of the HS chains. These can be 
distinguished by measuring the mobility of the brushes in the presence of the FGF. 
Mobility of HS chains binding FGF4, FGF9, FGF10, FGF17 and FGF18  
FRAP of fluorescent SAv was used to determine whether the observed rigidification 
of the HS chains was due their cross-linking by the FGFs. When HS-FGF4 and HS-FGF9 
bound to HS brushes a quick and complete recovery was observed, reaching 100% 
recovery within the measurement time (Figure 5.11). Thus, more than 95% of the HS-
FGF4 and HS-FGF9 brushes remained mobile. Though HS-FGF9 recovered 
fluorescence slightly faster than HS-FGF4; their mobility parameters were not 
significantly different from one another nor different from the ones of HS-FGF1 
(Supplementary figure 5.5). Therefore, the monovalent FGF9 (possessing just a HBS1) 
and the divalent FGF4 (possessing HBS1 and HBS3) interact with HS in the same 
manner as the trivalent FGF1 (HBS1, HBS2 and HBS3). These data support the 
conclusion drawn earlier from the comparison of FGF1 and FGF2 that the number of 
HBS does not account fully for the property of an FGF to immobilise HS brushes. 
In contrast HS-FGF10, HS-FGF17 and HS-FGF18 showed slower and partial recoveries 
of the fluorescence (Figure 5.11). These three proteins induced a significant 
reduction in the mobile fractions of the SAv and this was accompanied by lower 
diffusion constants for the mobile fraction, compared to the bare HS brushes 
(Supplementary figure 5.5). 
The mobility parameters of HS-FGF17 were significantly lower than those of the bare 
HS brush (Supplementary figure 5.5), as only 67 ± 1% of the HS-FGF17 brush was 
mobile with a diffusion constant of 0.82 ± 0.20 m2.s-1 whereas 95 ± 2 % of the bare 
HS brush is mobile with a diffusion constant of 1.82 ± 0.30 m2.s-1. HS-FGF10 and HS-
FGF18, respectively, presented mobile fractions of 65 % and 53% and diffusion 
constants of 0.63 ± 0.30 m2s-1 and 1.64 ± 0.19 m2s-1. A comparison of the mobility 
parameters show that HS-FGF10 and HS-FGF17 are equivalent in diffusion and so 
immobilise HS brushes to the same extent (Supplementary figure 5.5). FGF18, which 
is in the same subfamily as FGF17 possessed different immobilisation parameters. 
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That FGF1 differs from FGF2 and FGF17 from FGF18 in this respect suggests that the 
property assessed by the measurement of mobility of the HS brush provides insight 
into how different members of the same subfamily may have diverged in function. 
 
Figure 5.11: Mobility of FGF bound HS brushes as observed in FRAP. 
FRAP curve of SAv-atto supporting HS-FGF4 (A), HS-FGF9 (B), HS-FGF10 (C), HS-FGF17 (D) and 
HS-FGF18 (E) films. The black curve and the grey region around it are the mean and standard 
deviation, respectively, of 4 measurements obtained after rinsing with the working buffer 
following or protein incubation. 
 
Mobility of FGFs in HS brushes 
It has previously been postulated that the cross-linking of HS chains by FGFs may 
impact on the mobility of the FGFs (148). To evaluate the mobility of FGFs in HS 
brushes, FGF fusion proteins with an N-terminal halotag were used, as described 
previously (121, 185). Dense and immobile HS brushes were established by saturating 
the lipid with SAv as described in the methods. The SAv monolayer then served as an 
anchorage of the biotinylated HS. It was first important to determine whether the 
halotag had a major effect on the interaction of FGFs with the HS brush. This also 
provided the opportunity to measure the properties of FGF6 and FGF20, which only 
remain soluble as N-terminal fusions with HaloTag (121). However, the N-terminal 
fusions of FGF4, FGF9, FGF17 and FGF18 were not available. 
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Halo-FGFs as a model for native FGFs mobility  
QCM-D responses for the binding of 0.28 µM HaloFGF1, HaloFGF2, HaloFGF6, 
HaloFGF10 and HaloFGF20 to HS brushes are shown in Supplementary figure 5.10. 
However, ΔD increased in all cases and this continued during the desorption of the 
protein (Supplementary figure 5.10). The HaloTag protein itself, which has a slightly 
acidic isoelectric point does not bind hep(121). Thus, the difference in the changes in 
dissipation between the native FGFs and their N-terminal HaloTag fusion 
counterparts is likely to be due to the presence of the halotag. The latter is attached 
to the FGF via a flexible linker. Previous work has shown that rigid globular proteins 
attached via a flexible linker to surfaces can give rise to significant dissipation due to 
the liquid motion associated with the rocking of proteins upon the small-amplitude 
MHz mechanical oscillation of the QCM-D sensor surface (186). Thus, the drag of the 
HaloTag on solvent, aided by the flexible linker is likely to cause the increase in 
dissipation of HaloFGF compared to native FGFs. The parametric plot of HaloFGF1, 
HaloFGF2, HaloFGF6, HaloFGF10 and HaloFGF20 binding to an HS brush (Figure 5.12) 
shows that the despite the increased ΔD (Supplementary figure 5.10), the binding of 
HaloFGF1, HaloFGF2, HaloFGF6, HaloFGF10 and HaloFGF20 to the HS brushes 
rendered them more rigid, since the softness of the brushes decreases upon binding 
of the proteins (Figure 5.12). After rinsing of the brushes and the partial desorption 
of the proteins, the HS-HaloFGF1, HS-HaloFGF6 and HS-HaloFGF10 films recovered 
some of their softness, but not HS-HaloFGF2 and HS-HaloFGF20. These data indicate 
that the interaction of the Halo-FGFs is similar to that of the native FGFs, with the 
difference in dissipation likely being due to the HaloTag protein interacting with 
solvent.  
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Figure 5.12: Mid-dense HS film rigidification by HaloFGFs. 
Parametric plots of ΔD/-Δf (a measure of softness) vs. -Δf (a measure of surface coverage) 
for the HS film, first without (until -Δf ≈ 12 Hz, process of HS film formation indicated with 
black arrow) and then with HaloFGFs bound. HS brushes rigidify progressively upon HaloFGF 
binding for all HaloFGFs (original data presented in Supplementary figure 5.10). Upon rinsing 
(the start of rinsing is indicated with a blue arrow head), the HS films released FGFs and 
recovered some softness (HaloFGF6 and HaloFGF10), rigidified (HaloFGF20) or did not 
change (HaloFGF1 and HaloFGF2). The blue arrows represent the trends upon rinsing.  
 
By SE, we quantified the stoichiometry of HaloFGFs bound per HS chain in mid-dense 
brushes as described above for native FGFs (Figure 5.13). When we compared the 
binding of halo-tagged FGFs with the native counterparts (Figure 5.6, Figure 5.10 and 
Figure 5.13), at the maximum of binding HaloFGF1 and FGF1 bound equivalent 
amounts, 6 ± 3 FGF1 per HS and 5 ± 2 HaloFGF1 per HS chain. After rinsing, the 
numbers of FGF1 and HaloFGF1 per HS chain were also not significantly different: 2 
± 1 FGF1 per HS and 4 ± 2 HaloFGF1 per HS chains. Compared to FGF2, the amount 
of HaloFGF2 protein bound was around half at the maximum of binding, and after 
rinsing HS brushes contained 3 ± 1 HaloFGF2 per HS, which again is less than observed 
for FGF2 (5 ± 1 FGF2 per chain). In addition, there was a difference in the level of 
binding of HaloFGF10 compared to FGF10. Thus, after rinsing the brushes retained 2 
± 1 HaloFGF10 per HS chain compared to 5 ± 1 FGF10 per HS chain (Figure 5.10 and 
Figure 5.13). The origins of these differences are not clear, but they may be due in 
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part to a crowding effect, whereby the HaloTag protein obstructs some of the binding 
sites on HS.
 
Figure 5.13: Quantification of HaloFGF binding to mid-dense and dense HS brushes. 
The molar HaloFGF surface densities were determined by SE equilibrium after incubation at 
0.28 µM (left), and after rinsing with working buffer until stabilisation (right), and compared 
to molar HS surface densities obtained in the same measurements. The data for the binding 
to dense brushes are marked with an asterisk and means with significant differences are 
marked with bars above them. The presented is the range of 2 independent measurements. 
 
When we compared the binding of HaloFGFs to mid-dense and dense HS brushes. A 
difference was observed in HaloFGF1 binding before and after rinsing (Figure 5.13). 
HaloFGF1 showed a maximum binding of 5 ± 2 HaloFGF1 per HS chain in mid-dense 
brushes, but only 2 ±1 HaloFGF1 to dense brushes. However, after rinsing, the 
difference decreased, there was 4 ± 2 HaloFGF1 per HS chain in mid-dense brushes 
and 2 ± 1 HaloFGF1 per HS chain in dense brushes. The maximum level of binding of 
HaloFGF2 to mid-dense brushes was also higher than to dense brushes, however, this 
difference disappeared after rinsing (Figure 5.13). We did not observe any difference 
in binding stoichiometry of the other HaloFGFs between mid-dense and dense 
brushes. Thus, the differences in the amounts of Halo-FGFs bound, compared to their 
native counterparts were at a minimum after rinsing and may relate in part to 
obstruction of binding sites by the Halo protein. Since the properties of the brushes 
in terms of rigidity were very similar between Halo-FGFs and native FGFs, the halo-
FGFs were considered to be suitable for the analysis of the mobility of the FGFs in the 
brushes.  
 
Mobility of HaloFGF in HS brushes 
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HaloFGF1, HaloFGF2, HaloFGF6, HaloFGF10 and HaloFGF20 were incubated for 30 to 
60 min with an immobile dense HS brush. The immobility of the HS brushes was 
ensured by using SUVs containing 5% DOPE-CAP-biotin to form SLBs. At this biotin 
content, dense SAv monolayers are formed and SAv forms two-dimensional crystals 
that render the SAv-bound HS immobile (Supplementary figure 5.11). Thus, after 
rinsing, the FRAP of a region of interest was monitored and only the mobility of the 
labelled proteins was measured. HaloFGFs labelled with fluorescent TMR were 
bleached in a region of interest and the fluorescence recovery in that area was 
recorded for 300 or 600 s. 
The fluorescence recovery in a region of interest containing TMR labelled HaloFGF1 
was followed, HaloFGF1 recovery was continuous and did not return to basal levels 
by the end of our assays (300 s, Figure 5.14A).Figure 5.14A). The quantitative analysis 
of HaloFGF1 mobility determined the mobile fraction as 15 ± 3% (Supplementary 
figure 5.12Supplementary figure 5.12) and a diffusion constant of 0.22 ± 0.08 µm2.s-
1, represented by the slow fluorescence recovery in the recovery curve of HaloFGF1. 
In contrast, the fluorescence recovery curve of HaloFGF2 showed that the protein 
was immobile in the brushes, as no significant change in the recovery level was 
observed between 0 and 600 seconds (Figure 5.14B). The “mobile” fraction of 
HaloFGF2 was not detectable (Supplementary figure 5.12).  
Labelled HaloFGF10 recovered in two phases, the curves show an initial short burst 
that was followed by a continuous recovery until stabilisation at 36 ± 7 % of the 
original level (Figure 5.14D). The mobile fraction of HaloFGF10 bound to the HS brush 
was 32 ± 5% and its diffusion constant 0.18 ± 0.08 µm2.s-1 (Supplementary figure 
5.12). Compared to HaloFGF2 that was immobile, both HaloFGF1 and HaloFGF10 
were somewhat mobile in the HS brushes, with low and slow mobile fractions. There 
was no significant difference between their diffusion constants, but the mobile 
fraction of HaloFGF1 was smaller than the one of HaloFGF10.  
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Figure 5.14: Mobility of HaloFGFs in HS films. 
FRAP curve of TMR565 labelled HaloFGF1 (A), HaloFGF2 (B), HaloFGF6 (C), HaloFGF10 (D) and 
HaloFGF20 (E) in HS films. The black curve and the grey region around it are the mean and 
standard deviation, respectively, of 3 to 6 measurements obtained after rinsing with the 
working buffer. 
 
In the case of HaloFGF6 the fluorescence recovery was rapid, and fluorescence 
reached 82 ± 4% of the original level (Figure 5.14C). HaloFGF6 was 90 ± 5% mobile 
with a diffusion constant of 0.51 ± 0.15 µm2.s-1 (Supplementary figure 5.12). The 
recovery of HaloFGF20 was rapid and gradual and virtually complete, at 98 ± 1% 
(Figure 5.14D). Almost all the Halo-FGF20 was mobile 91 ± 2%) and had a diffusion 
constant of 0.15 ± 0.10 µm2.s-1 (Supplementary figure 5.12). Thus, both HaloFGF6 and 
HaloFGF20 were mobile in HS brushes, with HaloFGF20 diffusing rather faster than 
HaloFGF6.  
Taken together, we identified 3 distinct dynamics of diffusion for the HaloFGFs in HS 
brushes: (1) immobile, HaloFGF2 did not present any fluorescence recovery in the 
bleached region of interest, (2) slightly mobile, HaloFGF1 and HaloFGF10 with a 
mobile fraction well below 50% and (3) mobile, HaloFGF6 and HaloFGF20 with a 
mobile fraction close to 100% (Figure 5.17 and Supplementary figure 5.10). 
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Figure 5.15: Surface electrostatic potential mapping and position of heparin binding lysines 
in FGF2. 
Identified hep binding lysines in HBS1, HBS2 and HBS3 in FGF2 (1BLA) are labelled in green 
(103). The electrostatic mapping of partial charges [-1.8 (red), 0 (white) and +1.8 (blue)] was 
generated using the Poisson-Boltzmann algorithm in SPDBV. The N-terminal residue is 
labelled in black. 
 
 
 
Figure 5.16: Surface electrostatic potential mapping and position of heparin binding lysines 
in FGF1. 
Identified hep binding lysines in HBS1, HBS2 and HBS3 in FGF2 (1BLA) are labelled in green 
(104). The electrostatic mapping of partial charges [-1.8 (red), 0 (white) and +1.8 (blue)] was 
generated using the Poisson-Boltzmann algorithm in SPDBV. The N-terminal residue is 
labelled in black. 
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Figure 5.17: Representative sketch of supramolecular events in HS-FGF brushes. 
A. The FGF protein is not permanently cross-linking HS chains which allows the chains to be 
mobile (carried by the SAv) and is mobile in the brushes. B. The FGF protein is transiently 
cross-linking HS chains, thus they are slightly mobile. The FGF is mobile in the brushes, it 
travels from chain to chain. C. The FGF protein is stably cross-linking HS chains, thus they are 
immobile. The FGF are tightly bound to the chains and do not diffuse in the brush. 
 
Discussion 
The FGFs represent a group of a group of evolutionary related proteins, with well 
characterised HBSs and binding preferences for particular structures in the 
polysaccharide (101-103). These properties of FGFs follow their phylogeny, 
established from their amino acid sequence. Thus, as for FGFR isoform preferences 
(115, 175, 176), the pattern of HBSs and the saccharide binding selectivity are more 
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similar for members of the same subfamily, than for members from different 
subfamilies (56, 104). This indicates that these properties which provide functional 
differences between FGFs have been under natural selection pressure (56, 104).  
The HS brush provides a simple mimetic of one component of the extracellular 
matrix, HS, and a means to interrogate the interactions between proteins and the 
polysaccharide matrix quantitatively. In the first such measurements, using FGF2 and 
FGF9, it was found that the number of HBSs in FGFs correlated with their cross-linking 
of HS chains (148). Thus, FGF2, which has three HBSs (103) was found to cross-link 
and so immobilise HS chains in the brush, whereas FGF9, which has just a canonical 
HBS1 (104) did not (148). The present work aimed to test whether this might be a 
general principle, that is, proteins with multiple HBSs would possess the property of 
cross-linking HS chains. The importance of cross-linking HS chains is twofold. First, it 
would reduce the mobility of proteins in the ECM, and therefore steepen diffusion 
gradients. In the extreme, a protein would be immobile and require ECM degradation 
to diffuse. Second, crosslinking HS chains will change the stiffness of ECM, and so 
might have an effect on cellular mechanical signalling. Such cross-crosslinking can be 
proposed after observation of the stiffening of the brush accompanied by a decrease 
in dissipation in QCM-D. Relatively stable cross-linking is confirmed by a significant 
reduction of the mobile fraction and diffusion constant of an HS film in the presence 
of an FGF (FRAP). The current results demonstrate that the presence of multiple HBSs 
is necessary, but does not in itself bestow the property of stably cross-linking HS 
chains to an FGF. Thus, FGF1, which possesses the same pattern of three HBSs on its 
surface as FGF2 (56, 103, 104), does not cross-link HS chains stably. Thus, though it 
does cause a stiffening of the HS brush, the mobility of the SAv as reported by FRAP 
remains high (Figure 5.7 and Supplementary figure 5.2). FGF4, which has two HBSs, 
also does not cross-link HS chains stably (Figure 5.11 and Supplementary figure 5.5). 
Similarly, HaloFGF6, which is in the FGF4 subfamily and possesses two HBSs, fails to 
cross-link HS stably (Supplementary figure 5.13). However, other bivalent FGFs, 
FGF17 and FGF18 (with HBS1 and HBS2), and trivalent FGF10 and HaloFGF10 (HBS1, 
HBS3 and HBS4), cross-linked and partially immobilised the HS brushes (Figure 5.11 
84 
 
and Supplementary figure 5.13). The question arises as to what additional factor(s) 
may contribute to determining whether a protein may cross-link HS chains stably. 
One property that might explain why an FGF with multiple HBSs does not cross-link 
HS chains stably is structural, based on the surface between the HBSs. If this was 
neutral or basic it would not repel the chains, hence these may be able to wrap 
around the protein. In contrast if HBSs were separated by an acidic border, this would 
repeal the highly anionic HS, and hence the multiple HBSs would be more likely to 
engage different HS chains. Alternatively, the kinetics of binding of the FGFs to the 
HS chain could allow transient crosslinking, through cycles of dissociation-
association. This would not be detected as crosslinking on the time scale of the FRAP 
experiments. Rather than full dissociation, a mechanism analogous to sliding 
proposed to account for FGF diffusion in extracellular matrix (187) would allow the 
HBSs of an FGF to exchange HS chains without losing contact with a polysaccharide.   
The surface electrostatic potential of FGF2 (Figure 5.15), historically called basic FGF, 
presents a rather globally basic (blue) surface with some acidic (red) clusters. 
Although FGF2 is a very basic protein, the distribution of the surface charges results 
in the isolation of HBSs from one another by these acidic clusters. Thus, HBS1 (K128 
to K144), HBS2 (K86, K119), HBS3 (K27 to K30) in FGF2 are isolated by acidic borders. 
These borders comprise E87D88E89 and D99E100 that isolate HBS1 from HBS2 and 
D99E100 and E67E68 isolating HBS3 from HBS1 and HBS2. In the case of FGF1 (Figure 
5.16), historically called acidic FGF, because it has an acidic isoelectric point, its 
surface presents a predominantly acidic surface. Despite this, the distribution of 
surface charge results in HBS1 (K126 to K142), HBS2 (K71, K114K115) and HBS3 (K23 
to K26) forming an uninterrupted basic surface. Thus, HBS1 is connected to HBS2 by 
a basic/neutral surface contributed by the side chains and peptide bonds of Y29, S31, 
G33G34, F36, R49 and R51. HBS2 is connected to HBS3 by the basic surface of Y22 
and T73. Therefore, the HBSs in FGF1 may bind a single HS chain rather than 
crosslinking different chains. 
Examination of the surface electrostatic potential of the other FGFs supports the idea 
that isolation of HBSs by acidic borders is required for a protein with multiple HBSs 
to cross-link HS brushes. FGF4, has an HBS3 as a secondary HBS. However the hep 
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binding amino acids of HBS3 are not isolated from HBS1 (Supplementary figure 5.3), 
K142 (HBS1) and K158 (HBS3) are connected by Y172. The structure of FGF6 has not 
been resolved, however based on the structure of FGF4 (PDB: 4IJT), here again, the 
HBSs are likely not to be isolated. HBS1 and HBS3 are connected by P112Y113 and 
R132. Both FGF4 and HaloFGF6 did not cross-link HS chains. FGF9, contains HBS1 only 
and did not cross-link HS brushes as previously (148) described and verified here 
(Supplementary figure 5.4). FGF10, like other members of the FGF7 subfamily, has a 
canonical HBS1, an HBS4 perpendicular to the HBS1 and an HBS3 (56, 104). Whereas 
HBS4 and HBS1 are in contact on the surface and so offer a large binding surface to 
HS, with at least two different dispositions of the HS chain, there is an HBS3 N-
terminal to the first beta strand (104). The electrostatic mapping of the FGF10 shows 
that HBS3 is isolated by an acidic/neutral border from HBS1 and HBS4 
(Supplementary figure 5.6). This border is composed of Y130, V206 and H207. FGF17 
and FGF18 were found to slightly immobilise HS brushes in FRAP measurements and 
so cross-link HS chains. FGF17 and FGF18 are from the same subfamily and share 
similar HBSs: HBS1 and HBS2. Their surface electrostatic potentials show acidic 
borders isolating their HBSs (Supplementary figure 5.7and Supplementary figure 5.8). 
In FGF17, K82 (HBS1) is isolated from K76 (HBS2) by an E78D79G80 acidic border. In 
FGF18, the constituents of this acidic border are: E103, E105 and E78D79. These 
isolate HBS1 (K113 to K119) from HBS2 (K82, K102). FGF20 may have a secondary 
HBS, consisting a single K205 close to the N-terminal, which is separated from the 
neighbouring HBS1 residues by an acidic border (56). However, the present results, 
which demonstrate no cross-linking of HS by FGF20 argue that this is not an 
independent binding site.  
The above structural explanation, combining multiple HBSs and acidic borders would 
appear to be explain whether an FGF can crosslink HS chains. However, it does not 
explain why some FGF10, FGF17 and FGF18 only cause partial crosslinking. In FRAP 
experiments with these FGFs there is a significant mobile fraction of SAv, as well as 
the immobile fraction (Supplementary figure 5.5), which is a hallmark of stable 
crosslinking.  
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In terms of affinity and kinetics, there are no direct measurements on the secondary 
HBSs of FGFs. One study using synthetic peptide derived from the amino acid 
sequence of FGF2 indicates that its secondary HBSs are likely to be of low affinity and 
possess rapid off rates (102). However, when an FGF is bound to the polysaccharide 
via its HBS1, proximity effects would mitigate the lower affinity. Indeed, the selective 
identification of lysine side chains involved in hep binding in FGFs requires a stable 
interaction during the initial 5 min protection step (103). Data acquired by this 
approach (56, 103, 104) demonstrate that the majority of the lysine side chains 
remain bound over 5 min. There are instances where a single lysine is both 
biotinylated (so remains bound) and acetylated (has dissociated from the 
polysaccharide during the 5 min protection step). However, only some lysines in a 
given HBS are in such a dual state. Consequently, over 5 min, it would appear that 
neither primary nor secondary HBSs fully dissociate from the polysaccharide. This 
would seem to preclude cycles of dissociation-association explaining the partial 
cross-linking of HS chains by FGF10, FGF17 and FGF18 that have multiple HBS.  
Polysaccharide binding site exchange, is compatible with the data on modification of 
lysine residues. This mechanism does not require exposure of the lysine side chains 
to solvent. While there are no data on heparin-binding proteins, biophysical analysis 
of DNA binding proteins indicates that these not only slide along an individual strand 
of DNA but can exchange between strands without dissociating from the nucleic acid 
polymer (188).Five of the FGFs were available as Halo-tagged proteins and so could 
be used to measure the mobility of the FGF itself. There was some correspondence 
between an FGF’s ability to crosslink HS chains and its mobility in the HS brush. This 
holds for FGF2 (crosslinks and immobile), FGF10 (partly immobile and partly 
crosslinks), FGF6 and FGF20 (do not cross-link and highly mobile). However, FGF1 is 
a puzzle in this respect, since it does not cross-link HS chains, yet is only partly mobile. 
FGF mobility has been measured in various cell systems, most recently in rat 
mammary fibroblasts. The present results have some differences with those acquired 
in these cells. The most striking include the lack of mobility of FGF2 (mobile in cells), 
the mobility of FGF10 (immobile in cells) and the binding and mobility of FGF20 
(failed to bind fibroblast pericellular matrix). It is not known to what extent this 
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fibroblast pericellular matrix is representative. In any case these difference highlight 
that the HS brush is a model. Extracellular matrix is far more complex. The HS itself 
may be more complex in structure, endogenous HS binding proteins may affect HS 
chain structure and there are other sulfated GAGs present. Thus, the extent to which 
the physical basis of interaction of an FGF with HS determines the dynamics of that 
FGF in extracellular matrix must depend also on the properties of that extracellular 
matrix.  
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Supplementary figures 
 
Supplementary figure 5.1: Quantitative characterisation of a mid-dense HS brush by SE. 
A. Real time monitoring of SLB formation on a silicon oxide wafer. SUVs containing 99.5:0.5 
mol:mol DOPC:DOPE-CAP-biotin were injected in the SE chamber to a final concentration of 
50 µg.mL-1 and the areal mass density (m) was extracted from the SE data, the SLB obtained 
was characterised by m= 345 ± 12 ng.cm-2 (mean ± standard deviation of 23 experiments). B. 
Real time monitoring of the binding of SAv on the SLB. SAv was injected to a final 
concentration of 20 µg.mL-1, and the surface coverage at saturation was, Γ= 1.7 ± 0.1 
pmol.cm-2 was extracted from the SE data. C. Real time monitoring of the anchoring of 
biotinylated HS (HS) to the SAv layer. HS was injected to a final concentration of 5 µg.mL-1, 
and the areal mass density at saturation was Γ= 1.2 ± 0.3 pmol.cm-2 (assuming Mw = 12 kDa). 
D. Estimated root-mean-square distance between molecules of SAv and HS. A box plot of the 
standard error is presented with the mean of the values (black diamonds) marked by a line. 
The whiskers represent the standard deviations. 
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Supplementary figure 5.2: Quantitative analysis of the effect of FGF1 and FGF2 on HS 
mobility. 
Time-resolved profile analysis was used to extract the size (top) and diffusion constant 
(bottom) of the mobile fraction from FRAP data obtained before (HS) and after 30 min 
incubation with FGFs at 0.28 µM and rinsing with working buffer. A box plot of the standard 
error is presented with the mean of the values (black diamonds) marked by a line. The 
whiskers are indicate to the standard deviations. The mean comparisons tests (right panels) 
were carried out with a Fisher test at a level of significance of 5 %. The tables present the 
mean difference between factors; significant differences are highlighted in bold. The data 
presented is for a minimum of 3 independent measurements. 
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Supplementary figure 5.3: Surface electrostatic potential mapping and position of heparin 
binding lysines in FGF4. 
Identified heparin binding lysines in HBS1 and HBS3 in FGF4 (1IJT) are labelled in green (56). 
The electrostatic mapping of partial charges [-1.8 (red), 0 (white) and +1.8 (blue)] was 
generated using the Poisson-Boltzmann algorithm in SPDBV. The N-terminal residue is 
labelled in black. 
 
 
 
Supplementary figure 5.4: Surface electrostatic potential mapping and position of heparin 
binding lysines in FGF9. 
Predicted heparin binding lysines in HBS1 of FGF9 (1IHK) are labelled in green (56). The 
electrostatic mapping of partial charges [-1.8 (red), 0(white) and +1.8 (blue)] was generated 
using the Poisson-Boltzmann algorithm in SPDBV. The N-terminal residue is labelled in black.  
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Supplementary figure 5.5: Quantitative analysis of the effect of FGFs on HS mobility. 
Time-resolved profile analysis was used to extract the size (left) and diffusion constant (right) 
of the mobile fraction from FRAP data obtained before (HS) and after 30 min incubation with 
FGFs at 0.28 µM and rinsing with working buffer. The mean comparison tests (bottom panels) 
were carried out with a Fisher test at a level of significance of 5 %. The tables present the 
mean difference between factors; significant differences are highlighted in bold. The data 
presented is for a minimum of 3 independent measurements 
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Supplementary figure 5.6: Surface electrostatic potential mapping and position of heparin 
binding lysines in FGF10. 
Identified hepbinding lysines in HBS1 and HBS4 in FGF10 (1NUN) are labelled in green (56). 
The electrostatic mapping of partial charges [-1.8 (red), 0(white) and +1.8 (blue)] was 
generated using the Poisson-Boltzmann algorithm in SPDBV. The N-terminal residue is 
labelled in black. 
 
 
Supplementary figure 5.7: Surface electrostatic potential mapping and position of 
hepbinding lysines in FGF17. 
Identified hepbinding lysines in HBS1 and HBS2 in FGF17 (2FDB) are labelled in green (56). 
The electrostatic mapping of partial charges [-1.8 (red), 0(white) and +1.8 (blue)] was 
generated using the Poisson-Boltzmann algorithm in SPDBV on the structure of FGF8 (2FDB). 
The N-terminal residue is labelled in black. 
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Supplementary figure 5.8: Surface electrostatic potential mapping and position of heparin 
binding lysines in FGF18. 
Identified hepbinding lysines in HBS1 and HBS2 in FGF18 (4CJM) are labelled in green (56). 
The electrostatic mapping of partial charges [-1.8 (red), 0(white) and +1.8 (blue)] was 
generated using the Poisson-Boltzmann algorithm in SPDBV. The N-terminal residue is 
labelled in black.  
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Supplementary figure 5.9: SAv-coated SLBs are inert to FGF binding as monitored by QCM-D. 
After the formation of the SLB and SAv layer as described in Figure 5.3, the FGFs were infused 
at 0.28 µM to test for non-specific interactions with the HS-free surface. The tested FGFs: 
FGF1 (A), FGF2 (B), FGF4 (C), FGF9 (D), FGF10 (E), FGF17 (F) and FGF18 (G) did not present 
any interaction with the system. 
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Supplementary figure 5.10: QCM-D monitoring of HaloFGF binding to mid-dense HS films. 
The frequency (panels A, C, E, G and I) and dissipation (panels B, D, F, Hand J) shifts presented 
are offset after the formation of the HS brush. HaloFGF1 (panels A and B), HaloFGF2 (panels 
C and D), HaloFGF6 (panels E and F), HaloFGF10 (panels G and H) and HaloFGF20 (panels I 
and J) were infused at 0.28 µM until maximum of binding (blue arrows indicate the duration 
of the incubation) before rinsing with working buffer. The rinsing step was carried out for a 
minimum of 20 minutes. 
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Supplementary figure 5.11: Illustration of FRAP of biomolecules in the ECM models.  
HS. SUVs containing 99.5:0.5 mol:mol DOPC:DOPE-CAP-biotin were put in contact with a 
clean glass cover slip for 30 min at 50 µg.mL-1. After rinsing, SAv-atto was incubated for 30 
min at 20 µg.mL-1. The surface was rinsed with working buffer and incubated with 5 µg.mL-1 
HS for 30 min. Soluble HS was rinsed off with working buffer prior to FRAP. The panel shows 
that the bHS brushes recovered the fluorescence in the bleached area by lateral mobility 
within 100 s. SAv crystal. SUVs containing 95:5 mol:mol DOPC:DOPE-CAP-biotin were put in 
contact with a clean glass cover slip for 30 min at 50 µg.mL-1. After rinsing, SAv-atto was 
incubated for 30 min at 20 µg.mL-1. The surface was rinsed with working buffer prior to FRAP. 
Domains of homogeneous fluorescence intensity can be observed that are stable over time 
and immobile (one domains is outlined in red). These most likely represent single two-
dimensional crystals, with the fluorescence intensity varying between domains owing to 
their different orientation (fluorescence anisotropy). HaloFGF10. SUVs containing 95:5 
mol:mol DOPC:DOPE-CAP-biotin were put in contact with a clean glass cover slip for 30 min 
at 50 µg.mL-1. After rinsing, non-labelled SAv was incubated for 30 min at 20 µg/ml. The 
surface was rinsed with working buffer and incubated with 5 µg.mL-1 of HS for 30 min, 
forming an immobile dense HS brush. After rinsing, HaloFGF10 was incubated for 30 minutes 
at 0.28 µM, rinsed with working buffer and FRAP images were recorded to track the mobility 
of the HaloFGF proteins. 
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Supplementary figure 5.12: Quantitative analysis of HaloFGF mobility in HS films. 
Time-resolved profile analysis was used to extract the size (left) and diffusion constant (right) 
of the mobile fraction from FRAP data obtained after 30 min incubation with FGFs at 0.28 
µM and rinsing with working buffer. HAloFGF2 did not present a detectable mobile fraction. 
 
 
 
Supplementary figure 5.13: Quantitative analysis of the effect of HaloFGFs on HS mobility. 
Time-resolved profile analysis was used to extract the size (left) and diffusion constant (right) 
of the mobile fraction from FRAP data obtained before (HS) and after 30 min incubation with 
HaloFGFs at 0.28 µM and rinsing with working buffer. The mean comparison tests (bottom 
panels) were carried out with a Fisher test at a level of significance of 5 %. The tables present 
the mean difference between factors; significant differences are highlighted in bold. The data 
presented is for a minimum of 3 independent measurements 
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5.3 A HBS3- mutant of FGF2 also rigidifies and immobilizes HS 
brushes 
In section 5.2, we showed the differences and similarities between FGF1 and FGF2 
and suggested that the HBS composition along with acidic borders regulates the 
immobilisation of HS brushes by FGFs. Here we compare an HBS3- mutant of FGF2 
with its native counterpart to draw an understanding of the relative role of HBS3 in 
FGF2 interaction with HS. A cDNA encoding for a mutant of FGF2 with a silenced 
hepbinding site 3 (160K/A, 163K/A and 164R/A) (FGF2 HBS3-) (Life Technologies, 
Paisley, UK) with restriction sites for BamHI (New Englands Biolabs, Ipswich, USA) and 
NcoI (New Englands Biolabs) was amplified by polymerase chain reaction and 
inserted in the plasmid vector pET-M11 using the T4 DNA ligase (New Englands 
Biolabs) (57). 
 
 The binding of FGF2 HBS3- to HS in QCM-D triggered a drop in Δf that 
stabilised to a maximum of binding (Figure 5.18). The final change in Δf, 38 Hz was 
higher than the one of FGF2, 32 Hz (section 5.2), though the Δf (measure of surface 
coverage) in QCM-D encompasses not only the bound molecules but also the coupled 
solvent. Thus, the greater Δf, observed for FGF2 HBS3- may not reflect differences in 
the amount of bound protein. The rinsing step seemed to have the same effect on 
both brushes, partially desorbing the protein with a 16 Hz shift in Δf. The ΔD showed 
a transient increase quickly followed by a decrease, suggestive of a rearrangement 
of the film. The final ΔD was lower than that of the original brush, similarly to the 
level observed for native FGF2, suggesting the establishment of rigid structures.  
The quantification of FGF2 HBS3- in HS brushes by SE showed that at maximum 
binding the amounts of FGF2 and FGF2 HBS3- bound to HS were equivalent with no 
significant difference. Thus, at maximum of binding the areal mass densities of 6.1 ± 
0.7 and of 7.1 ± 1.0 pmol.cm-2 for FGF2 and FGF2 HBS3-, respectively, were not 
significantly different. Assuming a molecular weight of 12 kDa for the HS chains (181) 
and its areal mass density of 1.1 pmol.cm-2 (section 5.2), this yielded an average 
stoichiometry of 6 ± 1 FGF2 and FGF2 HBS3- molecules, per HS chain, respectively, at 
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maximal loading (Figure 5.19). After rinsing, the amount of FGF per brush decreased 
slightly to 4 ± 2 FGF2 and 4 ± 1 FGF2 HBS3- per HS chain, again the values for the 
mutant and the native FGF2 were not significantly different. Consequently, the 
greater reduction in Δf observed for FGF2 HBS3- will reflect a difference in coupled 
solvent. 
 
 
Figure 5.18: QCM-D monitoring of FGF2 HBS3- binding to a mid-dense HS brush. 
The frequency (A) and dissipation (B) were offset after the formation of the HS brush (cf. 
Figure 5.3). FGF2 HBS3- was infused at 0.28 µM until equilibrium (blue arrows indicate the 
infusion time) before rinsing with working buffer.  
 
 In QCM-D (Figure 5.18), the level of ΔD/-Δf = 0.07 × 10-6 Hz-1 at maximal 
coverage is comparable for FGF2 and FGF2 HBS3-, and a superposition of the 
parametric plots (Figure 5.20C) shows that the trends for rigidification on binding are 
similar for both the mutant and the native FGF2. Upon rinsing and release of the 
molecules both films did not recover softness while releasing some of the protein, 
suggesting that the established rigid film could release some FGF while staying stiffly 
crosslinked. However, during the dissociation the trends were different, as seen in 
the superimposed parametric plots (Figure 5.20), suggesting that the final structures 
of the films might differ. 
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Figure 5.19: Stoichiometry of FGF2 and FGF2 HBS3- binding to HS. 
Molar FGF surface densities were determined by SE at equilibrium after incubation at 0.28 
µM (dark grey), and after rinsing with working buffer for at least 60 minutes (light grey), and 
compared to molar HS surface densities obtained in the same measurements. The data 
presented is for a minimum of 2 independent measurements, and mean values with standard 
deviations are presented. The data for FGF2 from was extracted from section 5.2.2. 
 
 
Figure 5.20: HBS3 mutant of FGF2 subfamily bind and rigidify HS brushes. 
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Parametric plots of ΔD/-Δf (a measure of softness) vs. -Δf (a measure of surface coverage) 
for the HS film, first without (until -Δf ≈ 12 Hz, process of HS film formation indicated with 
black arrow) and then with FGFs bound (data extracted from Figure 5.18 and section 5.2). HS 
brushes rigidify progressively upon FGF2 (A) and FGF2 HBS3- (B) binding. Upon rinsing (the 
start of rinsing is indicate with a blue arrow head), the FGFs desorbed following protein 
specific trends (blue arrows). Overlay of the parametric plots (C) show that all binding curves 
fall on top of each other, indicating that the proteins have very similar coverage-dependent 
effects on HS film morphology. Unbinding curves were also similar upon rinsing and protein 
release. 
 
In FRAP measurements, we recorded the mobility of the SAv-anchored HS molecules. 
To this end, we exploit the inherently high lateral mobility of SAv when formed as 
mid-dense monolayers on SLBs. Figure 5.21 shows how the mean intensity of the 
bleached spot recovers over time for a film of bare HS (Figure 5.21A) and for HS films 
that were incubated with FGF2 and FGF2 HBS3- at 0.28 µM for 30 min and then rinsed 
with incubation buffer (Figure 5.21B-C). These plots provide a simple visual 
comparison of the recovery of fluorescence, and the mobility of the fluorescent SAv 
with bound HS chains. In addition, Figure 5.22 provides a quantitative analysis of the 
size and diffusion constant of the mobile fraction. 
The quantitative analysis of the FRAP data characterised an HS brush as 97 ± 1% 
mobile with a diffusion constant of 1.7 ± 0.5 µm2.s-1 (Figure 5.22). FGF2 essentially 
immobilised the HS chains, and only little recovery was observed for 300s post 
bleaching (Figure 5.21B). In contrast, HS in the HS-FGF2 HBS3- films was much more 
mobile (Figure 5.21C). HS brushes with bound FGF2 HBS3- recovered up to 80% of 
the fluorescence in the bleached area. Accordingly, the mobile fraction of the bHS-
FGF2 HBS3- brush was significantly higher than in the HS-FGF2 brush, but lower than 
in the bare HS brush (Figure 5.21 and Figure 5.22).  
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Figure 5.21: FGF2 and FGF2 HBS3- immobilise HS with different potencies. 
FRAP curve of atto488-SAv supporting HS (A), HS-FGF2 (B, extracted from section 5.2and HS-
FGF2 HBS3- (C) films. The black curve and the grey region around it are the mean and 
standard deviation, respectively, of 4 measurements obtained after rinsing with the working 
buffer. 
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Figure 5.22: Quantitative analysis of the effect of FGF2 and FGF2 HBS3- on HS mobility. 
Time-resolved profile analysis was used to extract the size (top) and diffusion constant 
(bottom) of the mobile fraction from FRAP data obtained before (HS) and after 30 min 
incubation with FGFs at 0.28 µM and rinsing with working buffer. A box plot of the standard 
error is presented with the mean of the values (black diamonds) marked by a line. The 
whiskers are indicate to the standard deviations. The mean comparisons tests (right panels) 
were carried out with a Fisher test at a level of significance of 5 %. The tables present the 
mean difference between factors; significant differences are highlighted in bold. The data 
presented is for a minimum of 3 independent measurements. 
 
5.4 Discussion 
The results in section 5.2 suggest that the HBS3 mutation did not affect the level of 
binding of the protein to the HS brush (Figure 5.20), but the generated film 
undoubtedly has a different structure and viscoelastic properties than the film 
formed by the native FGF2 and HS. The primary determinant for binding is HBS1, 
since this has an affinity that is over two orders of magnitude higher than the 
secondary HBSs (102, 189). So it is not surprising that the FGF2 HBS3- mutant binds 
to the same extent as the wild-type protein. However, it is clear that once bound, the 
presence or absence of HBS3 has an effect on the film’s properties. In terms of 
affinity, once HBS1 is engaged with the polysaccharide, proximity will mean that the 
secondary HBSs are likely to bind strongly, which is consistent with the efficient 
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selective labelling of the lysines in these sites (Ori et al., 2009). The FGF2 HBS3- 
mutant crosslinks HS, but compared to FGF2, a substantial fraction of the HS chains 
are somewhat mobile. Thus, FGF2 HBS3 is less effective at crosslinking HS chains than 
FGF2, which suggests a role for this secondary binding site in determining this effect 
of the FGF on HS. 
In terms of the relative importance of the different secondary HBSs in contributing 
to the crosslinking of HS by an FGF further mutants could not be analysed, since the 
FGF2 HBS2- and the double HBS2-/HBS3- mutants were not expressed as stable or 
soluble proteins, respectively. For an FGF to crosslink HS chains it would seem that it 
must have multiple HBSs and that these should be isolated from one another by an 
acidic border. It is also possible that HBS2 and HBS3 contribute differently. Thus, 
HBS2 is part of the core structure of the FGF, whereas HBS3 is at the N-terminus of 
this, lying at the start or in front of beta strand 1.  HBS3 is consequently on the 
opposite face of the protein to HBS1 and so may have a greater contribution to 
crosslinking than HBS2. Such ideas will require an extensive set of mutant proteins 
(section 8.2). 
In this chapter, the interactions of FGFs with HS have been measured. However, at 
least some FGFs interact with other sulfated GAGs. For example, FGF10 is 
demonstrated to bind CS and DS in vitro and also to CS/DS on cells (56, 185). 
Moreover, it has been established by others that the CS-E behaves for at least some 
proteins, notably, FGF2, similar to hepin terms of its ability to bind the protein and 
enable signalling through the FGFR (190). However, there have been very few 
quantitative analyses of the interactions of proteins, let alone FGFs, with sulfate 
GAGs other than HS/heparin. In addition, the backbone and sulfation pattern of the 
chondroitin based GAGs differs from heparin/HS (section 1.3.3). Thus, an analysis of 
the interactions of the FGFs used in this chapter with other GAGs would provide 
considerable insight into the potential roles that these different interactions might 
have. 
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6 Interaction of FGFs with brushes formed with different GAGs. 
6.1 Introduction 
In this chapter, I investigated the effect of FGFs on brushes made from a selection of 
sulfated GAGs other than HS. Specifically, I tested FGF1, FGF2, FGF2 HBS3-, FGF4, 
FGF9, FGF10, FGF17 and FGF18 with the GAGs: hep(Hep), chondroitin sulfate A (CS-
A), chondroitin sulfate C (CS-C), chondroitin sulfate E (CS-E), and dermatan sulfate 
(DS), and with DS-derived oligosaccharides of 18 monosaccharide units (DS dp18). 
The GAG brushes were prepared for QCM-D, SE and FRAP assays as described in 
sections Error! Reference source not found. and Error! Reference source not found. 
and the results were analysed as described in sections Error! Reference source not 
found. and Error! Reference source not found.. 
6.1.1 Origin, composition and structural characteristics of GAGs 
The GAGs differ by their glycosidic linkage, disaccharide composition, and sulfation 
as briefly described in section 1.3.3. 
Highly sulfated GAGs, HS and Hep. The HS polysaccharide used in (insert here 
reference to section 5) is relatively well characterized: it is from porcine intestinal 
mucosa, and the employed batch had an average molecular weight of 12 kDa, a 
polydispersity index of 1.6 and an average sulfation of 1.4 sulfates per disaccharide 
(124). Although we do not have the provenance of our hep batch, hep from various 
sources have been well characterised in the literature. The main disaccharide unit of 
porcine Hep is: 4-) L-IdoA,2S α (1-4) D-GlcNS,6S (1- (191-193), with an average of 2.75 
sulfate groups per disaccharide (43).  
Chondroitin and dermatan sulfates. The DS (dp18) oligosaccharide has an average 
size of 4.5 kDa and contains mostly IdoA (1-3) GalNAc,4S (88%) and also IdoA,2S (1-
3) GalNAc,4S (7%). It was obtained by partial chondroitin ABC lyase digestion of shark 
dermatan sulfate (125). The other GAG polymers were less characterized. Based on 
assumed molecular weights of 13 kDa for Hep and 30 kDa for CS-A, the molecular 
weights of CS-C, CS-E and DS polysaccharides were estimated at 26 kDa, 26 kDa and 
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6.5 kDa, respectively, using size exclusion chromatography analysis (section 4.2.3). 
The CS-A (GlcA (1-3) GalNAc,4S) sample is from bovine trachea, the provenance of 
the CS-C (GlcA (1-3) GalNAc,6S) is not known, and CS-E (GlcA (1-3) GalNAc,4,6diS) was 
prepared by chemical modification of the CS-C as described previously (194). DS, IdoA 
(1-3) GalNAc-4S is from porcine intestinal mucosa. The disaccharide composition of 
our CS-A, CS-C, CS-E and DS was not analysed and it is likely that these are not pure 
but do also contain fractions of other CS or DS disaccharides. Indeed in the case of 
the bovine trachea CS-A, it appears that this is a mixture of non- (10%), 4- (52%) and 
6- (39%) sulfated of GlcA (1-3) GalNAc disaccharides (195). Thus, it contains 
approximately 39% of CS-C disaccharides. All GAGs were biotinylated by oxime 
ligation at the reducing end (section 4.2.3, (123)).  
Brushes of non-HS GAGs have not been produced previously so the first step was to 
characterise these. Following their assembly and characterisation, they were probed 
with different FGFs. The in solution preferences of the FGFs used here for different 
GAGs have been extensively characterised (56, 104). However, these preferences 
may change when the GAG chains are presented as a brush, so the analysis was not 
restricted to just FGFs that are considered to bind GAGs such as CS-A. Otherwise, as 
in chapters 5, the measurements were QCM-D, SE and FRAP. 
6.1.2 Characterization of GAG brushes. 
Prior to the infusion of FGFs, GAG brushes were formed on mid-dense SAv 
monolayers as described earlier (sections 4.2 and 5.2). The GAG binding was 
monitored by QCM-D and the GAG surface density was quantified by SE (Error! R
eference source not found.). All GAG types were found to bind to the SAv monolayer: 
binding occurred at largely comparable rates, and all GAGs remained stably bound 
upon rinsing with working buffer (Error! Reference source not found.A). Moreover, 
the QCM-D frequency shifts (Error! Reference source not found.A) were associated 
with substantial increases in dissipation (Error! Reference source not found.B) 
indicating that relatively soft films are formed. All these responses are consistent 
with the specific attachment of the GAG chains via biotin at the reducing end, and 
indicate that GAG brushes formed as expected. 
108 
 
The parametric plot (Figure 6.1C) enables a comparison of the GAG film softness 
(parameterized as ΔD/-Δf) as a function of surface coverage (parameterized as -Δf). 
It can be seen that all GAGs produce films of similar softness: Hep, CS-C, CS-E and DS 
(6.5 kDa) exhibit a softness that is virtually indistinguishable from HS, and CS-A and 
DS (dp18) are only slightly softer. 
 
Figure 6.1: Characterisation of mid-dense GAG brushes.  
The changes in Δf (A) represent the evolution of mass adsorption at the surface of the sensor; 
ΔD (B) provides information about the mechanical properties of the film with an increase 
being associated with a softer film. The biotinylated GAGs were infused at 5 µg.mL-1 on mid-
dense SAv monolayers as described previously (sections 4.2 and 5.2). The time before 
infusion of each GAG was purposely varied to facilitate visibility of each data set. C. 
Parametric plot of the QCM-D data in (A) and (B). The binding of biotinylated Hep, HS, CS-C, 
CS-E and DS (6.5 kDa) followed the same trend while the ones of CS-A and DS (dp18) followed 
a slightly different one. D. Surface densities of mid-dense GAG polymer brushes as measured 
by SE (surface densities of DS (dp18) were not determined). 
 
Figure 6.1D shows the GAG molar surface densities at saturation. These where 
calculated from the areal GAG mass densities, measured by SE, and the nominal GAG 
molecular weights. It is notable that the molar surface densities varied: they were 
between 0.5 and 1 pmol.cm-2 for most GAGs, though CS-C and CS-E had exceptionally 
low surface densities of 0.11 ± 0.01 and 0.08 ± 0.02 pmol.cm-2, respectively. At first 
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view, these variations are unexpected, because the SAv monolayers have a defined 
density of free biotin binding sites and with one biotin per GAG the molar GAG 
surface density should equal the density of binding sites. Specifically, for a SAv 
density of 1.7 pmol.cm-2, the average residual valence has been estimated at 1.7 
(137), giving a surface density of free biotin binding sites of 2.6 pmol.cm-2. One 
explanation for the lower apparent surface densities is that the biotinylated hep, CS-
A, CS-C, CS-E and DS supplied still had individual free biotin. This would compete for 
the SAv. At least for the CS-A, CS-C, CS-E and DS there may also be uncertainty as to 
their average molecular weight. If so, the overestimated molecular weights would 
lead to apparent reduction of the surface densities. Moreover, the size distribution 
based measurements of hydrodynamic radius will, when converted to molarity, be 
skewed towards smaller polymers. Thus, even for the same reactivity, there may be 
a bias towards smaller sizes in the reacted product simply because of differences in 
concentration of larger and smaller reactants. There is also some uncertainty about 
the average molecular weight of the GAG polymers (Heparin, CS-A, CS-C, CS-E and DS 
(6.5 kDa)) in the solution phase. Taken together, the above analysis provides 
evidence that brushes can be formed with all GAG types, but that the molar surface 
density (and the average molecular weight) of GAG polymers in the brush should be 
considered with caution (196). These considerations are also applicable to the HS 
brush (Chapter 5), as described previously, where the average molecular weight of 
this HS batch appears to be 5.2 ± 0.6 kDa when anchored by our method (section 4) 
instead of the 12 kDa measured in the solution phase (120). 
6.2 Interaction of members of the FGF1 subfamily with sulfated 
GAGs  
In this section, I describe and characterise the binding of the members of the FGF1 
subfamily towards different GAG types and the consequent changes in the structure 
of the GAG brushes. In addition, the FGF2 HBS3- mutant was also used, to determine 
if the loss of the N-terminal secondary HBS, HBS3, had an impact on interactions with 
GAGs other than HS. 
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6.2.1 Binding of FGF1 and FGF2 to GAG brushes. 
To assess the binding propensity and stioichiometry of the members of the FGF1 
subfamily, the proteins were infused on GAG brushes in QCM-D to detect their 
interactions with the films and in SE to quantify the binding stoichiometry. Detailed 
plots of the QCM-D assays are presented in section 5 for HS, and in Supplementary 
figure 6.1 to Supplementary figure 6.3 for the other GAGs. 
FGF1. In the conditions of the assays, FGF1 showed detectable binding to Hep, CS-E, 
DS (6.5 kDa) and DS (dp18), but none to CS-A or CS-C (Supplementary figure 6.1). 
Upon rinsing in working buffer, some FGF1 dissociated from heparin, but not from 
DS and the DS-derived dp18. In contrast, the FGF1 rapidly and fully dissociated from 
CS-E. The binding of FGF1 to the brushes generated a decreased (DS (dp18)) or 
increased (Hep, DS (6.5 kDa), CS-E) ΔD signal. The ΔD remained stable during the 
rinsing (Hep, DS) or returned to the bare brush level in the case of CS-E. The small 
and rapid changes in Δf and ΔD (Supplementary figure 6.1) observed upon infusion 
of FGF1 on brushes of CS-A and of CS-C are likely to reflect changes in solvent. Thus, 
FGF1 bound to heparin, as expected, and DS, had a weak transient interaction with 
CS-E and did not interact with CS-A and CS-C. 
FGF2. FGF2, on the other hand, bound to brushes of all the tested GAGs 
(Supplementary Figure 6.2). The change in Δf was similar to that seen for HS brushes 
for brushes of hep but lower for brushes of CS-A, CS-C, and CS-E and very low for DS 
(Supplementary Figure 6.2). After rinsing there was little dissociation of FGF2 from 
the heparin, CS-A, CS-C, and CS-E brushes, whereas for DS the frequency shift 
returned to the level observed before the addition of FGF2, indicative of complete 
dissociation. The ΔD signals upon binding of FGF2 were significantly decreased (Hep) 
or increased (CS-A and CS-C), or unchanged (CS-E and DS). GAG brushes were also 
probed with FGF2 HBS3-, which has a mutated HBS3 (Sections 5) to determine 
whether this secondary binding site might affect interactions with GAGs other than 
HS (Supplementary figure 6.3). In these experiments, binding to CSC was not tested. 
FGF2 HBS3- bound hepto the same extent as HS, however it bound CS-E, DS (6.5 kDa) 
and DS (dp18) to a much lesser extent and failed to bind to brushes of CS-A (CS-C was 
not tested). After rinsing there was some dissociation of FGF2 HBS3- from hepand 
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proportionally more from CS-E, DS (6.5 kDa) and DS (dp18), suggesting that the 
interaction with the latter was quite transient. In the instances where FGF2 HBS3- 
bound the GAG brushes, the dissipation signal was the same as for FGF2: decreased 
(Hep) or unchanged (CS-E and DS).  
Individually, FGF1, FGF2 and FGF2 HBS3- thus presented different binding towards 
the tested GAGs, as also shown by the range of frequency shifts upon their exposure 
to the brushes. Notable differences were: (1) FGF2, but not FGF1, bound to CS-A and 
CS-C brushes; (2) FGF2 binding to CS-E was stable, but FGF1 binding was transient 
and so rapidly reversible; and (3) mutation of the HBS3 in FGF2 prevented the binding 
to CS-A and markedly affected the interaction with CS-E.  
The results for FGF1 concur with previous reports by others. In a study of genuine CS-
E isolated form a natural source, no binding of FGF1 was observed (190), which is 
consistent with the transient interaction seen with the CS-E brush here, since after 
washing, all the FGF1 dissociates. Similarly, a weak interaction of FGF1 with DS and 
an absence of interaction with CS-A or CS-C and a weak interaction with DS have 
previously been reported (104). Somewhat puzzling is the greater interaction of FGF1 
with the DS derived dp18 compared to DS itself. This may result from the partial 
digestion with chondroitinase ABC enriching binding sequences or to differences in 
grafting density of these DS species.  
The FGF2 data are more puzzling. The interaction with CS-E was expected, since this 
has been previously reported and indeed CS-E has been shown to enable the 
formation of a signalling complex between FGF2 and the FGFR (190). The weak, 
transient interaction with DS is also consistent with previous data (56). However, the 
marked interaction with CS-A and CS-C has not previously been reported. Indeed, 
these galactosaminoglycans are considered to not bind FGF2 (56). The interaction of 
FGF2 with brushes of CS-A and CS-C are unlikely to be due to contaminating HS, since 
FGF1 failed to bind. They are also unlikely to be due to simple charge density of the 
brush and ion-exchange, because the interaction with brushes of DS were much 
weaker. One possibility is that presentation of CS-A and CS-C in a mid-dense brush 
allows movement of the SAv and so local reorganisation of the brush upon initial 
FGF2 binding. This may allow good binding sites, likely contributed by several chains 
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to form, though the same would be expected for DS, which contains iduronate 
residues, known to be important in the interaction of the HBS1 of FGF2 with hep and 
HS (55). 
6.2.2 Rigidification of GAG brushes by members of the FGF1 subfamily 
The parametric plots of the QCM-D data were used to analyse the effect of FGFs on 
GAG brush stiffness. These plots are in Supplementary Figs 6.1, 6.2 and 6.3 for FGF1, 
FGF2 and FGF2 HBS3-, respectively. Figure 6.2 combines these data for HS, Heparin, 
CS-E and DS (i.e. for all GAGs that showed binding of FGF1 and FGF2), for comparison 
between the two members of the FGF1 subfamily. In all instances where FGFs bound 
to the GAG brushes, a decrease in ΔD/-Δf was observed, denoting a stiffening of the 
GAG films. 
 
Figure 6.2: Comparative parametric plot analysis of the interaction of members of the FGF1 
subfamily with GAG brushes.  
Representative data is shown for the formation of mid-dense HS (A), Hep (B), CS-E (C), DS 
(6.5 kDa) (D) and DS (dp18) (E) brushes (green arrows), binding of FGFs at 0.28 µM until 
equilibrium, and subsequent rinsing with the buffer until stabilisation of the signal. Data for 
HS are taken from (insert here reference to chapter V). All other data were extracted from 
Supplementary Figures 6.1 to 6.3. Data of FGF2 binding to CS-A and CS-C are not shown here. 
 
Binding to HS and Hep brushes. At a given frequency shift, FGF1 generated 
significantly softer Hep films than FGF2 (Figure 6.2B), indicating that the effect of the 
two FGFs on Hep brushes is distinct. This is in contrast to HS, where the effects of 
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FGF1 and FGF2 were indistinguishable (Figure 6.2A), as already discussed in detail in 
section 5. The difference between HS and Hep with regard to rigidification is notable 
given that their FGF binding to the two GAGs was quite similar. It may arise from the 
greater charge density of hep compared to HS and the acidic isoelectric point of FGF1, 
which, compared to FGF2, could result in a film where the constituents repel each 
other to a greater extent. In contrast, FGF2 and FGF2 HBS3- did not present any 
detectable difference in binding to heparin, and were very similar towards HS 
(section 5.2). Apparently, the mutation of HBS3 does affect neither the magnitude of 
binding nor the morphology of the FGF loaded hep or HS films. 
Binding to CS-E brushes. There were substantial differences in film softness between 
FGF1 and FGF2 with CS-E: at comparable loading (i.e. frequency shifts), the binding 
of FGF1 generates a much softer structure than FGF2 (Figure 6.2C). Notably, the FGF2 
HBS3- mutant also generated a softer CS-E film than wild type FGF2. These 
differences likely reflect that FGF1 and FGF2 HBS3- dissociated from the brush 
rapidly, indicative of a transient interaction. Moreover, they support a role for HBS3 
in the interaction of FGF2 with CS-E brushes. FGF2 is the only FGF from this subfamily 
that has bound CS-A and CS-C. The binding rigidified the films in a rather smaller 
extent than HS, Hep or even CS-E (Supplementary figure 6.6). Indeed, the ΔD signals 
of FGF2 binding to CS-A and CS-C were increased, suggesting the formation of softer 
films when it was decreased for other GAGs.  
Binding to DS brushes. FGF1, FGF2 and FGF2 HBS3- induced similar degrees of 
rigidification on DS (6.5 kDa) brushes (Figure 6.2D). This is despite the fact that FGF2 
and FGF2 HBS3- appear to bind transiently to this brush, whereas at least a part of 
the bound FGF1 did not dissociate. The observed stiffening of the brush may then 
simply reflect the presence of proteins of very similar structure.  
In binding to DS (dp18), FGF1 and FGF2 HBS3- presented different rigidification 
trends. FGF1 had a much higher propensity to stiffen DS (dp18) than FGF2 HBS3- 
(Figure 6.2E) .This again is likely to reflect the differences in the interactions of these 
two proteins with this particular brush. FGF1 remains bound after rinsing, whereas 
FGF2 HBS3- dissociates, as the interaction is transient.  
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6.2.3 Binding stoichiometries of the FGF1 subfamily. 
To quantify the surface density of FGFs in GAG brushes, I performed complementary 
SE measurements for selected FGF-GAG interactions observed in QCM-D. : presents 
the binding stoichiometries, expressed in FGF molecules per GAG disaccharide. This 
presentation is preferable over the number of FGF molecules per GAG chain, because 
of the uncertain average molecular weight of the GAGs employed. Moreover, it 
enables quantitative comparison of the binding across GAGs, whilst a comparison of 
absolute amounts of FGF binding would be compounded by the fact that the areal 
GAG mass density varies substantially between GAGs. 
From Figure 6.3 it can be seen that the highest binding stoichiometries at equilibrium 
are observed for FGF1 on HS and DS, and for FGF2 on HS, Hep and CS-C. In all these 
cases, approximately one FGF binds per 4 disaccharides, corresponding to a footprint 
of roughly 4 nm GAG chain per FGF, on average. 
The disparities in binding stoichiometry towards HS for FGF1 vs FGF2 and FGF2 HBS3- 
were previously described in section 5: stoichiometries at equilibrium were 
comparable, but the rinsing step desorbed more FGF1 than FGF2 and FGF2 HBS3-, 
suggesting that the binding to FGF1 to HS is weaker than those FGF2 and FGF2 HBS3-
; notable is also the similarity in FGF2 and FGF2 HBS3- bindings on HS. The new data 
for FGF2 and FGF2 HBS3- on Hep brushes (Figure 6.3) shows binding stoichiometries 
that are comparable to HS, at equilibrium and also after rinsing. This is surprising, 
given that FGF2 is expected to bind preferably to the highly sulfated regions which 
are more frequent in Heparin. 
FGF2 bound to CS-C with a similar stoichiometry as to HS and Heparin, but there was 
less FGF2 bound per disaccharide for brushes of CS-A, CS-E and DS. Whereas rinsing 
did not significantly alter the amount of FGF2 bound per disaccharide of HS, heparin, 
CS-E and DS, it did result in a very large reduction in binding for CS-C, such that the 
amount of FGF2 bound per disaccharide of these galactosaminoglycans after rinsing 
was equivalent (Figure 6.3).  
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Figure 6.3: Stoichiometry of binding of members of the FGF1 subfamily to GAG brushes.  
The molar FGF surface densities were determined by SE, at equilibrium after incubation at 
0.28 µM (A), and after rinsing with working buffer until stabilisation (B), and compared to 
the GAG surface densities obtained in the same measurements. Binding stoichiometries are 
expressed as FGF molecules per GAG disaccharide, and were calculated as 
(mFGF/MW,FGF)/(mGAG/MW,GAG disaccharide) where mFGF and mGAG are the areal mass densities of 
FGF and GAG (determined by SE), MW,FGF is the molecular mass of the FGF, and the average 
molecular mass of the GAG disaccharide was assumed to be MW,GAG disaccharide = 0.5 kDa (180). 
Results are presented for FGF1 on HS and DS (6.5 kDa), for FGF2 on HS, Hep, CS-A, CS-C, CS-
E and DS (6.5 kDa), and for FGF2 HBS3- on HS, Hep and DS (6.5 kDa). Error bars indicate 
minimal and maximal responses based on two independent measurements; where error bars 
are missing, a single measurement was performed. The equivalent FGF per GAG chains values 
are reported in Supplementary figure 6.4.  
 
6.2.4 Cross-linking of GAG brushes by FGF1 and FGF2. 
Rigidification of the films may result from the cross-linking of the GAG chains by the 
FGFs, and so the immobilisation of the chains (if cross-linking is stable), or from some 
other effect. Immobilisation occurs when the FGF has multiple HBSs and these 
interact with different GAG chains. It also depends on these interactions having a 
lifetime that is not similar to that of the measurement time of the FRAP experiments. 
These were discussed in detail in section 5. It should be noted that whereas the 
selective labelling of lysine side chains provides a direct insight into the kinetics of 
interaction of particular HBSs and individual lysines therein for hep and in all 
likelihood HS, this is by no means certain for other sulfated GAGs, as there are no 
equivalent data published. Therefore the mobility of GAG chains in the FGF-loaded 
GAG brushes was analysed by FRAP. Figure 6.4 shows FRAP traces for the different 
GAG brushes loaded with FGF1 vs FGF2, and Supplementary Figure 6.9 shows the 
corresponding quantitative analysis of the mobile fraction and its diffusion constant. 
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The trends of the fluorescence recovery curves in Figure 6.4B show that the binding 
of FGF2 but not FGF1 reduces the mobility of heparin. This observation is consistent 
with our previous observation that FGF2 but not FGF1 immobilised HS (Figure 6.4A 
and section 5.). Although the recovery in the FGF2-loaded Hep brush appeared to be 
slightly faster in the FRAP traces (compare Figure 6.4A vs. B), the mobility parameters 
did not reveal significant differences between Hep and HS (Supplementary Figure 
6.9). 
In stark contrast to Hep and HS, FGF2 did not affect the mobility of CS-A and CS-C 
chains: the FRAP traces (Figure 6.4C-D) and the mobility parameters were virtually 
indistinguishable with and without FGF2 loading (Supplementary Figure 6.8 and 
Supplementary Figure 6.9). This demonstrates that FGF2 does not have the ability to 
cross-link CS-A and CS-C stably. Moreover, the increase in ΔD upon FGF2 binding to 
CS-A and CS-C brushes (Supplementary Figure 6.2), and related to this the relatively 
small decrease in ΔD/-Δf (Supplementary Figure 6.7), show that FGF2 rigidifies CS-A 
and CS-C brushes to a much lesser extent than Hep and HS brushes. Collectively, 
these data suggest that the propensity of FGF2 to cross-link CS-A and CS-C, even 
transiently, is low. 
Neither FGF1 nor FGF2 reduced the mobility of CS-E, as seen in the FRAP assays 
curves (Figure 6.4E and Supplementary Figure 6.9) and from the mobility parameters 
which were equivalent to the bare CS-E brush (Supplementary Figure 6.9).  
In regard to DS (6.5 kDa), we observed differential behaviour of FGF1 and FGF2. 
Whilst FGF1 did not significantly immobilise the brush, FGF2 did. The mobile fraction 
and diffusion constant of the FGF2-DS (6.5 kDa) were lower than the ones of the bare 
brushes, clearly showing the presence of an immobilised fraction of GAGs in the 
FGF2-loaded brush (Supplementary Figure 6.9). 
 
  
117 
 
 
Figure 6.4: Mobility of GAG chains in GAG brushes with FGF1 or FGF2. 
FRAP curves of atto488-SAv supported GAG brushes with FGF1 and/or FGF2. Prior to the 
measurement, mid-dense GAG brushes were incubated for 30 min with 0.28 µM of FGF1 or 
FGF2, and rinsed 10 times with working buffer (insert here reference to method section). 
FGF1 did not bind CS-A and CS-C brushes (cf. Supplementary Fig. A-1), and thus FRAP 
measurements were not performed. The black (FGF1) and blue (FGF2) curves are the means 
and their standard deviation of 4 independent measurements. Reference curves for the 
mobility of GAGs in virgin GAG brushes (without FGFs) are shown in Supplementary Fig. A-8, 
and results of the quantitative analysis of FRAP data are shown in Supplementary Fig. A-9. 
 
In highly sulfated GAGs (HS and Hep), FGF2 generated cross-linked/immobile 
fractions, 100% in HS and 55% in Hep. However, FGF2 did not crosslink chains in 
brushes formed from galactosaminoglycans. This includes CS-E, which is an 
uncontroversial binding partner of FGF2 (190). It is interesting that a greater level of 
cross-linking was observed for HS than for heparin. Heparin, which has more GlcNS 
residues has less flexibility than HS around the glycosidic bond, due to transient H-
bonds between the N-sulfate and the neighbouring uronic acid’s C3 hydroxyl (197), 
but more flexibility around the uronic acid due to a greater IdoA content. These data 
suggest that crosslinking may depend in part on the flexibility of the glycosidic bond.  
6.3 Interactions of FGF4, FGF9, FGF10, FGF17 and FGF18 with GAG 
brushes. 
In this section, interactions of FGF4 (HBS1 and HBS3), FGF9 (HBS1), FGF10 (HBS1 and 
HBS4), FGF17 (HBS1 and HBS3) and FGF18 (HBS1 and HBS3) with GAG brushes were 
studied in QCM-D (Supplementary Figure 6.10 to Supplementary figure 6.19). 
118 
 
6.3.1 Binding of FGFs to GAG brushes 
FGF4 bound to Hep, CS-E and DS (dp18), generating decreases in Δf. Upon rinsing, 
these slightly desorbed from the brushes but the major part of the bound protein 
remained. The decreases in Δf were associated with decreases in ΔD, indicating FGF4 
bound only weakly to CS-A, CS-C and DS (6.5 kDa), the Δf of binding was minor and 
rapid desorption occurred upon binding. FGF4 has a binding preference for N-
sulfated and 2-sulfated disaccharides over 6-sulfated ones (56). 
FGF9 binding to HS, Hep and CS-E was slow and continuous, and did not reach 
equilibrium over the timescale of the measurement. The bound FGF9 was not 
released upon binding, suggesting strong interactions with the GAGs. FGF9 also 
bound DS (dp18) and (6.5 kDa) brushes though in these cases equilibrium was 
attained and the chemokines was released upon rinsing (Supplementary figure 6.12), 
indicating weak interactions. FGF9 did not bind CS-A. FGF9 is a dimer and each 
monomer contains one canonical HBS1. The dimer offers a long alignment of these 
two HBS1 (198) that thus require enough sulfated stretches on GAG chains to be 
stably bound. Furthermore, the restricted availability of HBSs to this elongated 
double HBS1 renders the binding of FGF9 specific to the sulfated patterns that are 
accessible in the GAG chains. In the GAG brushes, FGF9 did not bind to a chain that 
is mostly made of monosulfated disaccharides with glucuronic residues (CS-A), bound 
weakly to chains that are mainly composed of monosulfated disaccharides with 
iduronic residues (DS) and continuously bound to chains that contained disaccharides 
with at least 2 sulfations on their disaccharide units (CS-E, Hep and HS). This would 
suggest that the degree sulfation is a key driver of FGF9 binding, or alternatively, that 
the 6-sulfation is a condition to FGF9 binding on GAG chains. 
6.3.2 Rigidification of GAG brushes by FGFs 
As in previous sections, the parametric plot of QCM-D data was used to assess the 
changes in GAG brush softness (ΔD/-Δf) upon FGF uptake (-Δf). The GAG brushes have 
softness parameters between 0.20 and 0.32 10-6.Hz-1 before the introduction of the 
FGF. FGFs caused different rigidification of the brushes as observed by the variety of 
rigidification trends and final measure of softness (Figure 6.5). 
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The magnitude in the decrease of ΔD/-Δf with –Δf (that is, the slope of the curves) 
close to the onset of protein binding provides a measure for the intrinsic propensity 
of the FGFs to rigidify GAG brushes. The comparative analysis in Figure 6.7 shows 
clear trends. The magnitude of the slope for FGF9-loaded GAG brushes is the 
smallest. This is readily seen on Hep, HS and CS-E were FGF9 binding was substantial. 
From the slopes of the curves for Hep, HS ad CS-E, it can also be seen that FGF4 has 
the second weakest propensity to rigidify GAG films. Among the remaining FGFS - 
FGF10, FGF17 and FGF18 - the propensities to rigidify CS-D and DS (6.5 kDa) are 
comparable, and this is also the case for FGF10 and FGF18 with CS-A where no data 
for FGF17 is available. On Hep, FGF18 would appear to have a slightly higher 
propensity to rigidify than FGF10 and FGF17, whereas the trend is opposite for HS. It 
is though not clear if these differences are significant, and it may well be that FGF10, 
FGF17 and FGF18 have identical rigidification propensities for any of the GAGs. 
It should be noted that the effective film rigidity induced by binding of a given FGF 
depends on the intrinsic propensity to rigidify (measured by slope in the parametric 
plot) and on the amount of protein bound to the film (measured by –Δf). Thus, for 
example, FGF18 rigidified DS (6.5 kDa) much more (ΔD/-Δf = 0.01 × 10-6.Hz-1) than 
FGF17 (ΔD/-Δf = 0.13 × 10-6.Hz-1) did because even though both proteins have the 
same intrinsic propensity to rigidify, FGF 18 binds in much larger amounts.  
Taken together, it can be seen that the trends in the propensity to rigidify that were 
established for HS in Chapter 5, are recapitulated for all other GAGs tested. 
Moreover, these trends also correlate well with the ability of the FGFs to immobilize 
HS chains. That is, FGF9 and FGF4 with a low propensity to rigidify essentially do not 
affect the lateral mobility of HS, whereas FGF10, FGF17 and FGF18 with a similarly 
high propensity to rigidify all reduce HS mobility substantially (see Supplementary 
Figure 5.5 in Chapter 5). 
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Figure 6.5: Parametric plot analysis of FGFs interaction with GAG brushes. 
Mid-dense Heparan sulfate (A), Hep(B), CS-A (C), CS-C (D), CS-E (E), DS (6.5 kDa, F) and DS 
(dp18, G) brushes were formed (green arrows) and exposed to 0.28 µM FGF4 (black), FGF9 
(red), FGF10 (blue), FGF17 (magenta) or FGF18 (cyan) in QCM-D until equilibrium. The 
brushes were then rinsed with the buffer until stabilisation of the signal.  
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FGF10 bound to brushes of all tested GAGs. The binding reached various equilibrium 
values in Δf and no or little unbinding was observed upon rinsing (Supplementary 
figure 6.14). 
The binding of FGF17 to Hep, CS-E and DS (6.5 kDa) was slow and did not reach 
equilibrium, and the rinsing step did not remove the bound protein (Supplementary 
figure 6.16). This is in contrast to HS (section 5), where binding equilibrium was 
reached, where the magnitude of the frequency shift was larger, and where the 
protein was partially released upon rinsing. CS-A, CS-C and DS (dp18) were not tested 
with FGF17. 
FGF18 bound all tested GAG brushes (HS, Hep, CS-A, CS-E and DS (6.5 kDa)) to 
equilibrium. The magnitude of binding was relatively low in CS-A, CS-E and DS (6.5 
kDa) though there was no unbinding upon rinsing in these cases (Supplementary 
figure 6.18). In the cases of HS and Hep, the magnitude of Δf was noticeably higher, 
yet the rising step partially desorbed the FGF18. However, the remaining bound 
FGF18 was still significantly higher than in the CS-A, CS-E and Ds (6.5 kDa) brushes. 
6.3.3 Stoichiometries of FGF binding to GAGs 
Using SE, I measured the binding stoichiometry for FGF4, FGF10, FGF17 and FGF18 to 
Hep, and in addition for FGF9, FGF17 and FGF18 on DS (6.5 kDa). The results, and in 
addition the data previously obtained for HS (see Chapter 5) are reported in Figure 
6.6.  
FGF4 bound hep to a higher stoichiometry than HS at maximum of binding, but the 
rinsing step reduced it to a level equivalent to the final stoichiometry for HS (Figure 
6.6). This was consistent with QCM-D data where, at maximum of binding the 
measure of surface coverage was higher for hep than for HS.  
As observed in QCM-D, the binding of FGF9 to DS (6.5 kDa) was very low and the 
rinsing step completely desorbed the protein. This characteristic was confirmed in SE 
quantification of FGF9 on a DS (6.5 kDa) brush. The stoichiometry at the maximum of 
binding was very low and the bound FGF9 undetectable after rinsing (Figure 6.6). 
FGF10 was shown to bind hep brushes in larger amount than HS in SE, although the 
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QCM-D data suggested that they were equivalent. Here, the SE data is prevalent as 
it measures the absolute surface density, without trapped solvent of biomolecules 
on the surface. The binding stoichiometry of FGF17 for HS and hep were equivalent 
before at the maximum of binding as measured in the SE quantification of their 
surface densities. At the maximum of binding, we measured 6  1 and 5 FGF17 per 
HS and Hep chain respectively (Figure 6.6). Upon rinsing, FGF17 partially desorbed 
from both HS and Hep brush. The stoichiometry of binding to DS (6.5) was relatively 
low compared to HS and Hep. However, the bound FGF17 was not released from the 
brush during the rinsing step. The amount of FGF18 bound were variable across the 
GAG brushes as measured by SE. FGF18 bound hep in the largest amount, 
significantly higher than to HS and to DS (6.5 kDa). The binding to CS-A and CS-E was 
evaluated in QCM-D only and the Δf, measures of surface coverage showed relatively 
low amount of FGF18 compared to HS and Hep but similar to DS (6.5 kDa). 
 
 
Figure 6.6: Stoichiometric quantification of FGF bound to GAG brushes. 
FGF were incubated at 0.28 µM on HS (FGF4, FGF9, FGF10, FGF17 and FGF18), Hep (FGF4, 
FGF10, FGF17 and FGF18) and DS (FGF9, FGF17 and FGF18). The molar FGF surface densities 
were determined by SE equilibrium after incubation at 0.28 µM, and after rinsing with 
working buffer until stabilisation, and compared to molar GAG (HS, Heparin, DS (6.5 kDa)) 
surface densities (Error! Reference source not found.) obtained in the same measurements. T
he data presented is for 1 or 2 independent measurements. The binding stoichiometires for 
HS were previously reported in (section 5.2).  
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6.4 Discussion  
In this section, we have measured the interactions of FGFs with different GAGs. There 
are considerable data on some of these interactions acquired using other techniques, 
particularly for FGF1 and FGF2 (56, 104, 190).  
In the here presented assay, all FGFs bound to hep brushes in equivalent or higher 
amount than on HS brushes. This is consistent with the higher degree of sulfation in 
Hep than in HS and the expected preferential binding of FGFs to sulfated regions. For 
this purpose FGF1, FGF2, FGF2 HBS3-, FGF4, FGF9, FGF10, FGF17 and FGF18 were 
purified in-house using hep affinity chromatography and their binding affinity and 
thermos-stabilisation by hep oligosaccharides were studied (56, 103, 104, 190) and 
concurred with our results where all FGFs bound to HS and Hep (chapter 5 and 
sections 6.1 to 6.3).  
In the same prospect, interactions of CS-A and CS-C with FGF10, FGF17 (56) and 
FGF18 (104), and of CS-E with FGF2 (190) had been previously reported. Interactions 
of DS with FGF1 (104), FGF4, FGF10 and FGF17 (56) and FGF18 (104) have also been 
described. Some FGF did not interact with the GAG brushes they were probed with. 
In particular, there was no detectable interaction between FGF4 and CS-A and CS-C, 
and a very weak and transient interaction between FGF4 and CS-E. Our data support 
the weak or absent interactions between FGF4 and CS described previously (56). The 
lacking interactions between FGF1 and CS-E (190), between CS-C and CS-A and FGF1 
and FGF9, and between FGF2 and DS (56) were also reproduced here in the QCM-D 
measurements. Li et al (56) also reported that FGF2 did not bind CS but we could 
detect stable interaction with CS-A, CS-C and CS-E brushes and suggested that this 
may be the result of the latter being anchored as brushes on a surface. 
The mid-dense GAG brushes used here differ substantially from the solution and 
surface analyses used by others previously. In solution the GAG chains are dilute and 
possess 3 degrees of translational freedom, like the FGF ligand, whereas in past 
surface analyses, the GAG chains are immobilised on the sensor surface. In contrast, 
on a mid-dense brush, the GAG chains are anchored, but have two degrees of 
translational freedom, in x and y. A consequence is that FGF binding can alter the 
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organisation of the brush, which could in turn alter the likelihood of interaction with 
further FGF molecules and/or alter the probability of dissociation from the brush. 
The data are somewhat sparse, in that further experiments are required to repeat 
some measurements and some measurements were not done. Nonetheless, there 
are some intriguing conclusions that can be drawn, though some may at this stage 
be tentative.  
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Supplementary information 
Binding of FGFs to GAG brushes –  GAG type specificity of binding, brush 
rigidification and GAG mobility.  
 
 
Supplementary figure 6.1: QCM-D monitoring of FGF1 interaction with mid-dense GAG 
brushes.  
SUV, SAv and GAGs (Hep, CS-A, CS-C, CS-E, DS (6.5 kDa) and DS (dp18); green arrows) were 
infused at 50, 20 and 5 µg/ml, respectively. Every step was followed by a minimum of 5 min 
infusion of incubation buffer at 20 µl/min, and FGF1 was infused at 0.28 µM at a 10 µl/min 
flow rate (black arrow).  
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Supplementary Figure 6.2: QCM-D monitoring of FGF2 interaction with mid-dense GAG 
brushes.  
Measurements were performed, and data are presented, analogous to Supplementary 
Figure A-1. FGF2 binds stably to Hep, CS-A, CS-c, CS-E and DS (6.5 kDa). 
 
 
Supplementary figure 6.3: QCM-D monitoring of FGF2 HBS3- interaction with mid-dense GAG 
brushes. 
Measurements were performed, and data are presented, analogous to Supplementary 
Figure A-1. FGF2 HBS3- binds to Hep, CS-A, CS-E, DS (6.5 kDa) and DS (dp18). We did not test 
the binding to CS-C.  
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Supplementary figure 6.4: Stoichiometry of binding of members of the FGF1 subfamily to 
GAG brushes. 
The molar FGF surface densities were determined by SE, at equilibrium after incubation at 
0.28 µM (A), and after rinsing with working buffer until stabilisation (B), and compared to 
the molar surface densities of the GAGs (HS, Heparin, CS-A, CS-C, CS-E and DS (6.5 kDa), 
obtained in the same measurements. Results presented for experiment of FGF1 (on HS and 
DS (6.5 kDa)), FGF2 (on HS, Heparin, CS-A, CS-C, CS-E and DS (6.5 kDa)) and FGF2 HBS3- (on 
HS, Hep and DS (6.5 kDa)). Error bars indicate minimal and maximal responses based on two 
independent measurements; where error bars are missing, a single measurement was 
performed. 
 
 
Supplementary Figure 6.5: Parametric plot analysis of FGF1 interaction with mid-dense GAG 
brushes. 
Representative data is shown for formation of mid-dense Hep (A), CS-E (D), DS (6.5 kDa) (E) 
and DS (dp18) (F) brushes (green arrows) and binding of FGF1 at 0.28 µM FGF1 until 
equilibrium (black arrow), and subsequent rinsing with the buffer until stabilisation of the 
signal (blue arrow; not shown for DS as binding was fully stable in this case). Data were 
extracted from QCM-D experiments presented in Supplementary figure 6.1; data for CS-A 
and CS-B are not shown, as FGF1 did not bind to these GAGs. 
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Supplementary figure 6.6: Parametric plot analysis of FGF2 interaction with mid-dense GAG 
brushes. 
Plots are presented analogous to Supplementary Figure 6.5, and data were extracted from 
data presented in Supplementary Figure 6.2. 
 
Supplementary figure 6.7: Parametric plot analysis of FGF2 HBS3- interaction with mid-dense 
GAG brushes. 
Plots are presented analogous to Supplementary Figure 6.5, and data were extracted from 
data presented in Supplementary Fig. B-3; data for CS-A are not shown as FGF2 HBS3- did 
not bind to this GAG. 
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Supplementary Figure 6.8: Fluorescence recovery curves of mid-dense GAG brushes. 
FRAP curves of atto488-SAv supported GAG brushes prepared as described in section 4.6.4). 
The black curve and the grey area are the means and their standard deviations based on 4 
measurements, obtained after GAG brush formation. Briefly, SUVs containing 99.5:0.5 
mol:mol DOPC:DOPE-CAP-biotin were put in contact with a clean glass cover slip for 30 min 
at 50 µg.mL-1. After rinsing, SAv-atto was incubated for 30 min at 20 µg.mL-1. The surface was 
rinsed with working buffer and incubated with 5 µg.mL-1 biotinylated GAGs for 30 min. 
Soluble GAGs were rinsed off with working buffer prior to FRAP (section 4.6.1). 
 
 
Supplementary Figure 6.9: Mobility parameters of bare GAG brushes, and GAG brushes with 
bound FGF1 and FGF2. 
Mobile fraction (A) and its diffusion constant (B) were obtained from 4 independent 
measurements of FRAP on atto488-SAv supported GAG brushes. Data for bare GAG brushes 
were obtained after rinsing with working buffer; data for GAG brushes with FGFs were 
obtained after 30 min incubation with 0.28 µM FGF1 or FGF2. The soluble FGF1 and FGF2 
were rinsed off prior to the measurements. FRAP measurements were not performed for CS-
A and CS-C brushes with FGF1 as FGF1 did not bind to these GAGs (see Supplementary Fig. 
6.1). 
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Supplementary Figure 6.10: QCM-D monitoring of FGF4 interaction with GAG brushes. 
Measurements were performed, and data are presented, analogous to Supplementary 
Figure 6.1. FGF4 binds to Hep, CS-A, CS-E, DS (6.5 kDa) and DS (dp18). 
 
 
Supplementary figure 6.11: Parametric plot analysis of FGF4 interaction with GAG brushes. 
Plots are presented analogous to Supplementary Figure 6.5, and data were taken from 
Supplementary Fig. B-10; data for CS-C are not shown as FGF4 did not bind to this GAG. 
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Supplementary figure 6.12: QCMD monitoring of FGF9 interaction with GAG. 
SUV, SAv and GAGs (green arrow) were all infused at 50, 20 and 5 µg/ml respectively and a 
20 µl/min flow rate during 5 min prior to protein infusion. Every step was followed by a 
minimum of 5 min infusion of incubation buffer at 20 µl/min and FGF9 was infused at 0.28 
µM at a 10 µl/min flow rate (black arrow). The real-time monitoring of FGF9 binding to 
Heparin, CS-A, CS-E, DS (6.5 kDa) and DS (dp18) show a stable binding of the protein. 
 
Supplementary figure 6.13: Parametric plot analysis of FGF9 interaction with GAGs. 
Mid-dense Hep (A), CS-E (D), DS 6.5 kDa (E) and DS dp18 (F) brushes were formed (green 
arrow) and exposed to 0.28 µM FGF9 in QCM-D until equilibrium (black arrow). The brushes 
were then rinsed with the buffer until stabilisation of the signal (blue arrow). 
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Supplementary figure 6.14: QCMD monitoring of FGF10 interaction with GAG. 
SUV, SAv and GAGs (green arrow) were all infused at 50, 20 and 5 µg/ml respectively and a 
20 µl/min flow rate during 5 min prior to protein infusion. Every step was followed by a 
minimum of 5 min infusion of incubation buffer at 20 µl/min and FGF10 was infused at 0.28 
µM at a 10 µl/min flow rate (black arrow). The real-time monitoring of FGF10 binding to 
Heparin, CS-A, CS-C, CS-E, DS (6.5 kDa) and DS (dp18) show a stable binding of the protein. 
 
Supplementary figure 6.15: Parametric plot analysis of FGF10 interaction with GAGs. 
Mid-dense Hep (A), CS-A (B), CS-E (C), CS-C (D), DS 6.5 kDa (E) and DS dp18 (F) brushes were 
formed (green arrow) and exposed to 0.28 µM FGF10 in QCM-D until equilibrium (black 
arrow). The brushes were then rinsed with the buffer until stabilisation of the signal (blue 
arrow). 
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Supplementary figure 6.16: QCMD monitoring of FGF17 interaction with GAG. 
SUV, SAv and GAGs (green arrow) were all infused at 50, 20 and 5 µg/ml respectively and a 
20 µl/min flow rate during 5 min prior to protein infusion. Every step was followed by a 
minimum of 5 min infusion of incubation buffer at 20 µl/min and FGF17 was infused at 0.28 
µM at a 10 µl/min flow rate (black arrow). The real-time monitoring of FGF17 binding to Hep 
(A), CS-E (D), and DS (6.5 kDa, E) show a stable binding of the protein. 
 
Supplementary figure 6.17: Parametric plot analysis of FGF17 interaction with GAGs. 
Mid-dense Hep (left), CS-E (middle) and DS 6.5 kDa (right) brushes were formed (green 
arrow) and exposed to 0.28 µM FGF17 in QCM-D until equilibrium (black arrow). The brushes 
were then rinsed with the buffer until stabilisation of the signal (blue arrow). 
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Supplementary figure 6.18: QCMD monitoring of FGF18 interaction with GAG. 
SUV, SAv and GAGs (green arrow) were all infused at 50, 20 and 5 µg/ml respectively and a 
20 µl/min flow rate during 5 min prior to protein infusion. Every step was followed by a 
minimum of 5 min infusion of incubation buffer at 20 µl/min and FGF18 was infused at 0.28 
µM at a 10 µl/min flow rate (black arrow). The real-time monitoring of FGF18 binding to 
Heparin, CS-A, CS-E and DS (6.5 kDa) show a stable binding of the protein. 
 
 
Supplementary figure 6.19: Parametric plot analysis of FGF18 interaction with GAGs. 
Mid-dense Hep(A), CS-A (B), CS-E (D) and DS 6.5 kDa (E) brushes were formed (green arrow) 
and exposed to 0.28 µM FGF18 in QCM-D until equilibrium (black arrow). The brushes were 
then rinsed with the buffer until stabilisation of the signal (blue arrow). 
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7 Mobility of FGFs in pericellular matrices 
7.1 Introduction 
In chapters 5 and 6, I analysed the molecular interactions of FGFs with GAG brushes 
and evaluated their binding, ability to cross-link the GAG chains and their mobility in 
instances where a halotagged version of the FGF was available. In this chapter 
preliminary data are presented on the binding and mobility of fluorescently labelled 
halotagged FGFs in the pericellular matrix of keratinocytes. Previously, similar work 
has been done in a rat mammary fibroblast cell (185) and in the same cells at the 
single molecule level (187). However, it is not known if the pericellular matrix of an 
epithelial cell presents similar FGF binding properties. While the HS on the fibroblasts 
and the keratinocytes are expected to differ, these differences may be reduced, 
unaffected or magnified by the differences in endogenous HS binding proteins 
occupying a subset of binding sites in the polysaccharide and modifying at least some 
of the neighbouring sites. The basic controls of autofluorescence and fluorescence 
due to non-specific binding of the TMR dye and of TMR-labelled halotag were 
performed. Fluorescent images were then acquired following incubation with TMR-
labelled HaloFGFs. As care was taken to avoid saturation, the fluorescence could be 
quantified to provide a measure of the binding of the different HaloFGFs. The 
mobility of FGFs in the pericellular matrix of HaCaT cells was then measured using 
FRAP. 
7.2 HaloFGFs bind to the pericellular matrix of keratinocytes.  
7.2.1 Binding propensity and repartition. 
The level of autofluorescence in HaCaT cells and the level of fluorescence due to non-
specific binding of the TMR dye and of TMR-Halotag were first determined. TMR dye 
and TMR-Halotag protein were incubated with fixed HaCaT cells for 30 mins and then 
cells were rinsed in PBS prior to imaging (4.6.3). There was no detectable 
fluorescence (Figure 7.1), indicating that non-specific binding would not contribute 
to any signal observed with a TMR-HaloFGF. 
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Figure 7.1: Non-specific binding control of TMR and TMR-Halotag on HaCaT cells. 
Overlaid images of bright field and confocal fluorescence of fixed HaCaT cells. The cells were 
incubated for 30 minutes with 2 nM TMR (left) or TMR-Halotag (right) and rinsed with PBS 
before imaging. The cells were visible with no apparent fluorescent dye (TMR) or protein 
(TMR-Halotag). 
 
The fluorescence of HaloFGF1 and HaloFGF2 was preferentially associated to lateral 
surfaces/edges of the cells, as shown by the elevated fluorescence on this area 
(Figure 7.2). In contrast, the fluorescence after incubation of the cells with HaloFGF6 
was diffuse across the cell, yet also quite granular in appearance, indicating uneven 
association of the FGF6 with different parts of the pericellular matrix. The HaloFGF7, 
HaloFGF10 and HaloFGF17 fluorescence was diffuse across the cell and more 
homogeneous. HaloFGF18 fluorescence was somewhat granular, but less so than 
that of HaloFGF6, whereas FGF20 fluorescence was very heterogeneous (Figure 7.2). 
In some cases, e.g., HaloFGF20, fluorescence was punctate, resembling the size of an 
endosome or similar type of vesicle, but as the cells were fixed, it is unlikely that the 
FGFs associate with intracellular vesicles. Although z-stacks of images were not 
acquired, the focal plane in each case was similar, since the nucleus is apparent in 
each image. This suggests that the structures in HS that bind these FGFs on the lateral 
and the basal or apical surfaces of the cells may differ. While in the absence of z-
stacks, it is not certain that the FGFs did not in some cases bind intracellular 
structures, it should be noted that there is no nuclear fluorescence. At least FGF1 and 
FGF2 bind strongly to nucleic acids (199, 200) (201) and it is likely that this is true for 
all FGFs, due to the similarity between the sugar-sulfate of HS and the sugar-
phosphate of nucleic acids.  
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Figure 7.2: Fluorescent labelling the pericellular matrix of HaCaT cells with HaloFGFs. 
The fixed cells were incubated with 2 nM TMR-HaloFGFs for 30 minutes at 37°C and rinsed 
10 times with PBS. Images of the cells were taken in the same conditions (described in 4.6.3) 
for all FGFs using the LSM 780 microscope and processed with the Fiji software.   
138 
 
Thus, this suggests that all the fluorescence is extracellular, in accord with the 
absence of a cell permeabilisation step during fixation and previous results (185, 
187). 
The fluorescence intensities were extracted using Fiji® (Figure 7.3). The fluorescence 
intensities of HaloFGF1 (41 ± 8 A.U. µm-2) and HaloFGF2 (38 ± 15 A.U. µm-2) were the 
lowest and were equivalent to one another. Other HaloFGFs (HaloFGF6, HaloFGF10, 
HaloFGF18 and HaloFGF20) had a fluorescence intensity similar or higher than those 
of HaloFGF1 and HaloFGF2 (Supplementary figure 7.1). HaloFGF7 and HaloFGF17 has 
the highest fluorescence intensities at 77 ± 10 and 68 ± 10 A.U. µm-2, respectively 
(Figure 7.3).  
 
Figure 7.3: Average binding intensities of HaloFGFs to the pericellular matrix of HACaT. 
500 µL fluorescently labelled HaloFGFs (2 nM) were incubated with fixed HaCaT cells for 30 
min. The unbound fluorescent HaloFGFs were rinsed off and the fluorescence intensities per 
cell were measured using Fiji® (section 4). Each data point corresponds to the average 
fluorescence intensity across one cell. The means (square), the standard errors (box), the 
median (line) and the standard deviations (whiskers) are represented and the individual data 
points are also shown, as is their distribution. 
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However, these are values averaged across an entire cell, so the very heterogeneous 
distribution of some of the HaloFGFs, e.g, HaloFGF1, HaloFGF2 and Halo-FGF20 
associated fluorescence means that their binding sites in pericellular matrix are far 
from evenly distributed. 
7.2.2 HaloFGF mobility in native pericellular matrices 
To measure the mobility of the HaloFGFs in the pericellular matrix of HaCaT 
keratinocytes, their binding is assumed to be stable, in that they are not expected to 
dissociate from the pericellular matrix and diffuse into the bulk culture medium. This 
stability was observed in the HS brushes after rinsing (section 5.2) and in fibroblasts 
previously (185, 187). The time scale of the FRAP experiments on a single dish of cells 
varied between one to two hours, so the assumption is reasonable, but yet not 
verified since we have not measured the fluorescence changes over time, unlike in 
fibroblasts (185). Images of FRAP assays are presented in Supplementary figure 7.3 
and 6.4 and the recovery curves in Figure 7.4. 
Following photobleaching, the fluorescence of HaloFGF1 recovered gradually, but 
never attained a maximal level (Figure 7.4A). After 300 s, the HaloFGF1 had recovered 
to 29 ± 12 % of the initial level whilst a plateau was not reached. The fluorescence of 
HaloFGF2 recovered to 19 ± 9 % of the initial level, which was not significantly 
different from HaloFGF1 in this respect. In contrast to HaloFGF1, the recovery of 
HaloFGF2 reached a plateau before the end of the assay. This suggests that the 
fluorescence recovery of HaloFGF2 is the result of a small (19 ± 9%) mobile fraction, 
whereas the remaining part of HaloFGF2 is essentially immobile. In contrast, the slow 
gradual recovery of fluorescence of HaloFGF1 indicates that a much greater level of 
recovery would be observed at longer times. Consequently, although the recovery 
level would seem equal after 300 s (Supplementary figure 7.2), the mobile fraction 
of HaloFGF1 is likely to be much more substantial than that of HaloFGF2. The mobility 
of HaloFGF6 (FGF4 subfamily) was low and reached a plateau of recovery of 14 ± 17% 
(Figure 7.4C and Supplementary figure 7.2). Thus, HaloFGF6 was similar to HaloFGF2, 
in that the majority of the protein appeared to be immobile.  
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HaloFGF7 and HaloFGF10 possessed distinct motilities even though they belong to 
the same FGF subfamily (FGF7). The recovery of fluorescence of HaloFGF7 had a very 
fast element: images acquired immediately after photobleaching already showed a 
considerable amount of recovery (Figure 7.4D and Supplementary figure 7.2), and 
within less than 1 min a recovery of 88 ± 12% was reached. In contrast, the 
fluorescence of HaloFGF10 recovered slowly, and reached only 27 ± 12% after 300 s. 
In the case of the two members of the FGF8 subfamily, HaloFGF17 and HaloFGF18, 
their fluorescence recovery was more similar (Figure 7.4F and G, and Supplementary 
figure 7.2). Thus, HaloFGF18 was completely immobile and HaloFGF17 contained 
only a small mobile fraction (18 ± 11%). HaloFGF20 (FGF9 subfamily) exhibited a 
gradual recovery of fluorescence and reached 41 ± 9% recovery but not a plateau 
after 300 s, indicating that the mobile fraction is rather large.  
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Figure 7.4: Fluorescence recovery of HaloFGFs following photobleaching in the pericellular 
matrix of HaCaT cells. 
TMR565 labelled HaloFGFs were incubated with cells and, following washing with PBS, FRAP 
measurements were performed. All HaloFGFs were added at 2 nM and the number of 
measurements is indicated in parenthesis. A: HaloFGF1 (13), B: HaloFGF2 (12), C: HaloFGF6 
(12), D: HaloFGF7 (10), E: HaloFGF10 (8), F: HaloFGF17 (10), G: HaloFGF18 (8) and H: 
HaloFGF20 (3). Recovery levels were extracted from the fluorescence data, as described in 
section 4.6.3. The thick curves and the light regions around them are the means and standard 
deviations, respectively, of 3 to 13 measurements.  
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7.3 Comparison of FGF mobility in HS brushes and pericellular 
matrices 
The measurement of the binding and mobility of FGFs in the pericellular matrix of 
fixed HaCaT cells provides an important complement to the work on GAG brushes. 
The work in this and the previous chapters can be compared to previously published 
data on the characterisation of the structural basis of protein-GAG interactions and 
the mobility of FGFs in pericellular matrix. 
In terms of comparing the pericellular matrix of HaCaT keratinocytes and the GAG 
brushes, it is interesting that despite the latter being a highly simplified model of 
pericellular matrix, some of the FGFs behave similarly in both. Thus, HaloFGF2 was 
immobile in HS brushes and has a very limited mobility on HaCaT, illustrated by the 
superimposition of the recovery curves (Figure 7.5A). HaloFGF1 (Figure 7.5B) and 
HaloFGF10 (Figure 7.5D) also had very similar motilities in the HS brush and in the 
pericellular matrix of HaCaT cells. However, in the case of HaloFGF6 and HaloFGF20, 
these proteins had a substantially reduced mobility in the pericellular matrix of 
HaCaT cells compared to HS brushes (Figure 7.5C and D). These differences may be 
due to the FGF6 and FGF20 binding structures in the HS produced by the HaCaT cells, 
which could specifically reduce the mobility of these FGFs. Such structures might be 
due to biosynthesis of HS and/or to the effect of the endogenous HaCaT cell HS 
binding proteins on the structure of HS chains. A role here for core proteins cannot 
be excluded. Different HSPG core proteins have been shown to carry HS chains with 
distinct protein binding structures. Thus, HS chains that preferentially engage FGF6 
and FGF20 may be on particular core proteins that localise to a subdomain of the 
pericellular matrix that prevent protein movement. There is limited evidence for this, 
since the fluorescence of the FGFs is not uniform, and that of HaloFGF20 is 
particularly punctate in places, though such subdomains could easily be below the 
limit of diffraction of an optical microscope. In addition, without controls for 
specificity, such as digestion of HS with heparinases, or CS with chondroitinase ABC, 
it cannot be excluded that HaloFGF6 and HaloFGF20 also engage protein partners, 
which may cause their immobility (185).  
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Figure 7.5: Comparison of mobility of HaloFGFs in HS brushes and native pericellular 
matrices. 
FRAP curve of fluorescently labelled HaloFGFs; A: HaloFGF1, HaloFGF2, HaloFGF6, HaloFGF10 
and HaloFGF20 in dense HS brushes (as previously reported in section 5.2, black) and 
pericellular matrix of HaCaT (as previously reported in Figure 7.4, red). Recovery levels were 
extracted from the fluorescence data as described in section 4. The thick curves and the light 
regions around them are the means and standard deviations, respectively, of a minimum of 
4 independent measurements obtained after rinsing with the working buffer. 
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7.4 Discussion 
In this chapter, the halo-tagged FGFs were used as a tool to track FGFs in the 
pericellular matrix of fixed HaCaT keratinocytes. In work described in chapters 5 and 
6, I showed that HaloFGFs possessed sufficiently similar binding properties to a GAG 
brush that they could be used as proxy to track the mobility of FGFs. This validates 
previously published work using HaloFGFs and FRAP to measure their mobility in the 
pericellular matrix of fibroblasts (177, 185). There are interesting differences in both 
the binding and mobility of the HaloFGFs in keratinocytes and fibroblasts. 
One difference is the binding of HaloFGF20 to HaCaT pericellular matrix, as this FGF 
failed to bind to fibroblast pericellular matrix (185), yet bound to both the GAG 
brushes and the pericellular matrix of HaCaT cells. FGF20 is a dimer (202) and has 
been found to require long oligosaccharides for optimal binding (56). This 
requirement was the explanation for the lack of interaction with fibroblast 
pericellular matrix. Thus it would seem that in HaCaT pericellular matrix there may 
be relatively frequent unoccupied long sulfated tracts (contiguous NAS and S 
domains) that enable FGF20 binding. 
In terms of mobility, only FGF6 was similar between fibroblast and keratinocyte 
pericellular matrix.  Thus, FGF1 and FGF2 both had substantial mobile fractions in 
fibroblast pericellular matrix (185), but not in that of keratinocytes. In contrast, 
FGF10 was immobile in the pericellular matrix of fibroblasts (185), but at least 
partially mobile in the one of keratinocytes (Figure 7.4). This presumably relates to 
the sulfation pattern of the GAGs (FGF10 binds HS and CS/DS) produced by the two 
cell types. FGF10 has been previously suggested to be immobile in extracellular 
matrix, since it was found to require the activity of heparanase to exert its growth 
and morphogenetic activities in salivary gland development (203). This is consistent 
with the immobility of the HaloFGF10 in fibroblast pericellular matrix. In vivo, FGF10 
is the product of mesenchymal fibroblasts, but its target is the neighbouring 
epithelium, whose cells produce FGFR2b. It would be interesting to test a range of 
fibroblasts and epithelial cells to see whether FGF10 is immobile on the source cells 
(the fibroblasts), but mobile in the pericellular matrix of the target epithelial cells. 
There are no comparator data for FGF17 and FGF18 in the literature.   
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Supplementary figures 
 
Supplementary figure 7.1: mean comparison of HaloFGF binding intensities. 
The fixed cells were incubated with 2 nM TMR-HaloFGFs for 30 minutes at 37°C and rinsed 
10 times with PBS. Images of the cells were taken using the LSM 780 microscope and 
processed with the Fiji® software. The data were reported in Figure 7.3 and a mean 
comparison Fisher statistical test was carried out at the significance level of 5%.  
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Supplementary figure 7.2: Mobility parameters of HaloFGFs in the pericellular matrix of 
HaCaT. 
Half recovery times and final recovery levels of FRAP on TMR labelled HaloFGFs in the 
pericellular matrix of HaCaT. The fixed cells were incubated for 30 min at 37°C with 2 nM 
TMR-HaloFGF and rinsed with the working buffer before the measurements. Final recovery 
level is the recovered intensity at the end of the experiment (300 s) and calculated as 
described earlier in section4.6.4. The half-recovery time is the time at which 50% of that level 
is reached. The data is presented as a box of its standard error with the mean represented 
as a square. The whiskers represent the standard deviation and the line shows the median 
of the data.   
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Supplementary figure 7.3: FRAP images of HaloFGFs on HaCaT cells. 
The fixed cells were incubated with 2 nM TMR-HaloFGFs for 30 minutes at 37°C and rinsed 
10 times with PBS. Images of the cells were taken using the LSM 780 microscope and 
processed with the Zen software. The fluorescence intensities were recorded in the bleached 
(red), the background (blue) and the reference (green) as described earlier (section 4.6.3).  
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Supplementary figure 7.4: FRAP images of HaloFGFs on HaCaT cells. 
The fixed cells were incubated with 2 nM TMR-HaloFGFs for 30 minutes at 37°C and rinsed 
10 times with PBS. Images of the cells were taken using the LSM 780 microscope and 
processed with the Zen® software. The fluorescence intensities were recorded in the 
bleached (red), the background (blue) and the reference (green) as described earlier. The 
scale shows a length of 20 µm. 
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8 Discussion and further work 
8.1 General discussion 
Literature and proteomic data have identified more than 435 human hep binding 
proteins (47, 48). Though their physiological partner is more often than not HS or 
another sulfated GAG, they have been termed ‘heparin-binding’ as this is the GAG-
binding property that has been established in vitro. The paracrine FGFs (section 1.4) 
represent a group of evolutionarily related heparin-binding proteins, with the two 
members of the FGF1 subfamily, FGF1 and FGF2 the most studied in this and other 
respects (Section 1.4.1). For 11 of the paracrine FGFs, the interaction with model 
GAGs is reasonably well established in terms of the binding sites on the protein 
recognized by hep and the size and the sulfation pattern in hep necessary for binding 
(56, 103, 104, 114). It is also now established that some paracrine FGFs can also 
interact with GAGs other than hep and HS (56, 104). One aspect of FGF function 
controlled by the interaction with GAGS is their transport in the extracellular matrix 
and between tissue compartments. This was discovered when FGF2 bound to 
extracellular matrix, was found to remain trapped there, rather than being released 
into the bulk cell culture medium. Nevertheless, the matrix bound FGF2 was able to 
stimulate endothelial cells, leading to a first hypothesis that FGF2 could be stored in 
extracellular matrix and from there activate its receptors on the cell surface (25). 
FGF2 was indeed observed in the extracellular matrix of tissues (204) and, at least 
during the development of the mammary gland, the binding capacity of HS was 
related to tissue growth. Subsequently the transport of FGF2 in extracellular matrix 
of different cell types was measured directly (205-207). An intriguing idea to emerge 
was that the domain structure of HS might allow relatively rapid movement of bound 
proteins. This was proposed to occur through a sliding mechanism, with the proteins 
‘hopping’ over the NA domains and binding/sliding along NS-NAS units (208). These 
and other observations led to the idea that binding of growth factors to HS may 
contribute to the formation of gradients.   
More recently direct measurements have been made. Thus, Duchesne et al tracked 
single FGF2 molecules in the pericellular matrix of fibroblasts. They demonstrated 
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that FGF2 is not transported by free diffusion, but rather has different types of 
movements involving binding to HS, ranging from confined motion though short 
displacements to long and directed ones (187). It was suggested that these types of 
movements are determined by the distribution, availability and selectivity of effector 
binding sites/patterns on the ECM GAGs. Later work using FRAP of HaloTag FGFs in 
the pericellular matrix of the same fibroblasts was consistent with the single 
molecule study.  
Our understanding of protein-HS interactions is largely based on in vitro structure 
and biophysical characterization, measurement of cell activity in systems engineered 
to be deficient in HS and the analysis of the distribution of the proteins in cells and 
tissues. There is thus a major gap, since the former uses highly defined molecules 
usually in solution and never organised into a matrix-like structure, while the latter 
involve the full complexity of the extracellular matrix. Consequently, in this thesis 
supramolecular assemblies of GAG chains, in the form of a brush, have been used.  
This has allowed an exploration of new aspects of protein-GAG interactions, namely 
the ability of a GAG-binding protein to alter the supramolecular structure of the 
brush. This has been done in the context of paracrine FGFs and HS (chapter 5), and 
other sulfated GAGs (chapter 6). Finally, the same FGFs were used in experiments on 
HaCaT pericellular matrix (chapter 7).  
In chapter 5, the data acquired did not fit a hypothesis established from a previous 
analysis of just FGF2 and FGF9. Thus, although the presence of multiple HBSs remains 
a requirement for an FGF to crosslink HS chains, it was not sufficient. This led to the 
development of a hypothesis incorporating both multiple HBSs and their isolation 
from one another by acidic borders as an explanation that was consistent with the 
data. All hep binding proteins identified to date (47, 48) must contain at least one 
HBS. In addition to the FGFs, some others are known to possess multiple HBSs, for 
example, the matrix proteins fibronectin (209) and collagens (210).  
The analysis of movement of the FGFs in the GAG brushes provides direct evidence 
for a sliding/hopping mechanism to contribute to FGF mobility.  This interpretation 
is only possible because of the experiments done by others that labelled the lysine 
side chains involved in hep binding. This work involves a first protection step, where 
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side chains of non-binding lysine side chains are blocked with N-hydroxysuccinimide 
acetate. This reaction is fast and employs a very large molar excess of N-
hydroxysuccinimide acetate, to guard against false positives (103). As the time of 
reaction is similar to that of FRAP, the presence of biotinylated lysines in an HBS, that 
are not identified as acetylated demonstrates that the lysine’s ionic or hydrogen 
bond with the polysaccharide is not broken and replaced by an interaction with 
water. At least not for significant lengths of time. In the cases where an FGF moves, 
because a dense brush is used in these experiments, where the underlying SAv forms 
2-D crystalline domains, movement has to be due to the FGF and not the HS 
chain/SAv unit. Thus, these experiments are consistent with a sliding/hopping 
mechanism for FGF movement, but not with cycles of substantial dissociation prior 
to re-association. It is interesting to note observations made on DNA and DNA 
binding proteins. DNA possesses a largely regular sugar-phosphate backbone 
(‘largely regular’ owing to different forms of DNA and kinks). Some of these 
experiments have demonstrated in vitro that DNA binding proteins could slide along 
a nucleic acid and indeed even move to a neighbouring strand without ever 
dissociating (188). This is not simply an in vitro curiosity, this has been illustrated by 
single molecular analysis of the lac repressor in E. coli (211). Key to the mechanism 
whereby the lac repressor protein ‘finds’ its binding site on the bacterial 
chromosome is sliding along DNA, which is balanced by periods of dissociated and 
re-binding; together these provide for a very efficient ‘search’ mechanism to enable 
the small number of lac repressors (1-2/cell) to perform their function of inhibiting 
transcription from the lac operon. The underlying chemistry of the DNA-binding 
protein binding to the DNA backbone is the same as FGFs binding to GAGs, although 
the DNA strands are longer and have a homogenous ion charge repartition, whereas 
GAG chains do not. It was reasonable to propose sliding/hopping as a mechanism for 
the movement of hep binding proteins (208). The data in this thesis, coupled to that 
on the labelling of lysine side chains in HBSs strongly suggest that such a mechanism 
occurs at least in the context of a GAG brush. 
The present data suggest that FGS that are monovalent or multivalent but without 
an acidic border behave similarly: they do not cross-link HS chains and are mobile in 
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an HS brush. Bivalent FGFs without acidic borders isolating the HBSs from one 
another as is the case for FGF4 and FGF6 (used as HaloFGF6), would slide/hop in a 
similar way to monovalent FGFs. FGFs with two or more HBSs separated with acidic 
borders, cross-linked HS brushes and were either immobile or exhibited a mix of a 
mobile fraction and an immobile one. Thus there appears to also be a relationship 
between the ability of an FGF to cross-link HS chains and its mobility in an HS brush. 
In chapter 6, I have probed the various GAG (HS, Hep, CS and DS) chains with the 
FGFs (FGF1, FGF2, FGF2 HBS3-, FGF4, FGF9, FGF10, FGF17 and FGF18) and evaluated 
the viscoelastic properties and in some instances the mobility of theses FGF-GAG 
films. I here highlighted interesting observations in viscoelastic and dynamic 
properties of FGF-GAG films based on their submolecular features. The sugar 
backbone of HS/Hep offer more versatility in sulfate disposition along the chains than 
CS/DS. This led to a clear preference for FGF to bind HS/Hep (all tested FGFs did) 
when only a few bind to CS/DS. The binding propensity and stoichiometry were 
higher for HS and Hep than for other GAGs and many failed to bind (FGF1, FGF2 HBS3-
, FGF9) or bound very little (FGF4, FGF17) to CS/DS. Furthermore, the cross-linking of 
HS (1.4 sulfates per disaccharide) and Hep (2.7 sulfates per disaccharide), but not CS-
E (2 sulfate per disaccharide) by FGF2 showed that this is, not a consequence of “low” 
sulfate groups in CS/DS, but rather a matter of pattern and disposition. It also leads 
to to cross-linking of HS/Hep but not of CS/DS as depicted by FGF2 and FGF1.  
The measurement of the mobility of FGFs in keratinocyte pericellular matrix is 
described in chapter 7. This provides an insight into the extent to which hypotheses 
generated from the work on brushes may apply in vivo. As the cells were fixed, it is 
expected that the pericellular matrix components are also fixed – there is an 
extensive discussion of this point in Duchesne et al., 2012. The fixative does not affect 
FGF binding, since it is a primary amine reactive reagent, and so will not modify N-
acetyl or N-sulfate groups. It is well established that matrices from different cell types 
and tissues have distinct binding capacities for different heparin-binding proteins. 
This is central to the idea that the regulation of HS biosynthesis is central to the 
regulation of a cell’s and a tissue’s response to heparin-binding effectors. The present 
data demonstrate that the mobility and the transport of FGFs, and so presumably 
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hep binding proteins in general, can be differentially regulated by cells varying the 
menu of sulfated GAG structures they incorporate into their extracellular matrix. The 
data also demonstrate that movement of FGFs differs in the pericellular matrix of 
different cell types: fibroblast (Sun et al) and keratinocyte. Though there is no 
information on this, since cells are known to produce HS with different structures 
during development (159), as well as in ageing (212). Thus, an important conclusion 
is that the diffusion and gradients of FGFs, and in all likelihood other hep binding 
proteins are determined by the structure of HS (and to a lesser extent CS/DS species) 
produced by cells. A corollary is that because cells and tissues regulate the 
biosynthesis of their HS dynamically in response to environmental cues, this may 
concomitantly regulate diffusion of heparin-binding proteins. Another likely means 
to regulate binding and diffusion of proteins in matrix is the profile of endogenous 
hep binding proteins. These, at the very least will occupy a good many binding sites 
on HS chains. Binding may also alter the 3-dimensional structure of the chain. Both 
should impact on binding and diffusion of an exogenous hep binding protein. 
8.2 Further work  
Two FGFs from each subfamily and a panel of 6 different GAGs were investigated. 
However, there are a number of combinations of FGF-GAG for which some data are 
missing, more repeats and further enzyme digestion controls for specificity are 
required. Finally, one mutant, FGF2 HBS3- was tested in this thesis. The generation 
of further mutants, which would involve not just HBSs, but also acidic borders would 
provide direct evidence for the architecture(s) required for crosslinking HS chains. An 
understanding of the reason underlying the observation of an interaction of FGF2 
with CS-A and CS-C here, but not by others is also important, as this establishes the 
limits of particular measurement systems, e.g., solution vs brush. As discussed in 
Chapter 6, should the interaction observed here be due to the presentation of the 
CS-A and CS-C in a brush, this may have implications for scarring and attempts to 
wounded tissues, particularly in the context of spinal cord injuries, where dense 
networks of CS chains may act rather like the brush. In addition, it would be 
particularly interesting to test the hypothesis regarding the structural features 
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required for HS chain crosslinking with proteins fibronectin, laminin and selected 
collagens, e.g., collagen I and collagen IV. 
The analysis of the interaction of matrix proteins would then lead to the assembly of 
a more complex brush. This would have the HS chain as now, but then incorporate 
matrix proteins. The ability to control precisely assembly would enable testing of the 
ideas above on the effects of endogenous hep binding proteins on the binding and 
diffusion of exogenously added FGFs. 
The work in this thesis provides the impetus to test rigorously a hopping/sliding 
mechanism for FGF movement. The parallel development in the research Group of 
chemistry to label arginine residues in hep binding sites will provide a complete 
picture of the side chains that are involved in binding to hep and that are not exposed 
to solvent. However, a weakness of the selective labelling of lysines and now 
arginines is that hitherto it has only been achieved using hep affinity chromatography 
supports. This means that the applicability of the results to HS or another GAG is 
uncertain. However, very recently, a member of the research group has successfully 
extended the methodology to soluble GAGs and applied it, in solution, to not just to 
FGF-hep interactions, but also to those with CS and DS. A more direct test of sliding 
would be to conduct force spectroscopy using AFM. A recent paper demonstrates 
that this is feasible (213). However, the method of immobilising the FGF (adsorption) 
and in particular the HS chain (conjugated via internal free carboxylic acids) 
precluded the possibility of detecting sliding. In contrast, using HaloFGFs and oxime 
ligation at the reducing end of the polysaccharide would enable such measurements. 
While these would not provide insight directly to what occurs in an actual 
extracellular matrix, the quantification of sliding in vitro would strengthen this as a 
candidate mechanism for FGF diffusion in vivo. Moreover, in situ selective labelling 
of FGFs in an extracellular matrix (rather than on a hep affinity column) would 
determine whether lysines and arginine residues involved in GAG binding are 
protected from solvent, as is the case on a hep affinity column. Measurement of the 
movement of such an FGF then closes the case for the sliding/hopping mechanism. 
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